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It was men of Indostan
To learning much inclined,
Who went to see the Elephant
(Though all of them were blind),
That each by observation
Might satisfy their mind
And so these men of Indostan
Disputed loud and long,
Each in his own opinion
Exceeding stiff and strong,
Though each was partly in the right,
And all were in the wrong!
So oft in theologic wars,
The disputants, I ween,
Rail on in utter ignorance
Of what each other mean,
And prate about an Elephant
Not one of them has seen!
John Godfrey Saxe (1816-1887)
    In memory of my Mom and dedicated to my Dad.
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General Introduction
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1.1 Endothelial cells and vascular function.
The vascular endothelium is a one cell-layer thick lining of endothelial cells (EC) in all 
blood- and lymphatic vessels in the body and represents a dynamic border between blood 
and surrounding tissue. Besides being a physiological barrier,  regulating transfer of several 
molecules and cells,  the endothelium also produces a variety of factors that control vascular 
tone. These regulatory factors, such as nitric oxide (NO), endothelin-1 and prostaglandins, 
have either vasodilating or vasoconstricting properties1.  Under normal physiological 
conditions the monolayer provides a non-adhesive, uninterrupted surface for circulating 
platelets and leukocytes. However, inflammation of the endothelium caused by several 
stimuli such as hyperglycemia, hyperlipidemia and other circulating cardiovascular risk 
factors lead to EC activation. A cascade of events is ignited by EC activation such as 
upregulation of cell adhesion molecules, adhesion of leukocytes to the endothelial cell 
lining and trans-endothelial migration of mononuclear cells. These events are also 
associated with EC apoptosis and disruption of the EC layer; further increasing endothelial 
dysfunction and the risk of cardiovascular disease2 (figure 1).
 
Figure 1 Activated endothelium displays different characteristics, contributing to 
cardiovascular disease.
Healthy endothelium forms a smooth monolayer of elongated EC, with out adhesive capacities, 
whereas, injured and inflamed endothelium is disrupted and forms an adhesive surface to all blood 
cells and platelets. Healthy endothelium protects against cardiovascular disease.
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1.2 Postnatal neovascularization 
Postnatally, the development and maintenance of the vascular system requires constant 
remodeling and dynamic adaptation of vessel and network structures in response to 
functional needs3. For this so-called angioadaptation, the formation of new blood vessels 
(neovascularization) is crucial and the process involves angiogenesis and arteriogenesis4. 
Recently, it was shown that bone marrow-derived cells are also involved in 
neovascularisation in a process called vasculogenesis5.
1.2.1. Angiogenesis
Angiogenesis describes the formation of new capillaries from already existing capillaries. It 
is a physiological process required postnatally for non-pathological processes like 
endometrial remodeling during the menstrual cycle and wound healing.  It also plays a role 
in pathological processes such as tumor growth, inflammation and rheumatoid arthritis. 
Angiogenesis is a complex and not yet fully understood process that is tightly controlled by 
over 20 activators and a similar number of inhibitors. Hypoxia is a driving force for 
angiogenesis. When an oxygen consuming tissue is deprived of oxygen there is a high need 
for an adequate blood supply. Hypoxic tissues releases molecules, such as vascular 
endothelial growth factor (VEGF), that trigger the angiogenic response. VEGF production 
is stimulated by binding of hypoxia inducible factor-1alpha (HIF-1 alpha) to the hypoxia 
response area in the VEGF gene promoter region.  Many of the angiogenic stimuli promote 
proliferation, migration of EC and inhibit apoptosis and VEGF is one of these stimuli that 
mediate these crucial processes of angiogenesis. VEGF activates EC to produce nitric oxide 
(NO), which mediates vasodilatation and VEGF can also stimulate the release of proteolytic 
enzymes to dissolve basement membrane surrounding parent vessels creating an 
environment supporting EC migration and VEGF-receptor mediated proliferation of EC 
into the tissue. New vessels further mature by production of extra cellular matrix and 
recruitment of supporting cells like smooth muscle cells and pericytes by for instance 
platelet-derived growth factor (PDGF)-B and Tie-2. The process of angiogenesis is mainly 
associated with formation of microvascular networks.
 
1.2.2 Arteriogenesis
Arteriogenesis is the process of increasing the lumen of a pre-existing vessel to form 
collaterals6. This formation of collaterals includes recruitment and invasion of circulating 
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blood cells, proliferation of cells in the vessel wall and remodeling of the vessel in order to 
withstand larger blood flow. After occlusions of a supplying artery, arterioles become large 
conductance collateral vessels that maintain blood flow. Once an occlusion in a main artery 
takes place, blood flow is directed towards low resistance in the periphery via pre-existing 
arterioles. This redirection of blood flow increases shear stress at the arteriolar wall and 
activation of shear stress-responsive receptors on the EC membrane.  Once activated, EC 
from the arteriole divert from a quiescent non-adhesive monolayer to a highly adhesive 
monolayer for circulating blood leukocytes by expressing different adhesion molecules and 
chemokines. With the help of selectins leukocytes can role over the endothelium and slow 
down and firm adhesion is achieved by interaction of integrins on the leukocytes and the 
adhesion molecules on the EC. Leukocytes can invade the vessel wall due to vascular 
permeability. The recruitment of monocytes has been extensively studied and is crucial for 
arteriogenesis.  By using an ischemic hindlimb animal model in which new collaterals are 
formed due to a ligated femoral artery, several groups have shown that when monocytes are 
depleted from the animal the formation of collaterals is diminished and subsequently also 
the recovery of the blood flow7,8. This process seems to be dependent on the monocytes 
chemo attractant protein-1 (MCP-1) and the CCR-2 receptor signaling9,10.  Stabile et al, 
showed that lymphocytes are mediators of collateral formation as diminished blood flow 
recovery in a hindlimb model of T cell deficient mice could be recovered with injection of 
functional T cells11. The exact mechanisms and triggers for the entry of leukocytes into the 
vessel wall at arteriogenesis still need to be further explored.  These mechanisms together 
with EC sensing shear stress will drive a cascade of signaling transduction events that drive 
transcription factors and induce cellular responses. Important transcription factors induced 
by shear stress are activator protein-1 (also induced by inflammatory responses) and 
transcription factors of the Ets-family (driving VEGF and Tie expression). These 
transcription factors then drive events that induce EC and SMC replication. The vascular 
wall of the arteriole is remodeled by metalloproteinases that also help to create the space 
needed for vessel enlargement.  Growing collateral arteries have a corkscrew-like pattern 
because of a relatively quick growth in length between two already fixed points. The 
collaterals are initially tortuous in order to compensate for the still increased shear forces, 
but the collateral eventually becomes indistinguishable from a normal artery with a medial 
layer and normal reactivity. 
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1.2.3 Vasculogenesis 
Almost a decade ago the group of Isner discovered another mechanism that was involved in 
neovascularization5. They described for the first time that cells from the peripheral blood 
could be isolated which had the capacity to differentiate into cells with EC properties in 
vitro.  Interestingly, these cells in vitro resembled angioblasts of blood islands during 
embryonal development as further explained in figure 2. Since these early observations, 
progenitors of EC (EPC) are being studied extensively for their angiogenic properties and 
potential therapeutic application in angiogenesis/neovascularization as well as re-
endothelialization. 
 
Figure 2: EPC cultures do resemble embryonic vasculogenesis. 
Embryonic vasculogenesis begins as a cluster formation. The growth and fusion of multiple blood 
islands give rise to the yolk sac capillary network. After the onset of blood circulation, this network 
differentiates into an arteriovenous vascular system. The centers of these clusters will generate 
hematopoietic cells and are termed hematopoietic stem cells. Angioblasts are located at the periphery 
of the blood islands and are responsible for forming the vessel.  EPC, derived from peripheral blood 
MNC fraction have properties similar to those of embryonic angioblast. At day 4 of culture, EPC can 
be defined as spindle shaped migratory endothelial cells. A great number of spindle shaped 
hemangioblasts can be seen. These hemangioblasts differentiate into EPC and hematopoietic stem 
cells (HSC). The HSC detach from the plate during culture and the attached EPC can be cultured 
further. After short term culture of 8 days cordlike structures of the spindle shaped EPC are formed.
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1.3 Endothelial progenitor cells: Origins and differentiation.
The nature of the "true" circulating EPC is poorly defined. Different sources of EPC have 
been identified with each source having distinct properties12,13. In general,  a common 
denominator for the different populations of cells that are termed EPC is the expression of 
EC-specific genes such as vascular endothelial-cell growth factor receptor-2 (VEGFR2). 
1.3.1 Origins of EPC
Circulating EPC (CEP) that are characterized by the expression of the early hematopoietic 
stem cell markers CD34, CD133 and VEGFR2 can be recruited from the bone 
marrow5,14,15. CEP share these characteristics with hematopoietic stem cells and CEP have 
properties similar to the embryonic hemangioblast, which can give rise to both circulating 
blood cell lineages and vascular cells (Figure 2)5,16. Cultured with endothelial cell growth 
factors, purified CEP differentiate into endothelial-like cells that display a classic 
endothelial cell morphology and characteristics like the expression of von Willebrand factor 
(vWF), vascular endothelial (VE) cadherin and the capacity to take up acetylated low-
density lipoprotein (acLDL). Although normally the number of CEP are limited (< 0,005% 
PB-MNC), their levels can be markedly elevated within days after the administration of 
CEP mobilizing agents17,  vascular trauma18 or myocardial infarction19,20.  
Second, a subpopulation of peripheral blood mononuclear cells (PB-MNC) cultured on a 
gelatin- or fibronectin-coated dish in endothelial cell differentiation medium acquire the 
phenotype of endothelial cells within a short time period (4 to 7 days).  These attaching 
cells, that are also referred to as EPC, display a spindle-like morphology and express 
endothelial cell markers like vWF, VEGFR2 and VE-cadherin. They are usually 
characterized by the binding of endothelial cell-specific lectins and the uptake of 
acLDL12,13. The large number of attaching cells that can be obtained from the PB-MNC 
cultures (up to 10%) make it unlikely that all these cells are derived from the low number of 
circulating CD34+ cells. Most likely, these EPC are derived from more abundant 
subpopulations present in the mononuclear cell fraction like monocytes13,21-24.
Several studies have shown that when these short term cultured EPC (4-7 days) were 
cultured further under EC growth conditions they could grow out into a monolayer of cells 
with cobblestone morphology resembling mature EC25. These so called late-outgrowth cells 
did exhibit true EC properties as they showed vWF positive staining in Weibel pallade 
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bodies and perinuclear anti-eNOS staining. They also showed a higher capacity to form 
tubular structures in vitro when compared to short term cultured EPC.  Another source of 
EPC may be residing vascular progenitors so called “side population” cells (SP)13,26. Sainz 
et al.  showed convincingly that vascular SP cells could under specific growth conditions 
differentiate towards EC-phenotype and they showed that SP cells formed complex 
vascular structures on a matrigel scaffold13,26.
1.3.2 EPC differentiation
The exact differentiation cascade of EPC still needs to be elucidated1. It is currently unclear 
whether the different types of EPC are related through shared developmental stages, i.e. 
whether a monocyte-related intermediate is a required step in the differentiation of CD34+ 
cells into EPC. The latter might be true as a recent publication showed that a subset of 
circulating monocytes have a low expression of CD34 antigen using a very sensitive new 
antigen detection method27. These CD14+CD34low cells ranged from 0.6% to 8.5% of all 
peripheral-blood leukocytes and comprised most of the circulating KDR+ cells. Almost all 
CD14+ BM cells were CD14+CD34low double-positive cells with high multipotency and 
proliferation capacity when compared to the CD34- cells.  It is clear that EPC are derived 
from hematopoietic stem cell (HSC) that reside in the bone marrow and can give rise to all 
blood types28. A model for EPC differentiation and how it fits in total hematopoiesis is 
depicted in figure 3. Important to notice is that EPC and EC do share the same myeloid 
lineage as Dendritic cells and Macrophages. This close relationship is further supported by 
the fact that these three terminally differentiated cells do share many phenotypical 
characteristics29,30.  Differentiation of EPC in vitro and in vivo might share many common 
factors, as EPC in vitro do depend on the angiogenic growth factors present in the culture 
medium and also on the adherent surface. It is very likely that in vivo the same happens. 
Depending on the factors secreted and exposed by the injured sites,  the adhered progenitors 
will become EC or another myeloid cell. Physical factors might be important in the 
differentiation of progenitors towards EC as well,  as it was shown recently that shear stress 
could possibly induce EPC differentiation31. When EPC were in vitro subjected to shear 
stress their expression of KDR and other endothelial characteristics was markedly 
upregulated, inducing a cascade of differentiation and proliferation signals. 
A lot of contradictions are found in literature with regard to the capacity of EPC to 
incorporate in newly formed vessels and thus if EPC are true progenitors of EC or if they 
are cells secreting angiogenic factors. In ischemic tissue the incorporation efficacy of true 
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EPC differs from 0% till 50%32,33. A likely explanation for this difference could be the 
severity of the injury (the more ischemia the more recruitment the more incorporation) or 
the different isolation and subsequent culture of progenitor cells under special conditions 
can change their properties18,33. In many studies a significant perivascular accumulation of 
BM-derived cells was observed in areas of collateral artery growth and capillary growth. 
These “pericytic” cells stained positive for some angiogenic growth factors and 
chemokines13 and therefore it is highly likely that the capacity of EPC to promote 
neovascularization can also be accomplished by angiogenic paracrine effects13,33.
 
Figure 3: EPC in hematopoiesis.
EPC are thought to be derived from myeloid lineage and share common progenitors with the terminally 
differentiated DC and Mph. 
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1.4 Mobilization and homing of EPC
Figure 4 shows a schematic model for the concept of mobilization of EPC and their 
recruitment to sites of injury.
1.4.1 Mobilization of EPC
The mobilization of EPC from the bone marrow is regulated by various growth factors, 
cytokines and surface receptors. EPC are recruited from the bone marrow by factors that are 
secreted by ischemic or damaged tissue like VEGF and SDF-118,20,34,35. Peripheral release 
of these growth factors activates MMP-9,  that subsequently cuts membrane bound ckit 
resulting in the release of a soluble Kit Ligand36. cKit+ progenitor cells can then move 
towards the vascular zone of the BM. Factors regulating proliferation and differentiation 
remain largely unclear but VEGF binding KDR might mediate further differentiation of the 
early KDR+ progenitor. Endothelial specific nitric oxide synthase (eNOS) expressed by 
stromal cells in the BM has been shown to play an essential role in mobilization of EPC37. 
eNOS deficient mice show an impaired mobilization of progenitor cells, which was 
confirmed to be MMP-9 dependent.
1.4.2 Homing of EPC
Like other blood-leukocytes, EPC are attracted to sites of injury/ischemia by chemokines 
through their receptors.  Locally delivered SDF-1 augments neovascularization in vivo by 
recruiting EPC to the ischemic site using their CXCR4 receptor38. The uptake of apoptotic 
bodies from mature EC could stimulate proliferation and differentiation of EPC, which 
could potentially be a important mechanism for differentiation at sites of injury39.  That 
EPC home specifically to injured sites has nicely been shown by a tissue distribution study 
performed by Aicher et al,  in which EPC were radioactively labelled and injected into 
athymic nude rats with an induced myocardial infarction showing that EPC homed 
predominantly to the infarct border zone40. 
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1.5 Therapeutic options of EPC: neovascularization and 
reendothelialization
The therapeutic capacity of EPC can be explored in two different directions. The 
angiogenic capacity of EPC can be used as therapeutic option to rescue critical ischemia in 
patients41. Or the capacity of EPC to differentiate to EC can be used for reendothelialization 
of damaged vessels and maintenance of the integrity of the endothelium42,43.  
1.5.1 EPC for neovascularization 
The finding that human EPC incorporate in active sites of neovascularization5 in animal 
models after induction of local ischemia has led to a number of transplantation studies 
using freshly isolated human CD34+ (CB44 or BM recruited / PB5,45-49), human CD133+50,51, 
 
Figure 4: Schematic model of the concept of EPC mobilization and function. 
HSC in the bone marrow are stimulated by angiogenic growth factors derived from damaged or 
ischemic tissue. They mobilize to the PB stream and cells can home towards chemokines 
depending on their receptors. Arrived at the site of injury they can either stimulate the already 
existing EC to proliferate (angiogenesis) or they can incorporate into the endothelium, 
stimulating vessel growth. Two therapeutic properties of EPC, neovascularization and 
regenerating the injured/damaged endothelium, are highlighted in separate boxes.
General intoroduction
19
murine SCA-1+ 48 cells and ex vivo cultured early32,52-55 and late outgrowth EPC. This 
strategy of using local transplantation of (autologous) progenitor pools either directly 
obtained from bone marrow aspirates or from ex vivo cultured endothelial-like cells derived 
from the PB-MNC fraction has been explored widely preclinically as well as clinically. 
Preclinically, all cell-based studies confirmed a positive therapeutic efficacy of the 
angiogenic cells for neovascularization, however because these experiments were 
performed in different groups with different models it is hard to compare efficacies13. When 
early and late outgrowth cultured EPC were in vivo compared for their vasculogenic 
capacities they showed similar activities despite the higher angiogenic capacities of the late 
outgrowth EC in vitro. Furthermore, these preclinical studies suggested that EPC do have 
not-yet-defined but convincingly unique angiogenic characteristics, as terminally 
differentiated control cells (like human MVEC32, Macrophages (Mph) and Dendritic cells
(DC)55 didn’t show strong neovascularization capacities. In the last few years, there have 
been a couple of clinical transplantation trails using autologous cells for treatment of 
ischemic vascular disease using either BM-MNC56-61, BM-CD133+ cells62, G-CSF 
mobilized PB-MNC63 or PB-MNC derived early outgrowth EPC with56 or without G-CSF 
recovery64.  There is some contradiction between these trials about the beneficial effects of 
the progenitor cells. Most of these trials show minor57 beneficial effects while other trials 
show even adverse site effects62,63 and this matter will be discussed further in chapter 8. 
There were some trials in which comparisons were made between transplantations with 
different pools of progenitor cells. For instance, when BM-MNC and PB-derived early 
outgrowth EPC were compared for their effect on remodeling of postmyocardial infarction. 
They both showed beneficial effects and to a similar extend56. Furthermore, in ischemic 
limbs, BM-MNC were found to be much better in recovering blood flow than PB derived 
MNC were60. 
1.5.2 Agents and methods to increase the number of EPC
Not all therapies have been focused on autologous transplantation of EPC. A lot of groups 
have focused on agents/methods that were capable of mobilizing EPC in order to increase 
the total circulating EPC number. 
Two groups independently showed that physical exercise could increase EPC numbers and 
thus augment angiogenesis but also reduce neointima formation65,66. As already described, 
damaged tissue and hypoxia induced factors can mobilize EPC from the BM18,20,34,35. 
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Administration of growth factors have been shown to increase the number of circulating 
EPC in experimental models as well as clinical pilot trials67,68. 
Intramuscular administration of VEGF using viral vectors enhanced levels of circulating 
EPC and restored the impaired neovascularization in ischemic hindlimbs of diabetic 
mice69 .  Similar to VEGF, basic fibroblast growth factor (bFGF),  angiopoietin-1, SDF-1 and 
placental growth factor (PDGF) have also been shown to induce EPC mobilization and 
recruitment70,71. As EPC are thought to be myeloid cells derived from the CD34+ 
hematopoietic stem cell, an additional method to increase circulating EPC is to use stem 
cell or myeloid cell recruiting factors such as granulocyte-colony-stimulating factor (G-
CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and macrophage-
colony-stimulating factor (M-CSF). Indeed, these growth factors have been shown to 
mobilize EPC and/or interfere in their differentiation72,73. However, as these cytokines have 
also an inflammatory key role and play part in atherosclerosis and restenosis, their safety 
has been questioned by recent studies63,74. Recently, a stimulatory effect of erythropoietin 
(Epo) has also been described on EPC recruitment and angiogenesis and as Epo has less 
inflammatory actions it might be a safer to use compared to other highly inflammatory 
cytokines75,76. In addition to the use of growth factors and cytokines to mobilize EPC from 
BM, several pharmacological agents have been proven to increase EPC levels. Statins 
induce mobilization and proliferation of circulating EPC in vitro and in vivo and they 
increase the amount of EPC incorporating at sites of neovascularization77-79. Statins were 
originally designed to reduce lipid levels in patients, however they have also proven very 
beneficial in reducing vascular inflammation80. Statins,  but also many growth factors 
named above, have in common that they stimulate the Akt/PKB pathway and evidence is 
accumulating that the Akt/PKB pathway plays a central role in stem cell recruitment and 
survival of EPC.
Similar to statins,  the glucose-lowering and anti-inflammatory peroxisome proliferator-
activated receptor-γ agonists (PPARγ-agonists) can also enhance proliferation, 
differentiation and mobilization of EPC81,82.  Interestingly, some BP-lowering drugs have 
also been shown to enhance angiogenesis in hypertension. For instance, ACE inhibitors 
were shown to increase capillary density, as much as VEGF, in an ischemic hind limb 
model83 and enhanced EPC mobilization was also observed with ACE inhibition84.  
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1.5.3 EPC for EC regeneration
It is very important to keep a good integrity and function of the endothelium, as injury and 
damage of the endothelium leads to inflammatory responses that can induce the formation 
of atherosclerotic lesions, plaque rupture infarctions and eventually end organ damage85. 
Early support for a role of bone marrow derived EPC in vascular repair in humans stems 
from the observation that the neointima formed on the surface of a left ventricular assist 
device accumulates a CD133+ positive hematopoietic stem cell population that also 
expresses the endothelial cell marker VEGFR214. In a mouse model, it was shown that bone 
marrow derived EPC can home to denuded arterial vessels and contribute to 
reendothelialization86. Likewise, infusion of BM derived CD34-/CD14+ did enhance and 
contribute significantly to endothelial regeneration87. The importance of these findings was 
further explored in animal models with high risk for atherosclerosis. For instance, 
hyperlipidemic Apolipoprotein E-/- mice show a lower number of endothelial progenitors in 
blood, which correlated with enhanced atherosclerosis88.  
The effect of transplantation of cultured early outgrowth EPC in reendothelialization was 
examined in rabbits, where a rapid reendothelialization of balloon-injured carotid arteries 
together with a reduced neointima formation was observed89.  
Augmenting the number of circulating EPC by recruiting them from the BM as discussed 
above is of course also beneficial for reendothelialization purposes and in that respect many 
EPC mobilizing agents have been studied as well in different animal models. Indeed, statin-
induced mobilization of EPC was associated with an increased rate of reendothelialization 
and reduced neointimal thickening86,90. Likewise, PPARγ-agonist rosiglitazone promotes 
the differentiation of these EPC and attenuates neointimal formation in a mouse model with 
femoral angioplasty82. Mobilization of EPC with GM-CSF resulted in a reendothelialization 
and inhibited monocyte infiltration in an endothelium denuded artery in 
hypercholesterolemic rabbits91.  
It is not known if the beneficial effects of EPC are only due to reendothelialization or if 
EPC can facilitate other roles in atherosclerosis. For instance, here have been reports that 
EPC might contribute to facilitating plaque instability by inducing plaque angiogenesis92.  
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1.6 EPC dysfunction in ischemic vascular disease
1.6.1 EPC dysfunction in IVD
From the above it can be concluded that EPC of different hematopoietic lineages appear to 
play a crucial role in neovascularization of ischemic tissue and in the maintenance of 
endothelial cell integrity in injured vessels.  Following these insights, it was hypothesized 
that impaired EPC function would predispose to endothelial cell dysfunction and its clinical 
manifestations including premature atherosclerosis and ischemic vascular disease. Seminal 
observations supporting this concept were reported by Vasa et al. who demonstrated that 
the number and function of circulating endothelial progenitor cells inversely correlated with 
risk factors for coronary artery disease93.  It was shown that this concept holds true both for 
CD34 and VEGFR2 double positive CEP as well as for PB-MNC derived attaching EPC. 
 
Figure 5: Keeping a tight balance of the number of EPC might prevent ischemic 
vascular disease. 
As the number of EPC is diminished in patients suffering from classical risk factors, one could 
hypothesize that treatment with EPC mobilizing agents and angiogenic growth factors to keep the 
EPC number up could be beneficial. A key mechanism involved in the survival, proliferation 
apoptosis of the EPC is the PI3 kinase/ Akt pathway. 
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Hill et al. extended this observation showing that,  for patients at risk for CVD, there was a 
strong inverse correlation between the number of EC colonies that could be obtained from 
PB-MNC cultures and the subjects’ combined Framingham risk factor score94. Moreover, 
measurements of flow-mediated brachial-artery reactivity revealed a significant relation 
between endothelial function and the number of progenitor cells.  In addition, EPC from the 
higher risk score patients revealed a more rapid senescence than those from the lower score, 
indicating a possible exhaustion of EPC that can contribute to the pathogenesis of the 
vascular disease. Furthermore, these reports again suggest that the quality of the 
endothelium may well be related to the endothelium-regenerative potential of circulating 
EPC. 
1.6.2 EPC dysfunction and hyperglycemia
Schatteman and colleagues were the first to report data supporting the concept of EPC 
dysfunction in streptozotocin-induced diabetic nude mice49. Using an established model for 
neovascularization of the ischemic hindlimb they demonstrated that, as shown before in 
non obese diabetic mice, restoration of blood flow was significantly impaired in the 
diabetic mice. Whereas injection of human CD34+ cells, purified from the PB-MNC 
fraction, did not accelerate the rate of neovascularization in healthy controls, it markedly 
enhanced blood-flow restoration in the diabetic mice. When labeled, CD34+ cells were 
found to incorporate in the vasculature of previously ischemic tissue. It was concluded that 
in diabetic mice EPC function was deficient and that this could be corrected by 
transplantation of exogenous human CD34+ cells. These data indirectly provided evidence 
for deficient EPC function in experimentally diabetic mice and initiated subsequent studies 
to investigate the nature of the EPC dysfunction. 
Diabetes-associated metabolic factors may affect EPC function at several levels, including 
the number of available progenitor cells with capacity to differentiate into cells of the 
endothelial cell lineage, their capability to adhere and migrate to sites of 
reendothelialization and neovascularization and their pro-angiogenic (paracrine) potential.
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1.7 Vascular problems in type-1 Diabetes Mellitus.
The metabolic disorder Diabetes Mellitus (DM) is characterized by chronic hyperglycemia 
due to reduced insulin-stimulated glucose uptake and/or impaired insulin secretion by beta 
cells in the pancreas.  This thesis mainly focuses on the hyperglycemic state resulting from 
destruction of the insulin-producing β cells in humans (type 1 Diabetes Mellitus) and mice 
(streptozotocin-induced diabetes).
Hyperglycemia is one of the adverse metabolic risk factors associated with an increased 
risk of vascular disease. Type 1 diabetes is not only associated with microvascular 
complications95 but also with premature atherosclerosis and a reduced capacity to form 
collateral vessels after an ischemic insult96,97. Likewise, patients with type 1 diabetes have 
an increased risk of clinical consequences of macrovascular disease including myocardial 
infarction and peripheral vascular disease98. Numerous studies have shown that dysfunction 
of the vascular endothelium plays a central role in the pathophysiology of diabetic 
microangiopathy and macroangiopathy99. The metabolic abnormalities that characterize 
diabetes, particularly hyperglycemia, provoke molecular mechanisms that have a major 
impact on endothelial cell function and survival.  For instance, activation of protein kinase 
C (PKC) and increased oxidative stress can lead to endothelial cell dysfunction100. 
Moreover, prolonged exposure of endothelial cells to these adverse conditions increases 
endothelial cell apoptosis and turnover101. Although adjacent mature endothelial cells have 
the capacity to proliferate and replace these dying cells, chronic exposure to oxidative stress 
has been shown to lead to premature replicative senescence and limits this form of 
endothelial repair102,103. Eventually, endothelial cell death and shedding may lead to 
disturbances of the endothelial monolayer leaving a highly pro-atherogenic luminal 
surface42,104. 
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1.8 Hypothesis and questions of the thesis.
Taken the vascular problems in patients with type 1 diabetes and the potential importance 
of EPC in maintenance and repair of injured endothelium and neovascularization of 
ischemic tissue into consideration, we hypothesized that EPC dysfunction reduces the 
vascular regenerative potential and thereby contributes to the pathogenesis of ischemic 
vascular disease.  Thus, this thesis explores EPC dysfunction in diabetes mellitus focusing 
on angiogenic capacity, EPC differentiation and interventions to improve EPC function. 
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Questions addressed in this thesis are:
Chapter 2: How do different angiogenic cell subsets participate in 
neovascularization? 
Chapter 3:  Does EPC dysfunction exist in type-1 Diabetes Mellitus? 
Chapter 4: Could elevated oxidative stress be involved in EPC dysfunction in 
Diabetes Mellitus?
Chapter 5:  By using a transgenic mouse model, several questions could be answered.
Can EPC differentiation be tracked and how many cells are true EPC in 
short-term cultures?
How can EPC be distinguished from other myeloid differentiation 
lineages (macrophages and dendritic cells) as there are large phenotypic 
and functional overlaps? 
Which sub-fraction of the BM contains the progenitors for EPC? Can 
myeloid growth factors such as M-CSF and GM-CSF stimulate the 
expansion of EPC? 
Chapter 6:  How does hyperglycemia affect EPC precursors in the bone marrow? 
Chapter 7:  How does short-term treatment of type-2 Diabetes patients with PPARγ-
agonists affect the proinflammatory phenotype of monocytes and 
dysfunctional EPC?
Chapter 8: General discussion about the implications of the data presented in this 
thesis and suggestions for future studies.
 General intoroduction
27
References
(1)  Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible 
 clinical relevance. J Cell Mol Med. 2004;8:498-508.
(2)  Goligorsky MS. Endothelial cell dysfunction: can't live with it, how to live without it. Am J Physiol 
 Renal Physiol. 2005;288:F871-F880.
(3)  Zakrzewicz A, Secomb TW, Pries AR. Angioadaptation: keeping the vascular system in shape. News 
 Physiol Sci. 2002;17:197-201.
(4)  Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6:389-395.
(5)  Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for 
 angiogenesis. Science. 1997;275:964-967.
(6)  Heil M, Schaper W. Cellular mechanisms of arteriogenesis. EXS. 2005;181-191.
(7)  Heil M, Ziegelhoeffer T, Pipp F et al. Blood monocyte concentration is critical for enhancement of 
 collateral artery growth. Am J Physiol Heart Circ Physiol. 2002;283:H2411-H2419.
(8)  Pipp F, Heil M, Issbrucker K et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: 
 evidence for a monocyte-mediated mechanism. Circ Res. 2003;92:378-385.
(9)  Heil M, Ziegelhoeffer T, Wagner S et al. Collateral artery growth (arteriogenesis) after experimental 
 arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ Res. 2004;94:671-677.
(10)  Voskuil M, Hoefer IE, van Royen N et al. Abnormal monocyte recruitment and collateral artery 
 formation in monocyte chemoattractant protein-1 deficient mice. Vasc Med. 2004;9:287-292.
(11)  Stabile E, Burnett MS, Watkins C et al. Impaired arteriogenic response to acute hindlimb ischemia in 
 CD4-knockout mice. Circulation. 2003;108:205-210.
(12)  Rabelink TJ, de Boer HC, De Koning EJ, van Zonneveld AJ. Endothelial progenitor cells: more than an 
 inflammatory response? Arterioscler Thromb Vasc Biol. 2004;24:834-838.
(13)  Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. Circ 
 Res. 2004;95:343-353.
(14)  Peichev M, Naiyer AJ, Pereira D et al. Expression of VEGFR-2 and AC133 by circulating human 
 CD34 (+) cells identifies a population of functional endothelial precursors. Blood. 
 2000;95:952-958.
(15)  Shi Q, Rafii S, Wu MH et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 
 1998;92:362-367.
(16)  Eichmann A, Corbel C, Nataf V et al. Ligand-dependent development of the endothelial and 
 hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor 
 receptor 2. Proc Natl Acad Sci U S A. 1997;94:5141-5146.
(17)  Rabbany SY, Heissig B, Hattori K, Rafii S. Molecular pathways regulating mobilization of 
 marrow- derived stem cells for tissue revascularization. Trends Mol Med. 2003;9:109-117.
(18)  Gill M, Dias S, Hattori K et al. Vascular trauma induces rapid but transient mobilization of 
 VEGFR2(+) AC133(+) endothelial precursor cells. Circ Res. 2001;88:167-174.
(19)  Massa M, Rosti V, Ferrario M et al. Increased circulating hematopoietic and endothelial progenitor cells 
 in the early phase of acute myocardial infarction. Blood. 2005;105:199-206.
(20)  Shintani S, Murohara T, Ikeda H et al. Mobilization of endothelial progenitor cells in patients with 
 acute myocardial infarction. Circulation. 2001;103:2776-2779.
 Chapter 1
28
(21)  Fernandez PB, Lucibello FC, Gehling UM et al. Endothelial-like cells derived from human CD14 
 positive monocytes. Differentiation. 2000;65:287-300.
(22)  Harraz M, Jiao C, Hanlon HD, Hartley RS, Schatteman GC. CD34(-) blood-derived human endothelial 
 cell progenitors. Stem Cells. 2001;19:304-312.
(23)  Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived 
 from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003;107:1164-1169.
(24)  Schmeisser A, Garlichs CD, Zhang H et al. Monocytes coexpress endothelial and macrophagocytic 
 lineage markers and form cord-like structures in Matrigel under angiogenic conditions. Cardiovasc Res. 
 2001;49:671-680.
(25)  Gulati R, Jevremovic D, Peterson TE et al. Diverse origin and function of cells with endothelial 
 phenotype obtained from adult human blood. Circ Res. 2003;93:1023-1025.
(26)  Sainz J, Al Haj ZA, Caligiuri G et al. Isolation of "side population" progenitor cells from healthy 
 arteries of adult mice. Arterioscler Thromb Vasc Biol. 2006;26:281-286.
(27)  Romagnani P, Annunziato F, Liotta F et al. CD14+CD34low cells with stem cell phenotypic and 
 functional features are the major source of circulating endothelial progenitors. Circ Res. 
 2005;97:314-322.
(28)  Kondo M, Wagers AJ, Manz MG et al. Biology of hematopoietic stem cells and progenitors: 
 implications for clinical application. Annu Rev Immunol. 2003;21:759-806.
(29)  Schmeisser A, Strasser RH. Phenotypic overlap between hematopoietic cells with suggested 
 angioblastic potential and vascular endothelial cells. J Hematother Stem Cell Res. 2002;11:69-79.
(30)  Schmeisser A, Graffy C, Daniel WG, Strasser RH. Phenotypic overlap between monocytes and vascular 
 endothelial cells. Adv Exp Med Biol. 2003;522:59-74.
(31)  Yamamoto K, Takahashi T, Asahara T et al. Proliferation, differentiation, and tube formation by 
 endothelial progenitor cells in response to shear stress. J Appl Physiol. 2003;95:2081-2088.
(32)  Kalka C, Masuda H, Takahashi T et al. Transplantation of ex vivo expanded endothelial progenitor cells 
 for therapeutic neovascularization. Proc Natl Acad Sci U S A. 2000;97:3422-3427.
(33)  Ziegelhoeffer T, Fernandez B, Kostin S et al. Bone marrow-derived cells do not incorporate into the 
 adult growing vasculature. Circ Res. 2004;94:230-238.
(34)  Asahara T, Takahashi T, Masuda H et al. VEGF contributes to postnatal neovascularization by 
 mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999;18:3964-3972.
(35)  Ceradini DJ, Kulkarni AR, Callaghan MJ et al. Progenitor cell trafficking is regulated by hypoxic 
 gradients through HIF-1 induction of SDF-1. Nat Med. 2004;10:858-864.
(36)  Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow 
 niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-637.
(37)  Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for 
 mobilization of stem and progenitor cells. Nat Med. 2003;9:1370-1376.
(38)  Yamaguchi J, Kusano KF, Masuo O et al. Stromal cell-derived factor-1 effects on ex vivo expanded 
 endothelial progenitor cell recruitment for ischemic neovascularization. Circulation. 
 2003;107:1322-1328.
(39)  Hristov M, Erl W, Linder S, Weber PC. Apoptotic bodies from endothelial cells enhance the number 
 and initiate the differentiation of human endothelial progenitor cells in vitro. Blood. 
 2004;104:2761-2766.
(40)  Aicher A, Brenner W, Zuhayra M et al. Assessment of the tissue distribution of transplanted human 
 endothelial progenitor cells by radioactive labeling. Circulation. 2003;107:2134-2139.
 General intoroduction
29
(41)  Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal 
 neovascularization. J Clin Invest. 1999;103:1231-1236.
(42)  Dimmeler S, Zeiher AM. Vascular repair by circulating endothelial progenitor cells: the missing link in 
 atherosclerosis? J Mol Med. 2004;82:671-677.
(43)  Ong AT, Aoki J, Kutryk MJ, Serruys PW. How to accelerate the endothelialization of stents. Arch Mal 
 Coeur Vaiss. 2005;98:123-126.
(44)  Murohara T. Therapeutic vasculogenesis using human cord blood-derived endothelial progenitors. 
 Trends Cardiovasc Med. 2001;11:303-307.
(45)  Dekel B, Shezen E, Even-Tov-Friedman S et al. Transplantation of human CD34+CD133+ 
 hematopoietic stem cells into ischemic and growing kidneys suggests role in vasculogenesis but not 
 tubulogenesis. Stem Cells. 2006.
(46)  Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human 
 bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves 
 cardiac function. Nat Med. 2001;7:430-436.
(47)  Takagi Y, Omura T, Yoshiyama M et al. Granulocyte-colony stimulating factor augments 
 neovascularization induced by bone marrow transplantation in rat hindlimb ischemia. J Pharmacol Sci. 
 2005;99:45-51.
(48)  Takahashi T, Kalka C, Masuda H et al. Ischemia- and cytokine-induced mobilization of bone 
 marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434-438.
(49)  Schatteman GC, Hanlon HD, Jiao C, Dodds SG, Christy BA. Blood-derived angioblasts accelerate 
 blood-flow restoration in diabetic mice. J Clin Invest. 2000;106:571-578.
(50)  Handgretinger R, Gordon PR, Leimig T et al. Biology and plasticity of CD133+ hematopoietic stem 
 cells. Ann N Y Acad Sci. 2003;996:141-151.
(51)  Leor J, Guetta E, Feinberg MS et al. Human Umbilical Cord Blood-Derived CD133+ Cells Enhance 
 Function and Repair of the Infarcted Myocardium. Stem Cells. 2005.
(52)  Hur J, Yoon CH, Kim HS et al. Characterization of two types of endothelial progenitor cells and their 
 different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol. 2004;24:288-293.
(53)  Kawamoto A, Gwon HC, Iwaguro H et al. Therapeutic potential of ex vivo expanded endothelial 
 progenitor cells for myocardial ischemia. Circulation. 2001;103:634-637.
(54)  Murohara T, Ikeda H, Duan J et al. Transplanted cord blood-derived endothelial precursor cells 
 augment postnatal neovascularization. J Clin Invest. 2000;105:1527-1536.
(55)  Urbich C, Heeschen C, Aicher A et al. Relevance of monocytic features for neovascularization capacity 
 of circulating endothelial progenitor cells. Circulation. 2003;108:2511-2516.
(56)  Assmus B, Schachinger V, Teupe C et al. Transplantation of Progenitor Cells and Regeneration 
 Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation. 2002;106:3009-3017.
(57)  Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients 
 with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet. 
 2006;367:113-121.
(58)  Lunde K, Solheim S, Aakhus S et al. Autologous stem cell transplantation in acute myocardial 
 infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous 
 mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J. 
 2005;39:150-158.
(59)  Strauer BE, Brehm M, Zeus T et al. Repair of infarcted myocardium by autologous intracoronary 
 mononuclear bone marrow cell transplantation in humans. Circulation. 2002;106:1913-1918.
 Chapter 1
30
(60)  Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb 
 ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised 
 controlled trial. Lancet. 2002;360:427-435.
(61)  Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after 
 myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364:141-148.
(62)  Bartunek J, Vanderheyden M, Vandekerckhove B et al. Intracoronary injection of CD133-positive 
 enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: 
 feasibility and safety. Circulation. 2005;112:I178-I183.
(63)  Kang HJ, Kim HS, Zhang SY et al. Effects of intracoronary infusion of peripheral blood stem-cells 
 mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis 
 after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet. 
 2004;363:751-756.
(64)  Erbs S, Linke A, Adams V et al. Transplantation of blood-derived progenitor cells after recanalization 
 of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res. 
 2005;97:756-762.
(65)  Laufs U, Werner N, Link A et al. Physical training increases endothelial progenitor cells, inhibits 
 neointima formation, and enhances angiogenesis. Circulation. 2004;109:220-226.
(66)  Rehman J, Li J, Parvathaneni L et al. Exercise acutely increases circulating endothelial progenitor cells 
 and monocyte-/macrophage-derived angiogenic cells. J Am Coll Cardiol. 2004;43:2314-2318.
(67)  Kalka C, Tehrani H, Laudenberg B et al. VEGF gene transfer mobilizes endothelial progenitor cells in 
 patients with inoperable coronary disease. Ann Thorac Surg. 2000;70:829-834.
(68)  Moore MA, Hattori K, Heissig B et al. Mobilization of endothelial and hematopoietic stem and 
 progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF, and 
 angiopoietin-1. Ann N Y Acad Sci. 2001;938:36-45.
(69)  Rivard A, Silver M, Chen D et al. Rescue of diabetes-related impairment of angiogenesis by 
 intramuscular gene therapy with adeno-VEGF. Am J Pathol. 1999;154:355-363.
(70)  Luttun A, Carmeliet G, Carmeliet P. Vascular progenitors: from biology to treatment. Trends 
 Cardiovasc Med. 2002;12:88-96.
(71)  Szmitko PE, Fedak PW, Weisel RD et al. Endothelial progenitor cells: new hope for a broken heart. 
 Circulation. 2003;107:3093-3100.
(72)  Minamino K, Adachi Y, Okigaki M et al. Macrophage colony-stimulating factor (M-CSF), as well as 
 granulocyte colony-stimulating factor (G-CSF), accelerates neovascularization. Stem Cells. 
 2005;23:347-354.
(73)  Seiler C, Pohl T, Wustmann K et al. Promotion of collateral growth by granulocyte-macrophage 
 colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, 
 placebo-controlled study. Circulation. 2001;104:2012-2017.
(74)  Matsubara H. Risk to the coronary arteries of intracoronary stem cell infusion and G-CSF cytokine 
 therapy. Lancet. 2004;363:746-747.
(75)  Bahlmann FH, DeGroot K, Duckert T et al. Endothelial progenitor cell proliferation and differentiation 
 is regulated by erythropoietin. Kidney Int. 2003;64:1648-1652.
(76)  Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial 
 progenitor cell mobilization. Blood. 2003;102:1340-1346.
(77)  Dimmeler S, Aicher A, Vasa M et al. HMG-CoA reductase inhibitors (statins) increase endothelial 
 progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108:391-397.
 General intoroduction
31
(78)  Landmesser U, Engberding N, Bahlmann FH et al. Statin-induced improvement of endothelial 
 progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after 
 experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation. 
 2004;110:1933-1939.
(79)  Llevadot J, Murasawa S, Kureishi Y et al. HMG-CoA reductase inhibitor mobilizes bone 
 marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108:399-405.
(80)  Crisby M. Modulation of the inflammatory process by statins. Timely Top Med Cardiovasc Dis. 
 2005;9:E3.
(81)  Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to 
 neovascularization by mobilization of endothelial progenitor cells. Coron Artery Dis. 2004;15:235-242.
(82)  Wang CH, Ciliberti N, Li SH et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation 
 toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation. 2004;109:1392-1400.
(83)  Fabre JE, Rivard A, Magner M, Silver M, Isner JM. Tissue inhibition of angiotensin-converting enzyme 
 activity stimulates angiogenesis in vivo. Circulation. 1999;99:3043-3049.
(84)  Min TQ, Zhu CJ, Xiang WX, Hui ZJ, Peng SY. Improvement in endothelial progenitor cells from 
 peripheral blood by ramipril therapy in patients with stable coronary artery disease. Cardiovasc Drugs 
 Ther. 2004;18:203-209.
(85)  Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999;138:S419-S420.
(86)  Walter DH, Rittig K, Bahlmann FH et al. Statin therapy accelerates reendothelialization: a novel effect 
 involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. 
 Circulation. 2002;105:3017-3024.
(87)  Fujiyama S, Amano K, Uehira K et al. Bone marrow monocyte lineage cells adhere on injured 
 endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate 
 reendothelialization as endothelial progenitor cells. Circ Res. 2003;93:980-989.
(88)  Xu Q, Zhang Z, Davison F, Hu Y. Circulating progenitor cells regenerate endothelium of vein graft 
 atherosclerosis, which is diminished in ApoE-deficient mice. Circ Res. 2003;93:e76-e86.
(89)  Griese DP, Ehsan A, Melo LG et al. Isolation and transplantation of autologous circulating endothelial 
 cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. 
 Circulation. 2003;108:2710-2715.
(90)  Werner N, Priller J, Laufs U et al. Bone marrow-derived progenitor cells modulate vascular 
 reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a 
 reductase inhibition. Arterioscler Thromb Vasc Biol. 2002;22:1567-1572.
(91)  Cho HJ, Kim HS, Lee MM et al. Mobilized endothelial progenitor cells by granulocyte-macrophage 
 colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after 
 intravascular radiation. Circulation. 2003;108:2918-2925.
(92)  Hu Y, Davison F, Zhang Z, Xu Q. Endothelial replacement and angiogenesis in arteriosclerotic lesions 
 of allografts are contributed by circulating progenitor cells. Circulation. 2003;108:3122-3127.
(93)  Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial 
 progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 
 2001;89:E1-E7.
(94)  Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and 
 cardiovascular risk. N Engl J Med. 2003;348:593-600.
(95)  Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic 
 complications. JAMA. 2002;288:2579-2588.
 Chapter 1
32
(96)  Nathan DM, Lachin J, Cleary P et al. Intensive diabetes therapy and carotid intima-media thickness in 
 type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-2303.
(97)  Waltenberger J. Impaired collateral vessel development in diabetes: potential cellular mechanisms and 
 therapeutic implications. Cardiovasc Res. 2001;49:554-560.
(98)  Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 
 1979;241:2035-2038.
(99)  Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, 
 clinical consequences, and medical therapy: Part I. Circulation. 2003;108:1527-1532.
(100)  Inoguchi T, Sonta T, Tsubouchi H et al. Protein kinase C-dependent increase in reactive oxygen species 
 (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc 
 Nephrol. 2003;14:S227-S232.
(101)  Piconi L, Quagliaro L, Assaloni R et al. Constant and intermittent high glucose enhances endothelial 
 cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev. 2006.
(102)  Kurz DJ, Decary S, Hong Y et al. Chronic oxidative stress compromises telomere integrity and 
 accelerates the onset of senescence in human endothelial cells. J Cell Sci. 2004;117:2417-2426.
(103)  Serrano AL, Andres V. Telomeres and cardiovascular disease: does size matter? Circ Res. 
 2004;94:575-584.
(104)  Woywodt A, Bahlmann FH, de Groot K, Haller H, Haubitz M. Circulating endothelial cells: life, death, 
 detachment and repair of the endothelial cell layer. Nephrol Dial Transplant. 2002;17:1728-1730.
 General intoroduction
33
                                                                                   
                                                                                   
Arterioscler. Thromb Vasc Biol. 2005, 25: 1843-1850
Chapter 2
CD34+ Cells Home, Proliferate and 
Participate in Capillary Formation, and in 
Combination With CD34- cells Enhance Tube 
Formation in a 3-Dimensional Matrix
Maarten B. Rookmaaker1, Marianne C. Verhaar1, Cindy J.M. 
Loomans2,3, Robert Verloop6, Erna Peters4, Peter E. Westerweel1 
Toyoaki Murohara5, Frank J.T. Staal3, Anton Jan van Zonneveld2, 
Pieter Koolwijk4, Ton J. Rabelink2, Victor W.M. van Hinsbergh6
1Department of Vascular Medicine, University Medical Center Utrecht, the Netherlands; 
2Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands; 
3Department of Immunology, Erasmus Medical Center, Rotterdam, the Netherlands; and 
4Department of Biomedical Research, Gaubius Laboratory TNO-PG, Leiden, the Netherlands; 
5Department of Cardiology, Nagoya University Graduate School of Medicine, Japan; and 
6Department of Physiology, VU University Medical Center, Amsterdam, the Netherlands.
 Chapter 2
36
Abstract
Objective
Emerging evidence suggests that human blood contains bone marrow (BM)-derived 
endothelial progenitor cells that contribute to postnatal neovascularization. Clinical trials 
demonstrated that administration of BM-cells can enhance neovascularization. Most 
studies, however,  used crude cell populations.  Identifying the role of different cell 
populations is important for developing improved cellular therapies. 
 
Methods and Results
Effects of the hematopoietic stem cell-containing CD34+ cell population on migration, 
proliferation, differentiation, stimulation of, and participation in capillary-like tubule 
formation were assessed in an in vitro 3-dimensional matrix model using human 
microvascular endothelial cells. During movement over the endothelial monolayer, CD34+ 
cells remained stuck at sites of capillary tube formation and time- and dose-dependently 
formed cell clusters. Immunohistochemistry confirmed homing and proliferation of CD34+ 
cells in and around capillary sprouts. CD34+ cells were transduced with the LNGFR marker 
gene to allow tracing. LNGFR gene-transduced CD34+ cells integrated in the tubular 
structures and stained positive for CD31 and UEA-1. CD34+ cells alone stimulated 
neovascularization by 17%. Coculture with CD34- cells led to 68% enhancement of 
neovascularization, whereas CD34- cells displayed a variable response by themselves. Cell-
cell contact between CD34+ and CD34- cells facilitated endothelial differentiation of CD34+ 
cells.
Conclusions
Our data suggest that administration of CD34+-enriched cell populations may significantly 
improve neovascularization and point at an important supportive role for (endogenous or 
exogenous) CD34- cells.
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Introduction
The formation of new capillaries plays a critical role in physiological and pathological 
processes such as wound healing,  ischemia and tumor growth. It has long been thought that 
postnatal neovascularization occurred exclusively by migration and proliferation of 
preexisting endothelial cells (angiogenesis).  Increasing evidence indicates that bone 
marrow (BM)-derived circulating endothelial progenitor cells (EPCs) are also involved in 
postnatal new vessel formation a process that1, reminiscent of embryonic vessel formation, 
is termed adult vasculogenesis2. The concept of ‘therapeutic vasculogenesis’, 
administration of adult progenitor cells or progenitor-containing cell populations to 
stimulate neovascularization, and the potential of progenitor cells to serve as new vehicles 
for gene therapy has received a lot of scientific attention. Several small clinical trials aimed 
at therapeutic vasculogenesis by autologous transplantation of BM cells have been 
performed and improved clinical outcomes in patients with severe chronic limb ischemia or 
myocardial ischemia have been reported3-6.
An important question concerning therapeutic vasculogenesis is, which cell population 
should be administered? Thus far, most clinical studies have used nonselected BM 
mononuclear cells; however, administration of such crude cell populations may have 
unwanted side effects. Recent data suggest that beside EPCs, BM contains other progenitor 
cells that may contribute to atherosclerosis7, whereas hematopoietic cells were reported to 
have the capacity to produce profibrotic and angiogenic factors8,9.  Better characterization of 
the BM cell subpopulation that can generate EPCs is of critical importance to development 
of safer and better-targeted cellular therapies.
Several studies have suggested that in human postnatal life, analogous to the existence of 
the embryonic hemangioblast10, the CD34+ hematopoietic stem cell population contains 
cells that can give rise to EPCs and endothelial cells1,11,12. This would suggest the potential 
use of CD34+-enriched cell populations in therapeutic vasculogenesis. Various authors 
reported that administration of human leukocytes enriched for CD34+ cells effectively 
enhanced neovascularization in animal models1,13,14. However,  it has been argued that, 
because of lack of purity of the CD34+-enriched cell populations and use of vital dye 
labeling of CD34+ cells with possible dye transfer among cells, definitive proof that CD34+ 
cells are angioblasts is lacking15. Several investigators pointed at a more important role for 
the CD34-CD14+ monocytic cell population15-19. Interestingly, recent reports suggest that 
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the majority of blood-derived cultured acetylated low-density lipoprotein (LDL) and Ulex 
europeus double-positive cells,  which are commonly referred to as EPCs, may be derived 
from monocytes/macrophages20.  We previously demonstrated that a minor but significant 
subset (≈9%) of cultured EPCs originates from the CD34+ mononuclear cell population21. It 
has been suggested that EPCs derived from the monocyte/macrophage cell population exert 
their beneficial proangiogenic effects mainly by growth factor secretion and should be more 
appropriately called circulating angiogenic cells (CACs), whereas the hematopoietic stem 
cell-related populations may yield ‘late outgrowth EPCs’ in culture, also referred to as ‘the 
true EPCs,’ enhancing neovasculogenesis by providing a sufficient number of endothelial 
cells based on their high proliferation potency20-22.
 
The present study was conducted to determine the exact role of CD34+ cells in human 
neovascularization. Thus far, most studies on human vasculogenesis were performed with 
human cells in small animal models lacking an intact immune system. We have used a 3-
dimensional (3D) in vitro neovascularization model to study the role of human CD34+ cells 
in vasculogenesis and angiogenesis in a human microvascular endothelial system under 
controlled circumstances. This model provides a tool to dissect the different mechanisms 
involved: migration, proliferation, differentiation, stimulation of, and participation in 
capillary formation.
Methods
Materials
Histopaque 1077, diaminobenzidine (DAB), KDR antibodies (Clone KDR1) and 
tetramethyl rhodamine isothiocyanate (TRITC)-labeled Ulex europeus were obtained from 
Sigma Chemicals, St. Louis, MO; DiI-labeled acLDL from Biomedical Technologies Inc, 
Stoughton, MA; histofine AEC solution from Nichirei, Tsukiji, Chuo-Kutokyo, Japan; VE-
cadherin antibodies (clone BV6:MAB1989) from Chemicon, Temecula, CA; eNOS 
anitbodies from Transduction Laboratories, Lexington, KY; fluorescein isothiocyanate 
(FITC)-conjugated anti-human CD34 (clone8G12) antibodies, phycoerythrin (PE)-labeled 
goat anti-mouse IgG1-antibodies, FITC-labeled polyclonal goat anti-mouse antibodies and 
the Calibur flow cytometer from Becton Dickinson, Mountain View, CA; mouse anti-
human CD31 antibodies, and anti-Ki67 antibodies (clone MIB-1) from DAKO, Glostrup, 
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Denmark; powervision goat anti-mouse poly-HRP-conjugates from Immunovision 
Technologies, Springdale, AR; FITC-conjugated streptavidin, TRITC-conjugated 
streptavidin, biotin blocking kit, ABC-mouse-kit,  normal horse serum, biotinylated anti-
mouse IgG, avidin DH solution,  biotinylated peroxidase and vectashield from Vector 
Laboraties, Burlingame, CA; the magnetic cell sorter (MACS) from Miltenyi Biotec, 
Gladbach, Germany; StemPro-34-SFM medium (SCM), heat-inactivated newborn calf 
serum (NBCS) and fetal calf serum (FCS) from GibcoBRL, Grand Island, NY; stem cell 
factor (SCF), flt-3 ligand (FL), thrombopoietin (TPO) and basic fibroblast growth factor 
(bFGF) from Pepro Tech, Rocky Hill,  NY; mouse anti-human LNGFR antibodies (clone 
20.4) and the lymphoblast cell line Raji from ATCC, Manassas, VA; penicillin, 
streptomycin and medium 199 (M199) from Biowittaker, Verviers, Belgium; L-glutamine 
from ICN, Costa Mesa, CA; heparin from Leo Pharmaceutic Products, Weesp, The 
Netherlands; 0.4µm pore trans-well system from Costar,  Cambridge, MA. Tumor necrosis 
factor-α (TNF-α) was a kind gift of Dr J. Travernier, Biogent, Gent, Belgium. Blocking 
antibodies against P-selectin (AF137), E-selectin (AF724),  VCAM (BBA5) and ICAM-1 
(BBA3) were all obtained from R&D Systems, Minneapolis MI.
Isolation of human CD34+ cells
Mononuclear cells (MNCs) were isolated from human umbilical cord blood (hCB) by 
density centrifugation (Histopaque 1077). Cells were washed and CD34+ cells were isolated 
by magnetic bead separation method (MACS). The residual cells,  depleted from CD34+ 
cells, served as CD34- cell population. The purity of the cell populations was analyzed by 
flow cytometry. Protocols for sampling hCB were approved by the institutional ethical 
committee. Written informed consent was obtained from all mothers before labor and 
delivery.
Genetic marking of CD34+ cells
CD34+ cells were cultured for 2 days with StemPro-34-SFM medium containing stem cell 
factor, flt3 ligand and thrombopoietin. Genetic marking was performed as described 
previously23 using a retrovirus encoding the truncated low-affinity nerve growth factor 
receptor (LNGFR) as a marker gene. After transduction, CD34+ cell selection was repeated 
as described to remove cells that had lost CD34 expression during transduction. 
Transduction efficiency and CD34+ selection were evaluated by flow cytometry.
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Flow cytometry
After MACS separation of CD34+ cells the different cell populations were analysed by 
FACS. To evaluate the purity of the sorted cell populations,  25000 cells were stained FITC-
conjugated anti-human CD34 and analyzed using a Calibur flow cytometer. As negative 
control the first antibody was substituted with an irrelevant murine IgG of the same 
subclass.
After transfection of CD34+ cells with LNGFR, CD34+ cell selection was repeated to 
remove cells that had lost CD34 expression during transduction. Aliquots of 25000 cells 
were incubated with mouse anti-human LNGFR-antibody. A PE-labeled goat anti-mouse 
IgG1-antibody was used as secondary antibody. Subsequently cells were incubated with 
FITC-conjugated anti-human CD34-antibody. Controls were included by substituting the 
primary antibody by an irrelevant antibody of the same subclass. 
Differentiation and characterization of EPC/CAC
EPC/CAC were obtained as previously described24 by culturing hCB-MNC at a density of 
2*106 cells/cm2 on a gelatin-coated 6-well plate in M199 medium containing 20% fetal calf 
serum, penicillin/streptomycin, endothelial cell growth factor (ECGF), and heparin. At day 
7, nonadherent cells were removed by thorough washing. Adherent cells were harvested 
and used in the 3D neovascularization assay as described. 
To confirm endothelial phenotype, a subset of EPC/CAC were cultured on gelatin-coated 
coverslips for 7 days, fixed in cold methanol (-20ºC) and immunostained for the expression 
of the endothelial markers vascular endothelial (VE)-cadherin, endothelial nitric oxide 
synthase (eNOS) and kinase insert domain receptor (KDR) was performed using the ABC-
mouse-kit. After blocking with normal horse serum for 30 minutes cells were incubated 
with the primary antibody (VE-cadherin, eNOS, KDR) at 37°C for 1 hour, followed by 
incubation with biotinylated anti-mouse IgG and normal horse serum for 1 hour at 37.5°C. 
Subsequently, the cells were incubated in 2% avidin DH solution and 2% biotinylated 
peroxidase for 1 hour at 37°C. As chromogen the histofine AEC solution was used.  To 
assess the ability to take up acetylated LDL (acLDL) cells were incubated with DiI-labeled 
acLDL for 4 hours at 37°C and after fixation were incubated with FITC-labeled Ulex 
europeus agglutinin-I for 1 hour. For CD31-staining the fixed cells were incubated with 
mouse anti-human CD31 antibody for 1 hour, followed by incubation with FITC-labeled 
polyclonal goat anti-mouse antibodies. For all stainings controls were included in which the 
primary antibody was replaced by PBS or an irrelevant antibody of the same subclass.  
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In vitro neovascularization assay 
Human foreskin MVEC were isolated, cultured, and characterized as described 
previously25. Cells were cultured until confluence at 5% CO2/95% air on gelatin-coated 
dishes in M199 medium, supplemented with 2 mM L-glutamine, 20 mM HEPES (pH 7.3), 
10% heat-inactivated human serum (serum pooled from 10 donors,  obtained from a local 
blood bank), 10% heat-inactivated newborn calf serum (NBCS), 150 µg/mL endothelial cell 
growth factor (ECGF, prepared from bovine brain), 5 IU/mL heparin,  100 IU/mL penicillin 
and 100 µg/mL streptomycin at 37°C. Subcultures were obtained by trypsin/EDTA 
treatment of confluent monolayers at a split ratio of 1:3. The experiments were performed 
with confluent cells (0.7*105 cells/cm2) from passage 10-11 that were cultured without 
growth factor for at least 24 hours.
The in vitro neovascularization assays were performed in human fibrin matrices as 
described previously26. In short, highly confluent hMVECs (0.7*105 cells/cm2) were seeded 
in a 1.25:1 split ratio on fibrin matrices and cultured in M199 medium supplemented with 
10% human serum, 10% newborn calf serum, penicillin/streptomycin, basic fibroblast 
growth factor (bFGF) and tumor necrosis factor-α (TNF-α). After 24 hours, the medium 
was replaced with medium containing the mediators, with or without different cell 
populations. Fresh medium was added every second day. Invading cells and tubular 
structures of hMVECs in the 3D fibrin matrix were analyzed by phase-contrast microscopy. 
The length and amount of the tube-like structures was determined using an Olympus-CK2 
microscope equipped with a monochrome charge-coupled device camera (MX5) connected 
to a computer with Optimas image analysis software. Six fixed microscopic fields (7.3 mm2 
per field) per well were analyzed and used to calculate the total length of the tube-like 
structures, expressed as mm/cm2.
The effects of CD34+ cells on in vitro capillary formation: homing to foci of 
neovascularization
To compare different cell populations for their migrational behavior on the angiogenic 
hMVEC monolayer,  cells were added to the hMVEC culture medium in concentrations of 
1% and 10% (expressed as a percentage of the total number of hMVECs seeded on the 
fibrin gel) 24 hours after seeding of the hMVEC. The following cell populations were 
studied: CD34+ cell-enriched hCB-MNC (1%CD34+, 10%CD34+); CD34+ cell-depleted 
hCB-MNC (1%CD34-, 10%CD34-); and human umbilical vein endothelial cells (HUVEC) 
and cells from a lymphoblast cell line (Raji) as proliferating nonangioblast leukocyte-like 
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cell population27. The hCB-MNCs were obtained from 5 donors. All experiments were 
performed in duplicate. The cultures were evaluated 7 days after addition of the cells to the 
hMVEC culture by 2 independent and blinded observers using phase-contrast microscopy. 
Additionally, immunohistochemical analysis of cross-sections was performed.
The movement of CD34+ cells on MVEC monolayers was recorded by time-lapse video 
phase contrast microscopy during the initial 8 hour period (1 frame per 30 seconds). The 
movement of individual cells was followed in time. The number of CD34+ cells that 
reached and those that remained stuck at tubular structures were counted. The number of 
cells that entered and remained in randomly taken comparable areas without capillary tubes 
were evaluated as controls. 
Blocking antibodies against P-selectin (25µg/ml), E-selectin (50µg/ml), vascular cell 
adhesion molecule (30µg/ml), and intercellular adhesion molecule-1 (10µg/ml) were added 
30 minutes before CD34+ cells and their effects on CD34+ cell accumulation at tubular 
structures were evaluated after 24 and 72 hours (medium was renewed after 24 hours).
Participation in new capillary formation
To investigate whether CD34+ cells participate in the formation of new capillary-like tubes, 
LNGFR-transduced CD34+ cells were used. LNGFR-transduced CD34+ cells and 
nontransduced CD34+ cells were compared for phenotypic and functional characteristics. 
LNGFR-transduced CD34+ cells were added to the hMVEC monolayer alone and together 
with CD34- cells. After 7 days, cultures were terminated and prepared for 
immunohistochemical analysis. 
Stimulation of new capillary formation
The effects on 3D capillary-like tube formation were studied for CD34+ cells alone (1% 
CD34+), CD34+ cells together with CD34- cells (1% CD34+/10% CD34-, ie, ratio of 1:10, 
whereas the physiological ratio is 0.5:99.5), CD34- cells alone, EPC/CAC (1%), HUVECs, 
and Raji cells. The effects of subpopulations of hCB-MNC on new capillary formation were 
assessed in 9 independent experiments (9 hCB donors). All experiments were performed in 
duplicate. Cell populations were added to the hMVEC culture medium 24 hours after 
seeding of the hMVEC monolayer. Cultures were evaluated 7 days later. Total tube length 
was measured as described and expressed as percentage of tube length formed by bFGF/
TNF-α-stimulated hMVECs. 
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Immunohistochemical analysis 
Fibrin matrices were fixed and embedded in paraffin. Sections (5µm) were stained for 
LNGFR to identify labeled CD34+ cells and were analyzed by light microscopy. The 
number of LNGFR+ cells containing a nucleus was counted and averaged over 5 cross-
sections by a blinded observer and expressed as a percentage of the total amount of 
nucleus-containing cells in the monolayer.
To study proliferation of LNGFR+ cells in situ, consecutive sections were stained for 
LNGFR or Ki67 (expressed on all proliferating cells during late G1, S, G2, and M phases 
of the cell cycle)28. Fibrin matrices were fixed at 4°C in 2% p-formaldehyde in PBS 
(pH=7.4), and embedded in paraffin. Serial sections were cut (5µm) perpendicular to the 
surface of the matrix sheet. Sections were deparaffinated, blocked in buffer containing 
1.5% hydrogen peroxide and incubated in citrate buffer of 100°C for 20 minutes. Sections 
were washed and incubated with 150µl primary antibody (anti-LNGFR or anti-Ki67) for 60 
minutes at 21°C. After washing sections were incubated with 150µl PowerVision goat anti-
mouse poly-HRP-conjugates for 20 minutes 37°C. Diaminobenzidine was added as 
colouring substrate. Sections were counterstained with hematoxylin and mounted with 
pertex. Negative controls included substitution of the primary antibody with PBS or with an 
irrelevant murine IgG of the same subclass. Sections were analyzed by light microscopy. 
The number of LNGFR+ cells containing a nucleus was counted and averaged over 5 cross-
sections by a blinded observer. The amount of LNGFR+ cells containing a nucleus was 
expressed as a percentage of the total amount of nucleus containing cells in the monolayer. 
Immunofluorescence double-staining
Immunofluorescence double staining for LNGFR and CD31 or Ulex europeus lectin was 
performed to confirm the endothelial phenotype of LNGFR+, CD34+ cell-derived cells in 
newly formed capillaries. For LNGFR/CD31 double-staining a biotin-streptavidin detection 
system was applied. After blocking of endogenous biotin activity, sections were incubated 
with 100 µl of the first biotinylated anti-LNGFR primary antibody for 60 minutes, followed 
by incubation with 100 µl FITC-conjugated streptavidin for 30 minutes at room 
temperature. To augment the signal, sections were subsequently incubated with 100 µl anti-
streptavidin-FITC for 30 minutes. Remaining biotin binding sites were blocked and 
sections were incubated with 100 µl biotin-labeled anti-CD31 for 60 minutes followed by 
incubation with 100 µl TRITC-conjugated streptavidin for 30 minutes at room temperature. 
Sections were air-dried and mounted with Vectashield. Controls were included in which the 
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procedure was performed with omission of the primary antibody or substitution of the 
primary antibody with an irrelevant murine IgG of the same subclass.
For LNGFR/Ulex europeus double staining, sections were incubated in 100 µl anti-LNGFR 
for 30 minutes,  followed by incubation with 100 µl FITC-labelled polyclonal goat anti-
mouse for 30 minutes at room temperature. Subsequently, the sections were incubated in 
100 µl TRITC-labelled Ulex europeus for 30 minutes at room temperature and air-dried and 
mounted with Vectashield. 
Interaction between CD34+ and CD34- cells
To investigate the interaction between CD34+ and CD34- cells, we performed several 
differentiation experiments. Differentiation cultures to obtain EPC/CAC were performed as 
described. CD34+ cells were cultured in the presence or absence of CD34- cells (ratio 
1:100). Subsequently, cultures were performed in which CD34+ and CD34- cells were 
separated by a 0.4µm pore trans-well system allowing diffusion of soluble factors without 
physical contact between CD34+ and CD34- cells. Differentiation was expressed as total 
number of attached cells per mm2 or as number of attached cells relative to the number of 
cultured cells.
Statistical analysis 
The data are expressed as mean ± standard error of mean (SEM) unless otherwise specified. 
Because of variations in basal tube formation between different batches of hMVECs, 
stimulation of capillary-like tube formation is expressed as percentage of tube length formed 
by bFGF/TNF-α-stimulated hMVECs (ie,  versus ’control’  culture).  To determine whether the 
different cell populations (CD34+, CD34-, CD34+/- derived from the same 9 donors or EPCs, 
derived from 4 different donors) stimulated capillary-like tube formation significantly as 
compared with the reference value of 100%, 1-sample t tests with Bonferroni correction were 
performed. To compare the growth stimulating effects of CD34+ and CD34+/- cells, which 
were all derived from the same 9 donors,  a paired t test was performed. To compare the growth 
stimulating effect between CD34+ or CD34+/- cells and EPC, which are derived from 4 
different donors, separate independent sample t tests with Bonferroni correction were used. 
P<0.05 was considered statistically significant. 
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Results
Isolation and selection of CD34+ cells
Flow cytometry demonstrated that in the cell population that was enriched for CD34+ cells, 
90.1±1.8% of cells were CD34+. The CD34- cell population was largely depleted from 
CD34+ cells (99.8±0.1% CD34- cells). 
Characterization of EPC/CAC
Adherent EPC/CAC after 7 days of culture were characterized by immunohistochemistry. 
More than 90% of cells displayed a spindle-shaped morphology and stained positive for 
endothelial nitric oxide synthase, VE-cadherin, VEGFR2 (KDR), CD31, Ulex europeus 
lectin, and DiI-acetylated LDL uptake. All controls were negative. In long-term cultures (6 
weeks), clusters and confluent monolayers of cobblestone-like cells were formed (Figure 
1).
CD34+ cells home to foci of neovascularization
hMVECs seeded on top of a fibrin matrix and cultured without addition of growth factors 
or cytokines remained as a quiescent monolayer on top of the matrix.  When the hMVECs 
were exposed to both bFGF and TNF-α,  they invaded the underlying fibrin matrix and 
formed capillary-like tubular structures (Figure 2A and 2C). When CD34+ cell-enriched 
hCB-MNC were added to the hMVEC culture medium, formation of cell clusters was 
observed, specifically located at the sites of new capillary-like tube formation (Figure 2G 
and 2H). Addition of higher concentrations of CD34+ cells resulted in larger cell clusters 
(Figure 2B versus 2D and 2E).  In contrast,  no such clusters were seen in the cultures to 
which CD34- cells or HUVECs were added (data not shown). In the cultures to which cells 
from the Raji lymphoblast cell line were added, there was a large number of cells and cell 
clusters present already at day 2 (Figure 2F). However, they did not colocalize with newly 
formed capillary-like structures but were randomly scattered throughout the culture. Time-
lapse video image microscopy during the first 8-hour period revealed that the CD34+ cells 
moved randomly over the endothelial monolayer and remained stuck at the vascular 
structures once they reached them (Table 1). No accumulation was seen in randomly chosen 
control fields of the monolayers.  Viability of the homing cells was confirmed using a 
calcein uptake assay.  Addition of antibodies against P- and E-selectin, vascular cell 
adhesion molecule, and intercellular adhesion molecule-1, either alone or simultaneously, 
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did not reduce the accumulation of CD34+ cells at the vascular structures (tested with 3 
CD34+ populations from different donors) (Figure 3).
 
Figure 1
Characterization of EPC/CAC after 7 days of culture: expression of eNOS, perinuclear in the Golgi-
system (A); VE-cadherin staining at cell-cell contacts (B); KDR staining (C); CD31 staining with typical 
membrane expression (D, confocal scanning laser microscopy). Ulex europaeus positive cells (E) take up 
DiI-labeled AcLDL (F) in double-staining experiments. In long-term cultures (6 weeks) formation of cell 
clusters and confluent monolayers of cobble stone-like cells is observed (G, H). Magnification (A-F, H) 
630x; G 100x.
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CD34+ cells participate in new capillary formation 
To study the contribution of CD34+ cells to new capillary-like tube formation, CD34+ cells 
were retrovirally transduced with the marker gene LNGFR. The CD34+ cell population that 
was genetically marked with the LNGFR gene contained 92±2.6% CD34+ cells, which is 
similar to the nontransduced CD34+ cell-enriched mononuclear fraction. Transduction 
efficiency with the LNGFR gene was 39.3±2.9%. After retroviral transduction with the 
LNGFR gene CD34+ cells maintained their phenotypic and functional characteristics. 
Addition of transduced CD34+ cells to hMVEC monolayers caused similar homing of cells 
to angiogenic sites as observed after addition of nontransduced CD34+ cells. Addition of 
transduced CD34+ cells to hMVEC monolayers also caused a stimulatory effect on bFGF/
TNF-α-induced new capillary-like tube formation that was similar to the effect observed 
after addition of nontransduced CD34+ cells (data not shown). Immunohistochemical 
staining of cross-sections confirmed homing of LNGFR+ cells in and around new capillary 
sprouts and showed that LNGFR gene-marked cells participated in new capillary-like 
structures (Figure 4A). The transduced cells were fully integrated in the angiogenic 
endothelium and stained positive for the endothelial markers CD31 and Ulex europeus 
lectin (Figure 4B to 4G). In several sections LNGFR+ cells were observed deep in the 
tubular structures, suggesting a pioneering role of CD34+ cells (Figure 4A and 4F).  Double-
staining with proliferation marker Ki67 showed that 25% to 40% of the LNGFR+ cells were 
proliferating (Figure 4H and 4I). All controls were negative.
 
CD34+ cells accumulate specifically on endothelial tubular structures. Quantification of the accumulation 
of CD34+ cells was made by time-lapse video microscopy. CD34+ cells (104 cells per cm2) were added 
to monolayers of hMVECs that had been induced to generate tubular structures by incubation with bFGF 
and TNF-α. The movement of individual CD34+ cells over the endothelial monolayer was monitored 
between 2 and 8 hours after addition of the cells. To that end, 5 tubular structures in a field were encircled 
and the number of CD34+ cells that entered and left the marked areas were monitored. As controls, the 
surface areas of the 5 structures were projected in 3 directions to only monolayer areas without tubules or 
sprouting in the same microscopic field. The cell numbers of the 3 sets of control data were highly 
comparable and their sum is given for both experiments. Cell accumulation is given as the mean ± range.
Table 1
Experiment 1 Experiment 2 Cell Accumulation 
(% of Cells Entering the Area)
Tubular structures 13/16 27/34 80 ± 1%
Nonstructure monolayer
(sum of 3 control areas):
3/56 5/130 4.6 ± 1.2 %
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 Figure 2
HMVECs were seeded at confluent density on top of a 3D fibrin matrix and stimulated with bFGF (5 ng/
ml) and TNF-α (4 ng/ml). A,B,D,E Nonphase contrast photomicrographs after 7-day culture without (A) 
or with 1% CD34+ cells (B) or 10% CD34+ cells (D,E), which were added 24 hours after seeding the 
hMVECs. A, The arrows indicate sites of capillary-like tube formation by hMVEC. C, Cross-section of 
tubular structures at higher magnification. B,D,E, When 1% (B) or 10% CD34+ cells (D,E) were added to 
the hMVEC monolayer, clusters of CD34+ cells accumulated at sites of capillary-like tube formation. G, 
Cluster formation at angiogenic sites was visible after 4 days of culture after addition of 10% CD34+ cells 
(2x larger magnification). H, Early accumulated CD34+ cells at higher magnification. Addition of 1% or 
10% CD34- cells or 1% or 10% HUVECs did not cause such cell clustering. F, Addition of Raji cells 
(10%) led rapidly to increased amounts of cells and cell clusters, which were randomly scattered 
throughout the culture without preference for tubular structures. Nonphase photomicrographs were taken 
after 7 days of culture except for (G) and (H) (phase contrast), which were taken at day 4 and 3, and (F), 
which was taken at day 2 because of the extensive cell proliferation and overgrowth. A-E, Data are 
representative photographs of 6 independent experiments using CD34+ cells from different donors. 
Similar results were obtained when tubular structures were induced by addition of VEGF (20 ng/mL) and 
TNF-α (4 ng/mL). A,B,D-F, Same magnification.
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Quantification of LNGFR+ cell participation in capillary formation suggested that addition 
of CD34+ cells (1%) to the hMVEC monolayer led to a contribution of CD34+ cells of 1.0
±0.5% to the new vascular structures. This implies a significant incorporation of CD34+ 
cells in the endothelial lining, which was estimated >10% of the added CD34+ cells. The 
exact percentage of participation is difficult to estimate because CD34+ cells proliferated 
during the 7 days of incubation. 
It should be noted that the transduction efficiency of almost 40% causes a 2.5-fold 
underestimation of the total amount of participating CD34+ cells. 
CD34+ cells stimulate neovascularization, which is further enhanced by coculture with 
CD34- cells
Figure 5 shows the effect of different hCB-MNC subpopulations on capillary formation in 
the 3D fibrin matrix. Addition of 1% EPC/CAC to the hMVEC-monolayer caused a 60
±12% increase in capillary formation (p<0.05 versus controls). Overall, if CD34+ cells 
alone (>90% purity) were added to the hMVEC monolayer,  only a slight increase in new 
capillary-like tube formation was observed (17±5% increase compared with controls, 
p<0.05). When CD34+ cells were added in combination with CD34- cells, a considerable 
increase of total tube length was found, which was similar to the effect of cultured EPC/
CAC (68±15%; p<0.05). Overall, CD34- cells alone did not cause a significant increase in 
tube length (Figure 5A). However, 2 types of responses could be distinguished in the 
responding cells. In preparations of 6 different donors CD34- cells alone did not 
 
Figure 3
Cluster formation of CD34+ cells at 
sites of capillary-like tube formation. 
Culturing of cells in control medium 
(A); medium containing antibodies 
against P-selectin and E-selectin (B); 
medium containing antibodies against 
I-CAM and V-CAM (C); or medium 
containing antibodies against both P-
selectin and E-selectin, as well as I-
CAM and V-CAM (D), did not reduce 
CD34+-cell accumulation at vascular 
structures.
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 Figure 4
Histological sections showing homing, participation and differentiation of LNGFR gene-marked CD34+ 
cells in the capillary-like tubular structures in a fibrin matrix (400x). LNGFR gene-marked cells (LNGFR+ 
stained brown) home to sites of capillary formation, incorporate, become fully integrated in the endothelial 
cell monolayer, and acquire a phenotype that is morphologically similar to endothelial cells (A). LNGFR 
gene-marked cells can also be found deeper in the tubular structures in direct contact with the matrix (A, 
arrow). The small window within (A) gives a schematic overview. Immunofluorescent double-staining for 
LNGFR (green) (B) and Ulex europeus lectin (red) (C) strongly suggests that incorporated CD34+ cells 
differentiate into endothelial cells (yellow) (D). Homing cells before incorporation do not stain positive for 
the endothelial cell marker (arrow) (E). Some of the cells at the tip of the vascular in-growth are negative 
for the endothelial cell marker, suggesting a higher angiogenic capacity of EPC in an earlier phase (F). 
Immunofluorescent double-staining  for LNGFR (green) and CD31 (red) also implies endothelial 
differentiation of LNGFR gene-marked CD34+ cells (yellow) (G). Histological analysis of consecutive 
cross-sections of capillary-like tubular structures shows the presence of proliferating LNGFR gene-marked 
cells. H, LNGFR staining (brown). I, Corresponding consecutive cross-section, stained for Ki-67 nuclear 
antigen, expressed on proliferating cells (dark nuclear staining). The open arrows indicate LNGFR-Ki67 
double-positive cells, indicating the presence of proliferating CD34+ cell-derived cells.
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significantly increase tube length. In these preparations, stimulation of growth of vascular 
structures was only observed when CD34+ and CD34- cells were added together, whereas 
none of the separate preparations induced a significant response (Figure 5B).  In the 
preparations of 3 other donors the CD34- cells were able to increase the extent of 
endothelial tube formation by themselves, which could not be further enhanced by the 
presence of CD34+ cells (Figure 5C).  The latter finding suggests that in certain 
circumstances, for example when CD34- cells are in an activated state, CD34- cells may 
have a predominant effect on the observed tube length enhancement.  Neither HUVEC nor 
cells from the Raji cell line significantly influenced total tube length. 
Interaction between CD34+ and CD34- cells 
When isolated CD34+ cells were cultured alone, no differentiation into EPC occurred (0
±0%). However, coculturing of CD34+ cells with CD34- cells resulted in a significant 
increase in EPC differentiation (122±11/mm2, p<0.000 versus CD34+ cells alone). To assess 
whether this increase in differentiation rate was induced by soluble growth factors, CD34+ 
cells were cultured separated from CD34- cells by a membrane that allowed soluble 
molecules to diffuse freely but prohibited physical contact between CD34+  and CD34- 
cells. EPC differentiation from CD34+ cells in these cultures was rarely observed (6±1/
mm2, p=1.0 versus CD34+ cells alone). Subsequently, experiments were performed in 
which CD34+ cells were labelled with PKH-26. Previous experiments showed that with this 
labelling method under these specific culturing conditions for a period of 7 days minimal 
dye transfer (<0.1%) occurred. We observed that coculturing of CD34+ and CD34- cells led 
to a significant increase in differentiation of CD34+ cells to EPC as compared with cultures 
in which CD34+ cells were cultured alone or cultures in which CD34+ and CD34- cells were 
separated using a transwell system (72±9% versus 0% or 1.5±0.3%; p<0.05). These 
experiments suggest that cell-cell contact between CD34+ and CD34- cells is necessary for 
endothelial differentiation of CD34+ cells. 
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 Figure 5
Effects of different subpopulations of hCB-MNC on capillary-like tube formation. The left 
part of (A) shows the effects of different subpopulations of hCB-MNC on capillary-like 
tube formation expressed as a percentage of tube length formed by bFGF/TNF-α-stimulated 
hMVEC. The nonphase photomicrographs show representative examples of the observed 
tube formation in the hMVEC monolayer in the presence of the respective hCB-MNC 
subpopulations. CD34+ cells were added to the hMVEC culture medium in a concentration 
of 1% either alone (+) or in combination with 10% CD34- cells (+/-) and compared with 
control cultures (bFGF/TNF-α-stimulated hMVEC without addition of cell-populations). 
Data are expressed as mean±SEM of 9 independent experiments (9 hCB donors). The right 
part of (A) shows the effects of hCB-derived cultured EPCs/CACs (EPC) on tube formation 
under the same conditions as the left panel and represent the mean±SEM of 4 independent 
experiments. NS indicates nonsignificant. * Significant increase compared with controls 
(p<0.05). ** Significant increase compared with 1%CD34+ stimulation (p<0.05).  B and C, 
Effects of the 2 subpopulations of the hCB-MNC given in (A) on capillary-like tube 
formation, namely those in which there was no significant influence on tube formation by 
the sole addition of the CD34- cells (B; n=6) and the subset of the 3 CD34- cell preparations 
that were able to increase the extent of endothelial tube formation themselves.
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Discussion
In the present study,  we used a recently developed in vitro 3D model to study different 
aspects of human adult vasculogenesis under controlled circumstances and demonstrate that 
human CD34+ cells selectively home to sites of angiogenic microvascular human 
endothelium, proliferate, become fully integrated in the microvascular endothelial 
monolayer, are able to differentiate into endothelial cells in situ, and have a mild but 
significant stimulatory effect on new capillary formation. Interestingly, if CD34+ cells are 
cultured on an hMVEC monolayer in the presence of CD34- cells this results in marked 
enhancement of neovascularization similar to the effect of cultured EPC/CAC. 
Although evidence is accumulating that vasculogenesis occurs in human postnatal 
life1,12,29-31, the origin of the EPC is still under dispute. Previous studies suggested CD34+ 
cells as main source of EPC but were criticized because of CD34+-enriched cell populations 
of low purity and the possibility of vital dye transfer among cells. Our experiments, using 
CD34+ cells of high purity (>90%) and a very stable cell labeling method, ie, retroviral 
transduction with the marker gene LNGFR which results in permanent insertion of the 
LNGFR gene in the cells, strongly support a role for CD34+ cells as a source of EPC. 
Moreover, our data indicate that retroviral vectors can effectively transduce CD34+ cells 
and that transduction with a marker gene does not influence their phenotype, homing, or 
angiogenic capacity. Together with the ability of purified CD34+ cells to selectively home 
to angiogenic endothelium and incorporate in the endothelial monolayer, this suggests that 
CD34+ cells hold promise for gene therapy applications.
Although in our study administration of a purified population of CD34+ cells caused 
relatively modest integration of these cells in the hMVEC monolayer and only a mild 
stimulatory effect on neovascularization, it strongly suggests homing and incorporation of 
human CD34+ cells in human microvascular endothelium. Thus far,  integration of BM cells 
into the endothelium has been mainly assessed in animal models. Highly variable 
incorporation rates have been reported, probably because of differences between models in 
intensity of endothelial injury. Generally, the number of incorporated endothelial cells is 
quite low32.  Thus far, a few animal studies have assessed the effects of injection human 
CD34+ cells on neovascularization and incorporation in animal endothelium. Asahara et al 
were the first to report integration of DiI-labeled CD34+ cells in 13% or 10% of capillaries 
in mouse or rabbit hindlimb ischemia1. Kocher reported incorporation of human CD34+ 
cells in 20 to 25% of total myocardial capillary vasculature in a mouse myocardial 
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infarction model and considerable stimulation of neovascularization resulting in 
improvement of cardiac function13. In contrast, Schatteman et al demonstrated that human 
CD34+ cells incorporated and differentiated into endothelial cells (not quantified) but did 
not influence restoration of blood flow in nondiabetic mice with hindlimb ischemia14. In the 
latter experiments administration of CD34+ cells did cause a marked acceleration of flow 
restoration in diabetic nude mice, suggesting that the effects of injected CD34+ cells on 
neovascularization may depend on (dys)function of the resident population of endothelial 
cells and/or angioblasts. In our model, we used a normal hMVEC population,  which may 
already have had an optimal capillary-forming capacity. We cannot exclude the possibility 
that in the presence of resident endothelial cell dysfunction administration of CD34+ cells 
alone may be more effective. However, this cannot fully explain the modest stimulatory 
effect of CD34+ cells on neovascularization, as cultured EPC/CAC, administered in similar 
concentrations as CD34+ cells, did markedly enhance neovascularization in our model. 
An alternative explanation for the limited effect of purified CD34+ cells in our in vitro 
model as compared with animal models might be the absence of (endogenous) supporting 
cells. Emerging evidence suggests that subsets of hematopoietic cells support capillary 
growth. Hematopoietic cells have been shown to release angiogenic factors such as VEGF, 
angiopoietins and MMPs. Additionally, subsets of recruited hematopoietic cells, 
particularly myelomonocytic cells, were shown to support EPC-mediated 
neovascularization33.  Recently, several in vitro studies have suggested that loco regional 
interactions between CD34+ and CD34- cells may be important for proliferation and 
differentiation of CD34+ cells into endothelial cells1,24,34. Interestingly,  in our model 
homing or incorporation of CD34+ cells into the endothelial layer did not depend on the 
presence of CD34- cells, suggesting that angiogenic endothelium may not only express or 
secrete factors to recruit CD34+ cells but also for their incorporation and proliferation. 
However, our data show that although separate administration of selected CD34+ or CD34- 
cells for the majority of the donors had only limited effects on neovascularization, 
coincubation of both cell populations resulted in a consistent and marked increase (68%) in 
neovascularization, indicating that interactions between CD34+ cells and CD34- cells can 
contribute to stimulation of capillary growth. Our observations that coculturing of CD34+ 
cells with CD34- cells significantly enhances EPC differentiation in vitro, suggest that this 
is at least partly caused by enhanced differentiation and incorporation of CD34+ cells.
Apart from (CD34- cell-stimulated) CD34+ cell incorporation enhanced capillary growth 
after CD34+/- cell coincubation may be explained by a stimulatory effect of CD34+ cells on 
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endothelial differentiation of CD34- cells. Several studies have demonstrated that CD34- 
cells may differentiate into endothelial cells in vitro19,20,35. CD34- cells may even be the 
main source of cultured EPCs21. Several studies reported only rare incorporation of CD34- 
cells into new capillaries in vivo1,14 without functional improvements in blood flow. It has 
been suggested that CD34- and CD14+ cells yield the ‘early EPC,’ which have no 
significant proliferative capacity and contribute to neovascularization mainly by secreting 
angiogenic cytokines20,22.  However, Harraz et al15 demonstrated that CD34- cells and 
CD34-/CD14+ cells may incorporate into the neovasculature in vivo when coadministered 
with CD34+ cells. Such potential integration of CD34- cells is intriguing and warrants 
further study.  However,  our study was not designed to demonstrate or exclude endothelial 
differentiation or incorporation of CD34- cells. The aim of our present study was to 
investigate specifically the role of human CD34+ cells in human neovascularization. We 
chose to use retroviral transduction with a marker gene in our CD34+ cells because this is a 
very stable and reliable labeling method and because retrovirally transduced autologous 
CD34+ cells have already been applied for clinical use. This labeling method is, however, 
not suitable for labeling of the CD34- cell population. 
It should be noted that our study is confined to the formation of human capillary-like 
tubular structures in vitro.  However, if confirmed, our findings have important clinical and 
therapeutic consequences. They suggest that administration of a CD34+-enriched cell 
population may lead to a significant improvement of neovascularization, which is similar to 
the effects observed with cultured EPC/CAC. The use of CD34+-enriched cells has the 
advantage that fresh administration of these cells after brief manipulation is much easier 
than culturing EPCs, which involves prolonged sterile manipulation.  Furthermore, if 
cultured EPCs/CACs are indeed monocytes/macrophages, potentially harmful effects 
caused by their proinflammatory characteristics have to be taken into account. Finally, 
much experience has been obtained over the years as CD34+ cell-enriched cell populations 
have been used extensively for treatment of hematological and nonhematological 
malignancies and ex vivo expansion methods have been developed23,36,37. Our observation 
that human CD34+ cells selectively home and incorporate in angiogenic endothelium 
suggests their potential for gene therapy. At last,  our observations suggest an important 
supportive role for the CD34- cell population. Further studies should be aimed at unraveling 
the interactions between CD34+ and CD34- cells. 
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Abstract
Type 1 diabetes is associated with reduced vascular repair, as indicated by impaired wound 
healing and reduced collateral formation in ischemia. Recently, endothelial progenitor cells 
(EPC) have been identified as important regulators of these processes. We therefore 
explored the concept that EPC are dysfunctional in Diabetes Mellitus. The number of EPC 
obtained from type 1 Diabetes patients in culture was 44% lower compared to age- and 
gender- matched controls (P<0.001). This reduction was inversely related to levels of 
HbA1c (R=-0.68, P=0.01). In addition, we demonstrated that patient EPC were also 
impaired in function using an in vitro angiogenesis assay.  Conditioned media from patient 
EPC were significantly reduced in their capacity to support endothelial tube formation in 
comparison to control EPC. Therefore, despite culturing the EPC under normoglycemic 
conditions, functional differences between patient and control EPC were maintained.  Our 
findings demonstrate that adverse metabolic stress factors in type 1 diabetes are associated 
with reduced EPC numbers and angiogenicity.  We hypothesize that EPC dysfunction 
contributes to the pathogenesis of vascular complications in type 1 diabetes.
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Introduction
Hyperglycemia is associated with endothelial cell dysfunction and reduced 
neovascularization in response to tissue ischemia,  processes that are essential for wound 
healing and prevention of cardiovascular ischemia1-3. A growing body of evidence indicates 
that neovascularization does not exclusively rely on proliferation of local endothelial cells 
but also involves bone marrow-derived circulating stem cells4. These cells can be cultured 
from the circulating mononuclear cell fraction and are commonly referred to as endothelial 
progenitor cells (EPC) because they exhibit characteristic endothelial surface markers and 
properties. Moreover, a number of studies have shown that injected EPC home to sites of 
ischemia,  incorporate into the newly formed capillaries and augment neovascularization5. 
Consequently, if EPC are critical to endothelial maintenance and repair,  EPC-dysfunction 
could contribute to the pathogenesis of ischemic vascular disease. Indeed, studies have 
demonstrated that, in patients with cardiovascular risk factors,  the number of EPC that can 
be isolated from peripheral blood is reduced6 and EPC function is impaired7,8.  It was 
recently reported that a strong inverse correlation exists between the number of EPC and 
the subjects’  combined Framingham risk factor score9. In addition, measurements of flow-
mediated brachial-artery reactivity also revealed a significant relation between endothelial 
function and the number of EPC, supporting a role for EPC in the maintenance of 
endothelial integrity. 
In this study, we investigated the hypothesis that EPC dysfunction exists in type 1 diabetes 
patients. To that end, we determined the number of EPC obtained from peripheral blood of 
type 1 diabetes patients and its relation to glycemic control. Furthermore, we compared the 
capacity of patient and control EPC to support endothelial tube formation in vitro. 
Research design and methods
Patient characteristics
After informed consent was obtained, peripheral blood (PB) samples were collected from 
twenty type I diabetes patients and twenty age- and gender-matched healthy control 
subjects. Patients with type 1 diabetes, diagnosed at least 1 year before entering the study, 
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were recruited from the Department of Diabetology of the University Medical Center 
Utrecht. All patients were treated with insulin for at least one year. Patients with manifest 
macrovascular disease were excluded. Other exclusion criteria included: smoking, alcohol 
abuse, liver disease, creatinine >120 µmol/l and untreated thyroid disease. If patients were 
treated with vasoactive medication (angiotensin-converting enzyme inhibitors, statins, 
aspirin, non-steroidal anti-inflammatory drugs, angiotensin II antagonists, folic acid or 
vitamins), treatment was stopped at least 3 weeks before blood withdrawal.  Whole blood 
was used for assessment of HbA1c using an immunochemical method (Tina-quant, Roche/
Hitache, Mannheim, Germany).  Glucose concentrations were measured by a glucose 
oxidase technique.  The study protocol was approved by the Ethics Committee of the 
University Medical Center Utrecht.
EPC Isolation and Characterization
Peripheral blood was obtained in blood collection tubes containing EDTA (Venoject, 
Terumo Europe N.V., Leuven, Belgium). EPC were cultured as described10. Briefly, 
mononuclear cell fractions (MNC) were isolated from 60 ml whole blood by density 
gradient centrifugation (Histopaque 1077, Sigma, St. Louis, MO). MNC were plated at a 
density of 1 x 106 cells per cm2 on 6-well culture plates coated with 2% gelatin (Sigma) in 
M199 medium supplemented with 20% FBS (Invitrogen, Breda,  The Netherlands), 0.05 
mg/ml Bovine Pituitary Extract (Invitrogen), antibiotics and 10 U/ml heparin (Leo Pharma 
BV, Breda, The Netherlands). After four and seven days of culture, EPC characteristics 
were confirmed on the basis of morphology and by fluorescent confocal 
immunohistochemistry using Ulex europaeus agglutinin (UEA)-1 (Vector, Burlingame, CA, 
USA), a CD31 antibody (DAKO Diagnostics,  Glostrup, Denmark) and DiI-labeled 
acetylated LDL (Molecular Probes, Leiden, The Netherlands). 
Flow cytometry analyses  
Quantitative determination of the percentage of cells undergoing apoptosis was determined 
using an Annexin V apoptosis detection kit (BD Biosciences Pharmingen, San Diego, CA, 
USA) according to the manufacturers protocol. Briefly, fresh MNC and EPC, cultured for 
four days, were isolated as described.  After the recommended washing steps, 1 x 106 cells 
were incubated for 15 min with fluorescein isothiocyanate (FITC)-conjugated Annexin V in 
binding buffer (BD Biosciences) in the dark. Annexin binding was measured by flow 
cytometry (FACScan, BD Biosciences) within 1 h and quantified using CellQuest software 
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(BD Biosciences). Mean levels of  Annexin V binding were determined using specific 
monocyte and lymphocyte gates in the forward-sideward scatter plots and expressed as 
arbitrary units of fluorescence. 
In vitro Angiogenesis Assay
The angiogenic activity of EPC conditioned media was assessed using an in vitro 
angiogenesis assay kit (Chemicon,  Temecula, CA, USA) and passage two primary human 
umbilical vein endothelial cells (HUVEC). Conditioned media were obtained by replacing 
the medium of 4 day EPC cultures with serum-free endothelial cell basal medium-2 
(Clonetics, Baltimore MD, USA) supplemented with EGM-2 single aliquots (growth factors 
like VEGF and bFGF were omitted) and cultured for an additional 30 h. EPC were counted 
and in subsequent experiments conditioned media were diluted to correct for EPC numbers. 
After 16 h, tube formation by HUVEC was measured by staining the viable cells with 
Calcein-AM (5µg/ml) (Molecular Probes). Total tube area was determined using images 
obtained with an inverted fluorescence microscope and the Scion Imaging software (Scion 
Corporation, Maryland, USA) and expressed in arbitrary units.
Statistical Analysis
Statistical analysis was performed with a Student’s t test, and results are expressed as mean
±SD. Linear regression analyses and Pearson correlation were used for comparison of the 
number of EPC and glycosylated hemoglobin (HbA1c). Probability values of P<0.05 were 
considered statistically significant.
Results
Patient characteristics 
Subject characteristics are presented in table 1. The group of diabetic patients is 
representative of a type 1 diabetes population without macrovascular complications. They 
had a wide range of age and HbA1c. Background, preproliferative and proliferative 
retinopathy was present in 4, 3 and 2 patients, respectively. Microalbuminuria was present 
in 4 out of 20 patients. 
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Correlation of reduced EPC number and glycosylated hemoglobin in type 1 diabetes 
patients 
Peripheral blood MNC from type 1 diabetes patients and controls were cultured and 
differentiated. From four days on, next to cell clusters, EPC appeared with a typical 
spindle-shaped morphology4. EPC were further characterized by assessing the uptake of 
DiI-labeled acLDL, the binding of the lectin UEA-1 and the presence of the CD31 antigen, 
all three characteristic features of cells in the endothelial lineage. Already at day four, 80% 
of the attached cells stain positive for all three markers. At day seven the spindle shape 
morphology appears more pronounced and over 90% of the cells stain positive for all three 
markers. Figure 1A, shows a representative picture of a dual staining of a seven day EPC 
culture and Figure 1B, represents a confocal image of a representative spindle shaped cell 
in a seven day EPC culture, that shows uptake of DiI-labeled acLDL (red) and membrane 
staining with an anti-CD31 antibody (green).
Following the phenotypic characterization of our EPC cultures we assessed the number of 
EPC that could be obtained from four day cultures derived from the peripheral blood MNC 
fraction of type 1 diabetes patients and age- and gender-matched controls.  We observed a 
significant 44% decrease in the number of EPC obtained from 60 ml peripheral blood of the 
 
Table 1:  Subject characteristics
Controls Type 1 diabetes patients
n 20 20
Age (years) 39.9 ± 13.9 40.7 ± 14.8
Sex (M / F) 13 / 7 13 / 7 
BMI (kg/m2) 23.0 ± 2.6 24.7 ± 1.9
Glucose (mmol/l) 5.2 ± 1.3 7.8 ± 3.5
HbA1c (%) - 8.3 ± 1.5
Duration of diabetes (years) - 21.1 ± 15.2
Values are mean ± SD. 
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type 1 diabetes patients compared to the non-diabetic controls (4.3 ± 2.3 x 106 vs. 7.8 ± 3.3 
x 106, P<0.001,  Fig. 2A). Moreover, linear regression analyses revealed an inverse 
relationship between the number of EPC and the HbA1c in the patients (R= -0.68, P=0.01, 
Fig. 2B). 
No evidence for increased apoptosis in cultured EPC from type 1 diabetes patients 
To evaluate if the reduction in the number of EPC was due to apoptosis, we analyzed the 
binding of Annexin V to phosphatidylserine in both EPC cultured for four days and the 
MNC fraction they originated from. The display of phosphatidylserine in the outer leaflet of 
the plasma membrane of cells is considered an early marker of apoptosis. Quantitative 
analyses of data obtained by flow cytometry revealed no significant difference in the mean 
levels of Annexin V binding to EPC cultured from patients or controls when gated for 
viable cells (22.3 ± 10.7 and 20.4 ± 9.2 respectively, p=0.54), suggesting no increase in 
early apoptosis in these cells.  Likewise, in fresh MNC fractions which were the source of 
our EPC cultures we also did not observe a significant increase in the mean levels of 
Annexin V binding of total MNC fraction in the patient group compared to that of the 
controls (370.9 ± 78.5 v.s. 304.7 ± 139.5, p=0.17).
 
Figure 1. 
EPC characterization. Fluorescent microscopy shows a representative EPC culture containing over 
90% cells with a spindle-shaped morphology both staining positive for FITC labeled Ulex 
europaeus agglutinin and DiI-labeled acetylated LDL (A). Confocal microscopy picture showing 
dual staining of EPC by CD31 antibodies and uptake DiI-labeled acLDL (B).
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EPCs from patients with type 1 diabetes are impaired in their potential to augment 
angiogenesis in vitro 
EPCs are thought to augment neovascularization not only by integration of these cells into 
newly developing capillaries but also in a paracrine fashion through the secretion of 
angiogenic growth factors5. To investigate whether this paracrine function is affected in 
type 1 diabetes,  we determined the angiogenic potential of EPC (day 4) conditioned 
medium in an in vitro angiogenesis model. In this angiogenesis model, the degree of tube 
formation of mature endothelial cells on a solid gel of matrix proteins can be evaluated. As 
tube formation in this assay is dependent on the presence of angiogenic stimuli we assessed 
the angiogenic capacity of cultured EPC. HUVEC were seeded on extracellular matrix and 
subjected overnight to conditioned medium of diabetic EPC (n=10) or of EPC from age-
matched controls (n=10). Conditioned media of healthy controls markedly stimulated tube 
formation when compared to non-conditioned media (EGM -/-) demonstrating that EPC 
can facilitate angiogenesis in a paracrine fashion (Fig. 3). In contrast,  the conditioned media 
of the patient EPC significantly reduced tube formation when compared to non-conditioned 
media suggesting that cultured EPC from type 1 diabetes patients can secrete factors that 
impair angiogenesis in vitro.
 
Figure 2. 
MNC were isolated out of 60 ml peripheral blood from 20 controls and 20 type 1 diabetes patients. MNC 
were plated on gelatin-coated dishes and EPC were cultured for 4 days. The total EPC numbers were counted 
and a 44% reduction was seen in the type 1 diabetes patients compared to the healthy controls (A). This 
reduction in EPC numbers inversely correlated with glycemic control assessed by HbA1c (B).
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Discussion
Our data support the hypothesis that EPC are dysfunctional in patients with type 1 diabetes. 
First, a reduced number of EPC could be cultured from the MNC fraction of type 1 diabetes 
patients when compared to healthy control subjects. A reduction of the number of EPC in 
patients with risk factors for coronary artery disease has also been reported by others6-8. Our 
data are consistent with a previous report by Schatteman et al.7 who showed that CD34+ 
cells derived from type 1 diabetes patients produced less differentiated endothelial cells 
than their non-diabetic derived counterparts.  Here, we have extended their observation by 
showing that in type 1 diabetes,  EPC numbers inversely correlate with HbA1c levels 
demonstrating that the degree of glycemic dysregulation directly affects EPC proliferation 
or differentiation. 
As the number of circulating leukocytes is tightly regulated by the balance between 
proliferation and apoptosis11 and increased apoptosis has been associated with the adverse 
metabolic state and oxidative stress in diabetes12, we hypothesized that increased apoptosis 
 
Figure 3. 
Angiogenic capacity of conditioned media of EPC in an in vitro angiogenesis assay. HUVEC were plated on 
extra cellular matrix and subjected to EPC-conditioned media. Tubule networks were formed overnight and 
structures were visualized with Calcein-AM staining. Quantitative analyses of tube formation were performed 
using an imaging program. A significant inhibition of tube formation of patient EPC conditioned media is 
shown (A). Representative pictures of the stained tubule networks formed after incubation of HUVEC with the 
conditioned media of EPC derived from thee different patients and their age-gender matched controls (B). 
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could explain the reduced EPC numbers.  When we analyzed early apoptosis in EPC 
cultured for four days, or in the freshly isolated MNC fraction they originate from, no 
significant difference in the mean levels of Annexin V binding was detected in the type 1 
diabetes patient group compared to the control group. These data suggest that increased 
apoptosis is unlikely to be involved in the reduction of the number of EPC in type 1 
diabetes patients. An alternative explanation for the lower EPC counts in this study could 
be that the EPC precursors in the MNC fraction have an impaired capacity to adhere and/or 
differentiate in our culture conditions.  This would represent yet another level of EPC 
dysfunction that is currently under investigation.
Irrespective of the underlying mechanism, a reduced number of EPC is likely to impact on 
vascular integrity as it was recently reported that, in healthy men, the number of EPC serve 
as a surrogate marker for vascular function and cumulative cardiovascular risk9.
Having established that the number of EPC is reduced in type 1 diabetes, we determined if 
the function of the remaining cells was altered compared when compared to the controls. So 
far, only few studies addressed the subject of EPC dysfunction. It was reported that EPC 
isolated from patients with CAD displayed an impaired migratory response6 and that, in 
type 2 diabetes, EPC adhesion to stimulated endothelial cells is impaired8.  Although EPC 
enhance new vessel formation,  these cells do not form the entire vessel de novo and the 
process always includes mature endothelial cells13. Recently,  it has been suggested that a 
major function of EPC could be the secretion of angiogenic factors to activate resident 
mature EC14. Here we show that the angiogenic capacity of conditioned media from 
patient-derived EPC is not only reduced, but it may even contain an inhibitor for in vitro 
tube formation of endothelial cells. 
Furthermore, our data demonstrate that type I diabetes is associated with altered EPC 
function and that these changes are observed even though the EPC were cultured for 4 days 
in a normoglycemic environment. To begin to investigate whether these functional changes 
are reflected in the gene expression profiles of the diabetic EPC we have performed 
preliminary Affymetrix DNA microarray analyses. Indeed, we observed extensive 
differential gene expression in patient-derived cultured EPC compared to control subjects. 
Interestingly, many of these alterations have been reported to be associated with diabetes 
mellitus in general, hyperglycemia or oxidative stress such as plasminogen activator 
inhibitor 115 and osteopontin16. This demonstrates that may EPC function as “bio-sensors”, 
translating metabolic cues into altered gene expression. How the EPC “remembers” its 
metabolic descent in culture is unknown and needs further investigation.
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Taken together, we demonstrate that EPC cultured from type 1 diabetes patients are reduced 
in number and function. As a consequence, EPC dysfunction may reduce the vascular 
regenerative potential of this patient group and thereby contribute to the pathogenesis of 
vascular complications in type 1 diabetes. 
Finally, the notion that EPC dysfunction exists in certain patient categories, such as type 1 
diabetes, may have implications for currently explored cell-based clinical strategies to 
enhance tissue perfusion in patients with ischemic coronary and peripheral artery 
disease17,18. EPC or MNC isolated from these patients for autologous cell transplantation 
may retain their dysfunctional characteristics in vivo and as a consequence display a 
reduced capacity to augment therapeutic neovascularization.  Therefore it could be useful to 
set progenitor quality criteria and perform EPC function tests (such as assays for 
angiogenic growth factor secretion, adhesion or migration) in order to obtain optimal cells 
for transplantation. 
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Abstract
Endothelial progenitors Cells (EPC) have been shown to contribute to neovascularization 
and vascular maintenance and repair in adults. Recently, the concept has evolved that EPC 
dysfunction, in patients at risk for cardiovascular disease, may contribute to the 
development of atherosclerosis and ischemic vascular disease. Particularly, patients with 
Diabetes Mellitus are likely to be affected by EPC dysfunction as several studies have 
shown a reduced number and function of EPC in patients as well as in preclinical models 
for type 1 diabetes.  Here,  we review our current understanding of EPC (dys)function in 
diabetes and discuss some potential mechanisms underlying their altered properties. 
Moreover, we provide circumstantial evidence supporting that increased oxidative stress 
could play a role in the development of EPC dysfunction in type I diabetes. Finally, we 
discuss the potential implication of our findings for EPC-based therapies and the potential 
impact of pharmacological interventions on the vascular regenerative capacity of EPC.
 Endothelial progenitor dysfunction in diabetes
79
 Chapter 4
80
Introduction
Type 1 diabetes is not only associated with microvascular complications1 but also with 
premature atherosclerosis and a reduced capacity to form collaterals vessels after an 
ischemic insult2,3. Likewise, patients with type 1 diabetes have an increased risk for the 
clinical consequences of these macrovascular manifestations including myocardial 
infarction and peripheral vascular disease4. Numerous studies have shown that dysfunction 
of the vascular endothelium plays a central role in the pathophysiology of these diseases5. 
The metabolic abnormalities that characterize diabetes, particularly hyperglycemia, 
provoke molecular mechanisms that have a major impact on endothelial cell function and 
survival. Especially, activation of protein kinase C (PKC) and increased oxidative stress can 
lead to endothelial cell dysfunction. Moreover,  prolonged exposure of endothelial cells to 
these adverse conditions increases endothelial cell apoptosis and turnover. Although 
adjacent mature endothelial cells have the capacity to proliferate and replace these dying 
cells, chronic exposure to oxidative stress has been shown to lead to premature replicative 
senescence and limit this form of endothelial repair6,7. Eventually, endothelial cell death 
and shedding may lead to disturbances of the endothelial monolayer leaving a highly pro-
atherogenic luminal surface8,9. Hence, the integrity of the endothelium and thus the 
atherogenicity of the vasculature,  is likely to be determined by the balance between 
endothelial turnover and repair9. In recent years it has become clear that bone-marrow 
derived endothelial progenitor cells (EPC) represent an additional cellular source to 
rejuvenation of the damaged endothelium. EPC have been shown both in animal models 
and humans to contribute to neovascularization and reendothelialization indicating an 
essential role of these progenitor cells in the maintenance of endothelial integrity10. 
Recently, a number of studies have suggested that the classical risk factors for 
atherosclerosis not only affect the mature endothelium but also lead to EPC 
dysfunction11,12. This notion may not only contribute to our insight into the 
pathophysiology of atherosclerosis but may also have consequences for the use of 
progenitor cells in clinical protocols that use progenitor cell transplantation for the 
treatment of ischemic vascular disease. Here, we will review our current understanding of 
EPC dysfunction in type 1 diabetes. In particular, we will discuss the potential role of 
oxidative stress as an underlying cause of the dysfunction of these progenitors. Finally, we 
will address some potential approaches that may counteract EPC dysfunction in the clinical 
setting.  
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Endothelial progenitor cells: origins and species 
It is important to appreciate that the nature of the "true" circulating EPC is poorly defined. 
Different populations of EPC have been studied that each may have unique properties13. In 
general, two types of EPC can be distinguished. First, circulating EPC (CEP) can be 
recruited from the bone marrow that are characterized by the expression of the early 
hematopoietic stem cell markers CD34, CD133 and the vascular endothelial-cell growth 
factor receptor-2 (VEGFR2)14-16. The EPC share these characteristics with hematopoietic 
stem cells and CEP may function analogous to the embryonic hemangioblast, which can 
give rise to both circulating blood cell lineages and vascular cells14,17. Cultured with 
endothelial cell growth factors, purified CEP can differentiate into endothelial-like cells that 
display a classical endothelial cell morphology and characteristics like the expression of 
von Willebrand factor (vWF), vascular endothelial (VE) cadherin and the capacity to take 
up acetylated low-density lipoprotein (acLDL). Although normally the number of CEP are 
limited, their levels can be markedly elevated within days after the administration of CEP 
mobilizing agents18 or secondary to vascular trauma19 or tissue-ischemia induced by 
myocardial infarction20,21.  
Early support for a role of bone marrow derived CEP in vascular repair in humans stems 
from the observation that the neointima formed on the surface of a left ventricular assist 
device accumulates a CD133+ positive hematopoietic stem cell population that also 
expresses the endothelial cell marker VEGFR216. In a mouse model, it was shown that bone 
marrow derived CEP can home to denuded arterial vessels and contribute to 
reendothelialization. Interestingly, statin-induced mobilization of CEP was associated with 
an increased rate of reendothelialization and reduced neointimal thickening22. 
A second cell type that has been shown to be involved in vascular healing can be obtained 
by culturing peripheral blood mononuclear cells (PB-MNC) on gelatin or fibronectin for 4 
days in endothelial cell differentiation medium. These attaching cells, that are also referred 
to as endothelial progenitor cells (EPC), display a spindle-like morphology and also express 
endothelial cell markers like vWF, VEGFR2 and VE-cadherin and are usually characterized 
by the binding of endothelial specific lectins and the uptake of acLDL10,13. The large 
number of attaching cells that can be obtained from the PB-MNC cultures make it unlikely 
that all these cells are derived from the low number of circulating CD34+ cells. Most likely, 
these EPC are derived from more abundant subpopulations present in the mononuclear cell 
fraction like monocytes23-26. When human bone marrow derived monocyte-lineage 
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attaching cells were intra-arterially transplanted into denuded arteries of athymic nude rats 
they adhered to the injured endothelium, differentiated into EC-like cells and inhibited 
neointimal hyperplasia27. Likewise, transplantation of EPC cultured from PB-MNC in 
rabbits led to a rapid reendothelialization of balloon-injured carotid arteries and graft 
segments and, again, reduced neointima deposition28. It is currently unclear whether the two 
types of EPC are related through shared developmental stages, i.e. whether a monocyte-
related intermediate is a required step in the differentiation of CD34+ cells into EPC.
EPC dysfunction in type I diabetes
From the above it can be concluded that EPC of different hematopoietic lineages appear to 
play a crucial role in the maintenance of endothelial cell integrity in injured vessels and 
therefore may serve an important atheroprotective function. Following these insights, it was 
hypothesized that impaired EPC function would predispose to endothelial cell dysfunction 
and its clinical manifestations including premature atherosclerosis and ischemic vascular 
disease. Seminal observations supporting this concept were reported by Vasa et al.  who 
demonstrated that the number and function of circulating endothelial progenitor cells 
inversely correlated with risk factors for coronary artery disease11. It was shown that this 
concept holds true both for CD34 and VEGFR2 double positive CEP as well as for PB-
MNC derived attaching EPC.  Hill et al. extended this observation showing that, for 
patients at risk for CVD, there was a strong inverse correlation between the number of EC 
colonies that could be grown out from PB-MNC cultures and the subjects’ combined 
Framingham risk factor score12. Moreover, measurements of flow-mediated brachial-artery 
reactivity revealed a significant relation between endothelial function and the number of 
progenitor cells. These reports again suggest that the quality of the endothelium may well 
be related to the endothelium-regenerative potential of circulating EPC. 
Schatteman and colleagues were the first to report data supporting the concept of EPC 
dysfunction in streptozotocin-induced diabetic nude mice29. Using an established model for 
neovascularization of the ischemic hindlimb they demonstrated that,  like shown before in 
non obese diabetic mice30, restoration of blood flow was significantly impaired in the 
diabetic mice. Whereas injection of human CD34+ cells, purified from the PB-MNC 
fraction, did not accelerate the rate of neovascularization in the healthy controls, it 
markedly enhanced blood-flow restoration in the diabetic mice31. When labeled,  the CD34+ 
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cells were found to incorporate in the vasculature of the previously ischemic tissue. It was 
concluded that in the diabetic mice the EPC function was deficient and that this could be 
corrected by transplantation of exogenous human CD34+ cells. These data indirectly 
provided evidence for deficient EPC function in experimentally diabetic mice and initiated 
subsequent studies to investigate the nature of the EPC dysfunction.
Diabetes-associated metabolic factors may affect EPC function at several levels, including 
the number of available progenitor cells with capacity to differentiate into cells of the 
endothelial cell lineage, their capability to adhere and migrate to sites of 
reendothelialization and neovascularization and their pro-angiogenic (paracrine) potential. 
Effect on the number of endothelial progenitor cells
In the study by Schatteman29 it was shown that, although the absolute numbers of CD34+ 
cells isolated from peripheral blood from control subjects and type 1 diabetes patients did 
not differ significantly,  the number of endothelial-like cells that formed in vitro from the 
patient CD34+ cell fraction was reduced over three fold compared to the non-diabetic 
controls. In this study a similar analysis for type 2 diabetic patients failed to show different 
yields in CD34+ derived EPC. However,  Tepper et al. reported that when attaching cells 
were cultured from PB-MNC from human type 2 diabetics and age-matched control 
subjects the number of cells obtained from the patients were 48% percent lower than from 
healthy volunteers32. Likewise, we demonstrated that the number of attaching cells cultured 
from type 1 diabetic patients was reduced almost two fold compared to age and gender-
matched control subjects33.  In both studies this reduction was inversely related to the levels 
of HbA1C demonstrating that the degree of glycemic dysregulation is associated with EPC 
phenotype or differentiation. The most pronounced reduction of EPC numbers also was 
observed in a study using streptozotocin-induced diabetic mice31. It was found that the 
number of attaching cells cultured on vitronectin from BM-MNC of diabetic mice with 
femoral artery ligatures was five fold lower than that of control mice.
Hence,  in diabetes there appears to be a reduced number of cells in MNC fractions that can 
differentiate into EPC in vitro. 
Effect on the function of endothelial progenitor cells
EPC from a diabetic background have been studied for properties that are thought to be 
required for proper EPC function. In vitro, functions like adhesion to endothelial cells32, 
incorporation into endothelial tubular structures32 and paracrine release of pro-angiogenic 
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factors33 were assessed and in each reported study these functions appeared significantly 
impaired in cells obtained from a diabetic background. As attaching EPC may be closely 
related to monocytes or macrophages, these results may not come as a surprise as the 
response of monocytes to growth factors is also impaired in diabetic patients3.
Two reports directly asessed the function of "diabetic" progenitors cells in 
neovascularization in an in vivo model. One study investigated the effect of type 2 diabetes 
on the potential of exogenous stem cells to promote skin wound vascularization and 
healing34. Bone marrow stem cells from nondiabetic and diabetic Leprdb mice were 
injected underneath experimentally induced skin wounds. It was shown that, in contrast to 
nondiabetic stem cells, diabetic stem cell containing fractions not only failed to enhance but 
even inhibited wound vascularization. A second study reported that transplanted diabetic 
EPC, obtained from BM-MNC fractions of streptozotocin-induced mice, were markedly 
impaired in their capacity to enhance ischemia-induced neovascularization assessed by the 
ischemic/nonischemic angiographic score, capillary number and blood flow recovery. 
Taken together, evidence is accumulating that, in diabetes, the number and function of EPC 
pools are reduced and therefore may be involved in the pathogenesis of both vascular 
complications. 
Potential role of oxidative stress on EPC dysfunction in diabetes
Then,  what molecular mechanisms may cause this reduction in EPC capacity in diabetes? It 
is clear that the answer to this simple question will be complex and dependent on the 
particular risk factors present and type of diabetes that affects individual patients. In type 1 
diabetes, chronic hyperglycemia appears to be the major initiator of vascular complications 
through the increased production of reactive oxygen species (ROS) by the vascular 
endothelium5,35.  Endothelial cells are particularly sensitive to hyperglycemia as they, unlike 
most cell types,  are not capable of down regulating glucose uptake in high ambient glucose 
concentrations36. Hyperglycemia can lead to elevated ROS production in the endothelial 
cells via a number of enzymatic systems including the mitochondrial electron transport 
chain, activation of NADPH oxidase and uncoupling of endothelial nitric oxide synthase 
(eNOS)37. Although the endothelial cells are equipped with potent antioxidant systems, 
sustained production of ROS in chronic hyperglycemia can exhaust these protective 
mechanisms and lead to a state of "oxidative stress"38. This condition is associated with 
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endothelial cell dysfunction, a proinflammatory endothelial phenotype that is characterized 
by a reduced bioavailability of NO.
Oxidative stress and EPC mobilization
Another landmark study performed in the laboratory of  Stephanie Dimmeler provided a 
possible explanation for the reduced mobilization of EPC in patients with cardiovascular 
disease39.  Using eNOS knock-out mice they demonstated that NO expressed by bone 
marrow stromal cells plays an essential role in vascular endothelial growth factor (VEGF)-
induced mobilization of CEP (CD34+/VEGFR2+) from the bone marrow stroma to the 
vascular compartment.  As endothelial cell dysfunction and impaired NO bioavailability is 
the hallmark of most cardiovascular risk factors these data support the hypothesis that CEP 
mobilization is impaired secondary to oxidative stress.  Hyperglycemia also decreases 
endothelium-derived NO both in vitro5 and during hyperglycemic clamping in healthy 
subjects40. It therefore seems likely that also in diabetes a reduced bioavailability of NO in 
the bone marrow stroma is involved in the reduced mobilization of EPC.
Oxidative stress and EPC function
Given the central role of oxidative stress in type 1 diabetes, oxidative stress or altered redox 
signaling may also directly affect the survival, differentiation and function of EPC. 
Although little data on CEP function have been reported, a number of papers may provide 
indirect evidence for a role of redox signaling in the fate and function of MNC-derived EPC 
(attaching cells).  Given the fact that these cells are thought to function in sites of ischemia 
or reperfused tissue that can be characterized as an inflammatory, high oxidative stress 
environment13, Dernberg et al. investigated the anti-oxidative systems of cultured EPC41. 
They demonstrated that, compared to mature umbilical vein endothelial cells (HUVEC), 
EPC exhibited a significantly lower basal ROS concentration and a relative high expression 
of the intracellular anti-oxidative enzymes catalase, glutathione peroxidase and manganese 
superoxide dismutase (MnSOD). Incubation of HUVEC with H2O2 increased ROS 
production up to 4-fold and induced apoptosis. In contrast, H2O2 hardly affected ROS 
production and apoptosis in the EPC demonstrating that EPC display a reduced sensitivity 
towards ROS-induced cell death. Combined inhibition of the antioxidant enzymes 
increased ROS levels in the EPC and impaired EPC survival and migration. He et al. 
demonstrated a critical role for MnSOD in protecting EPC from cytotoxicity induced by the 
naphtoquinolinedione LY83583, a generator of intracellular superoxide42.   LY83583 
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inhibited in vitro tube formation by mature endothelial cells but not by EPC. These data 
suggest that although EPC are relatively resistant to oxidant stress,  elevation of ROS 
production can affect survival and function,  most likely by affecting redox-sensitive 
signaling pathways, such as the NF-κB pathway43.
Potential mechanisms of diabetes-associated ROS production by EPC
The question remains how in a diabetic environment oxidative stress would be elevated in 
these EPC. It is unclear to what extend mechanisms that are known to function in mature 
endothelial cells can be translated to EPC. For instance, can cultured EPC take-up glucose 
in the same apparently "uncontrolled" way as mature endothelial cells36. Nevertheless, 
hyperglycemia induced activation of PKC and its downstream effects on e.g. activation of 
NADPH oxidase could be a potential mechanism for elevation of ROS in EPC. Also, 
hyperglycemia-associated formation of extracellular and intracellular advanced glycation 
end products (AGE) may affect the redox state of the cells.  AGEs are the products of 
nonenzymatic glycation/oxidation of proteins and lipids and have been regarded as one of 
the main mechanisms responsible for vascular damage in patients with diabetes44. It was 
shown that, in streptozotocin-treated diabetic mice, blockade of AGE formation restores 
ischemia induced angiogenesis45. AGEs are signal transduction ligands for Receptor for 
AGE (RAGE) that, upon AGE binding, trigger the generation of ROS and the 
proinflammatory NFκB pathway via activation of NADPH oxidase46. RAGE is present on 
monocytes47 and also EPC cultures from PB-MNC (unpublished data our laboratory). 
 As hyperglycemia in type 1 diabetes is associated with activation of the renin angiotensin 
system48, angiotensin II signaling could comprise a third route to ROS production in EPC. 
Ramipril is an ACE inhibitor that is used to reduce RAAS activation in patients with stable 
coronary artery disease. A recent study showed that increased numbers of EPC could be 
cultured from ramipril treated patients with stable coronary artery disease and that the ACE 
inhibition resulted in improved functional properties like adhesion, proliferation, migration 
and an in vitro vasculogenesis assay49. These results show that EPC are sensitive to 
angiotensin II signaling and that this could indeed impact on number and function. 
 Endothelial progenitor dysfunction in diabetes
87
EPC from type 1 diabetes patients up regulate genes associated with oxidative stress
To further investigate whether EPC in type 1 diabetes are altered in function due to the 
adverse metabolic environment, we analyzed whether changes in gene expression could be 
observed between the patient and control EPC. Therefore,  we compared the gene 
expression profiles of pooled RNA isolated from cultured EPC obtained from five type 1 
diabetes patients (age 34.2 ± 10 years) and five age-and gender-matched controls (age 33.9 
± 7.7 years) using Affymetrix high-density oligonucleotide microarray analysis 
(summarized in table 1). In the diabetic EPC, out of 12,600 gene transcripts tested, we 
observed significant up- and down regulation of 472 and 360 genes respectively. Among 
the major differentially expressed genes we observed a striking number of genes that have 
been have been reported to be associated with diabetes mellitus in general,  with 
hyperglycemia, oxidative stress or AGEs, both in a clinical setting (e.g. osteopontin50, 
plasminogen activator inhibitor 151, thombomodulin52 and type IV collagen53) as well as in 
animal models (matrix metalloproteinase 154, lectin-like oxidized-LDL receptor55, 
 
Table 1. Differential expression of diabetes associated genes in cultured EPC from type 1 
diabetes patients.
Fold changes were calculated with control values as baseline comparison file.  P -values express the 
significance of the fold changes as calculated by Affymetrix Microarray Suite 5.0 software. Categories 
represent genes whose products were reported to be induced or repressed in hyperglycemia or type 1 diabetes 
(D) or as a consequence of increased oxidative stress (O).  
Protein name Gene name Genbank Fold Change P-value Category
Osteopontin SPP1 J04765 19.7 < 0.00001 D
Plasminogen activator inhibitor 1 PAI1 J03764 17.1 < 0.00001 D
Alpha-2 type IV collagen COL4A2 M33653 11.3   0.0002 D
Lectin-like oxidized-LDL receptor LOX1 AF079167 8.0 < 0.00001 D
Fructose-1,6,-biphosphatase FBP1 U21931 3.7 < 0.00001 D
Thombomodulin THBD J02973 3.5 < 0.00001 D
Cystatin A CSTA AA570193 2.3    0.00005 D
Heat shock protein HSP27 Z23090 1.9   0.0004 D/O
CD11b, Complement receptor 3 MAC1 J03925 1.3   0.0010 D
Matrix metalloproteinase 1 MMP1 Z48481 -1,9 < 0.00001 D
VEGF VEGF M97863 -2.5     0.0006 D
MHC class II HLA-DR2-Dw12 MHC2 M16276 -2.8 < 0.00001 D
GTP cyclohydrolase I GCH1 U19523 -4.3    0.00001 D
Macrophage scavenger receptor 1 MSR1 D13264 19.7    0.00001 O
Hepatic dihydrodiol dehydrogenase AKRC1 U05861 13.9  < 0.00001 O
Glutathione S-transferase A4-4 GSTA4 AF025887 8.6   0.0002 O
Peroxiredoxin 2 PRDX2 L19185 2.5    0.00003 O
A2b adenosine receptor ADORA2B X68487 2.5 < 0.00001 O
P8 protein P8 W47047 2.3  0.0002 O
Superoxide dismutase 1 SOD1 X02317 1.3  0.0008 O
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fructose-1,6,-biphosphatase56 and GTP cyclohydrolase I57). Our data demonstrate that EPC 
function as “bio-sensors”, translating metabolic cues into altered gene expression and 
support the hypothesis that dysfunction of the EPC in type 1 diabetes may be secondary to 
elevated oxidative stress. 
Conclusions and implications
Recent data shows that the vascular regenerative potential of patients with diabetes may be 
impaired as a consequence of reduced number and function of circulating progenitor cells 
that can support endothelial maintenance and ischemia-induced neovascularisation. 
Although direct evidence is lacking, indirect evidence supports a role for oxidative stress in 
the diabetes-associated EPC dysfunction. Notably,  our DNA microarray analysis suggests 
that EPC cultured from PB-MNC fraction from type 1 diabetes patients display a pro-
inflammatory phenotype. The implication of these findings is that autologous 
transplantation of progenitor cells that are affected by risk factors, such as high glucose, 
may not only be hampered by a dysfunctional nature of these cells58 but in fact may 
stimulate pro-atherogenic mechanisms such as monocyte recruitment or vascular smooth 
muscle cell proliferation. Interestingly,  a recent study, in which G-CSF mobilized vascular 
progenitor cells were infused into patients with mycoardial infarction to improve cardiac 
function, showed enhanced in-stent restenosis which led to a premature termination of the 
trial59. 
A current concept is therefore that autologous progenitor cell therapy, in patients with 
cardiovascular risk factors, probably should be accompanied by drug therapy that 
modulates the dysfunctional and adverse phenotype of these cells.  First,  the particular risk 
factor should be carefully treated through conventional approaches.  In diabetes this would 
mean that an optimal control of hyperglycemia should be pursued for some time in advance 
of the isolation of progenitor cell fractions. Second, an adjunctive therapy could be used to 
improve EPC function. For instance, HMG-CoA reductase inhibitors have been shown to 
increase the number of circulating EPC both in animal models60,61 as well as in patients 
with stable coronary artery disease62. In these studies, statins were also shown to improve 
functional aspects of the studied EPC populations in vitro, like proliferation, migration60,62, 
chemotaxis60, and adhesion22.  Statin treatment also augmented corneal neovascularization 
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in mice60 and reendothelialization after vascular injury in rats22 and in both models the 
contribution of BM-derived EPC to these effects was increased.
In coronary artery sections it was shown that statins can reduce glucose induced ROS 
production by the endothelium through the inhibition of GTPase mediated activation of the 
NADPH subunit p22Phox63.  This observation together with the fact that EPC can respond 
to statins would suggest that inhibition of HMG-CoA reductase may also counteract the 
adverse EPC phenotype observed in EPC cultured from the PB-MNC of type 1 diabetes 
patients or in vivo.  
Likewise, pharmacologic intervention in angiotensin II signaling by ACE inhibitors or 
angiotensin receptor 1 antagonist may also proof beneficial to EPC number and function. 
Whatever future therapeutic strategy will prove effective, it seem most likely that redox 
signaling will be one of its targets.
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Abstract
Objective
Endothelial progenitor cells (EPC) contribute to postnatal neovascularization and are 
therefore of great interest for autologous cell therapies to treat ischemic vascular disease. 
However, the origin and functional properties of these EPC are still in debate. 
Methods and results
Here, ex vivo expanded murine EPC were characterized in terms of phenotype, lineage 
potential, differentiation from bone marrow (BM) precursors and their functional properties 
using eNOS-GFP transgenic mice. Despite high phenotypic overlap with macrophages and 
dendritic cells, EPC displayed unique eNOS expression, endothelial lineage potential in 
colony assays and angiogenic characteristics but also immunological properties such as 
IL12p70 production and low levels of T cell stimulation. The majority of EPC developed 
from an immature, CD31+Ly6C+ myeloid progenitor fraction in the BM. Addition of 
myeloid growth factors such as M-CSF and GM-CSF stimulated the expansion of spleen-
derived EPC, however not BM-derived EPC. 
Conclusion
The close relationship between EPC and other myeloid lineages may add to the complexity 
of using them in cell therapy. Our mouse model could be a highly useful tool to characterize 
EPC functionally and phenotypically, to explore the origin and optimize the isolation of 
EPC fractions for therapeutic neovascularization.
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Introduction
Human peripheral blood contains bone marrow (BM)-derived progenitor cells with 
angiogenic properties1-3. These cells have the potential to differentiate towards endothelial 
cells and are therefore named endothelial progenitor cells (EPC). Transplantation of EPC 
has been shown to be effective in animal models for re-endothelialization4,5 and adult 
neovascularization6,7 as well as in human patient studies aimed to enhance myocardial 
regeneration after acute myocardial infarction7.  Although EPC are used in clinical trials, 
the exact phenotypic and lineage-/differentiation parameters of ex vivo expanded EPC are 
poorly defined and it is not clear which cell populations will be most effective in repair 
studies. EPC can be derived from CD34+ as well as CD34- or CD34low cells and can be 
isolated and expanded ex vivo using BM aspirates and peripheral blood CD14+ mononuclear 
cell fractions8-12. In many studies, EPC are characterized by their adhesive spindle-like 
morphology, staining with the endothelial cell binding lectin Ulex europaeus agglutinin 
(Ulex) and the capacity to endocytose acetylated LDL2,11. Although this may generally 
suffice for EPC studies dealing with EPC obtained from healthy animal models or humans, 
the different culture conditions and sources used may lead to a large heterogeneity and 
functionally  suboptimal EPC populations13,14. It has even been suggested that 
transplantation of certain cell fractions may contribute to adverse side effects15.  Clinical 
studies demonstrated that in patients suffering from diabetes and hypertension, the number 
of circulating EPC is severely decreased and the cells are dysfunctional16-19.  This altered 
phenotype of EPC could contribute to and might even endow the progression of the 
pathogenesis of ischemic vascular disease in these patients.
It has been shown that cells from the myeloid lineage, e.g. EPC, show a wide phenotypic 
overlap20 and as we demonstrate here that Ulex and the uptake of acLDL, among other 
often used endothelial markers, are not specific for EPC. Therefore discrimination is 
difficult between EPC and other myeloid cells such as dendritic cells (DC) and 
macrophages (Mph) which are also in close contact with the vascular system21,22. Myeloid 
progenitor cells exhibit a very high plasticity and under different circumstances a precursor 
cell can be skewed towards alternative differentiation directions14,23-26. 
To characterize better the nature of the angiogenic myeloid cell (EPC) compared to other 
myeloid cells and mature EC, we first performed a detailed comparative phenotypic and 
functional analysis of cells stimulated to differentiate into EPC, DC or Mph starting from 
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the same progenitor cell populations. Secondly, we have employed a transgenic mouse 
model expressing endothelial Nitric Oxide Synthase (eNOS) fused to green fluorescent 
protein (GFP)27.  The expression of the transgene is driven by the native human eNOS 
promoter and the transgenic mice show an endothelium specific expression pattern in many 
different organs. This transgenic mouse model therefore is expected to precisely distinguish 
cells from the EC lineage from other myeloid cells. 
Materials and methods
Animals.
C57BL/6J, and FVB wildtype mice 6-22 wk of age were obtained from Harlan (Horst, The 
Netherlands).  eNOS-GFP transgenic mice were generated as described previously27 and 
bred at the Central Animal Department of the Erasmus MC (Rotterdam, The Netherlands) 
under the institutional guidelines. 
Isolation and differentiation of murine EPC, DC and Mph 
Single-cell BM suspensions, were prepared by flushing femora and tibiae with medium. 
Mononuclear cells were isolated by ficoll density gradient centrifugation. Unless mentioned 
otherwise, EPC cultures were plated at a density of 1 x 106 cells per cm2 on 24-well plates 
(Nunc) coated with 10 µg/ml fibronectin (Sigma) and cultured up to 7 days in M199 
medium supplemented with 20% FBS (Invitrogen), 0.05 mg/ml Bovine Pituitary Extract 
(Invitrogen), antibiotics, and 10 units/ml heparin (Leo Pharma BV). Several different 
culture conditions were tested for optimal EPC culture condition14,16,18. Two different 
coating materials fibronectin (10 µg/ml ) and gelatin (2%, Sigma) were tested with either 
BPE-containing medium described above18 or endothelial basal medium (EBM) (Clonetics) 
supplemented with endothelial growth medium SingleQuots and 20% FCS16 with or without 
extra addition of Vascular Endothelial Growth Factor (VEGF, 100 ng/ml, Peprotech)14. 
Experiments using eNOS-GFP tg BM revealed that the combination of BPE containing 
medium and fibronectin-coated surfaces  are the most optimal conditions for generating the 
highest number of GFP+ EPC after 7 days of culture. These EPC culture conditions are used 
throughout the study, unless mentioned otherwise.
Mph and DC were cultured from total BM isolates in 10 cm Petri dishes (BD Biosciences) 
at a density of 2 x106. For DC culture we used 20 ng/ml recombinant murine GM-CSF 
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(Biosource) and for Mph cultures we used 10 ng/ml recombinant murine M-CSF 
(Peprotech). For activation, EPC, Mph and DC were incubated with 50 ng/ml 
Lipopolysaccharide (LPS, Sigma) at day 6. After overnight incubation at 37ºC, the culture 
supernatants were collected and frozen for cytokine measurements and the cells were 
harvested for mixed leukocyte reactions (MLR). 
An often used mouse brain derived mature endothelial cell line; bEnd3 was used for 
phenotypic comparisons as well as lung EC isolated from eNOS-GFP transgenic mice. The 
lung EC were harvested by collagenase treatment of murine lung tissue. Single cell 
suspensions were cultured with BPE containing medium (as described) on fibronectin 
coated flasks and the cells were cultured for 4-6 passages. 
HUVEC were isolated by trypsin treatment of umbilical cords and cultured with BPE 
containing medium for 3 passages.
Antibodies and conjugates for cell sorting, flow cytometric and immunohistochemical 
analysis
Undiluted culture supernatants of the hybridomas ER-MP12 (anti-CD31), ER-MP20 (anti-
Ly-6C), F4/80, MECA-20 (mouse endothelial cell antigen-20) were directly used for 
staining28. Phycoerythrin- (PE-) labeled anti-CD11c, biotinylated anti-MHC class II and 
anti-CD14 were purchased from BD Biosciences. Secondary antibodies FITC- or PE-
labeled goat anti-rat IgG (GαR-FITC or GαR-PE) were purchased from Caltag Laboratories 
and BD Biosciences respectively. ER-MP12 was purified and biotinylated and ER-MP20 
was labeled with FITC conjugate29. Biotinylated antibodies were detected with 
allophycocyanin-conjugated streptavidin (BD Biosciences). Directly PE-labeled murine 
antibodies directed to KDR, Sca-1, ckit and CD34 were purchased from BD Biosciences as 
well as the directly labeled PE isotype controls.  Unlabeled MECA-32 and VE-cadherin (BD 
Biosciences) and isotype controls were labeled with PE-labeled goat anti-rat IgG PE (BD 
Biosciences) and Flt-1 (Santa Cruz) and its isotype control was labeled with PE-labeled 
goat-anti Rabbit IgG (BD Biosciences). For lectin staining, cells were stained with 
rhodamine labeled Bandeiraea Simplicifolia lectin (BS-1 lectin 10µg/ml, Vector labs). This 
labeling was performed in cell suspension for flowcytometric analyses and for 
immunohistochemical stainings. To that end,  cells were attached to fibronectin coated-glass 
slides and incubated for half an hour and fixed with 3% paraformaldehyde. To visualize 
each cell nucleus, Hoechst (33258,  Invitrogen) staining was performed according to the 
manufacturers’ protocol. To measure the uptake of DiI-labeled acetylated LDL (Molecular 
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Probes) with flow cytometric analysis, cells were incubated (2.4 µg/ml) for 2 hours at 37°C 
and counterstained with Ulex europaeus agglutinin (UEA)-1 (10 µg/ml, Vector), further 
referred to as Ulex, for 1 hour.  Flowcytometric analyses expression were assessed using 
FACScan (BD Biosciences) and analyses were quantified using CellQuest software (BD 
Biosciences).
Cell sorting 
For cell sorting, BM-derived cells were labeled with ER-MP12bio (anti-CD31) and ER-
MP20fitc (anti-Ly-6C)29. Before sorting (FACSVantage; BD Biosciences), cell suspensions 
were filtered over a 30-µm pore size sieve (Polymon PES) to avoid clogging of the nozzle. 
After sorting, the purity of the cell suspensions was checked by re-analyzing sorted 
samples, and purity exceeded 95%. 
Cytokine detection
IL-10 and IL-6 ELISA kit (Biosource),  and IL-12p40 and IL-12p70 ELISA kits (R&D) 
were used according to the manufacturers protocol. 
MLR assay 
Mixed leukocyte reactions (MLR) were done with allogeneic T cells from C57/Bl6 
splenocytes. Cells were incubated with Abs recognizing CD11b, CD45 and MHCII and 
anti-rat IgG microbeads. Naïve T cells were obtained by negative selection using a 
magnetic cell sorter.  Stimulated (LPS) or non-stimulated DC, Mph and EPC were irradiated 
sub-lethally.  T  cells (1.5 x 105 cells/well) were added to varying concentrations of 
stimulator cells depending on the desired stimulator-responder cell ratio. Proliferation of T 
cells was measured after 4 days by uptake of ³H-thymidine (1 µCi/well, DuPont-NEN) and 
expressed as counts per minute (cpm).
 In vitro angiogenesis assay
 Conditioned media were obtained by replacing the medium of 6-day EPC cultures with 
serum-free EC basal medium-2 (Clonetics) supplemented with EGM-2 single aliquots (no 
vascular endothelial growth factor and basic fibroblast growth factor) and culturing the cells 
for an additional 16-20 h. EPC were counted and conditioned media were diluted to correct 
for cell numbers.  After 14 h,  tube formation by HUVECs was measured by staining the 
viable cells with Calcein-AM (5 µg/ml) (Molecular Probes). For quantification, total tube 
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area was determined using images obtained with an inverted fluorescence microscope and 
the Scion Imaging software (Scion Corporation) and expressed in arbitrary units. To see the 
ability of EPC, DC and Mph to incorporate and/or participate in the formation of vessel-
like structures, HUVEC were stained with PKH26 (Sigma),  a red fluorescent cell linker 
dye, according to the manufacturer’s protocol. EPC, DC and Mph were stained with 
Calcein-AM and the labeled cells were applied on the in vitro angiogenesis assay kit in a 
ratio of 1:4 (EPC: HUVEC). After 14 hours, incorporation/participation of EPC, DC and 
Mph were evaluated with a confocal microscope (Carl Zeiss) using z-stack images. 
Endocytosis assay. 
Uptake of dextran-FITC was done at 37°C and 4°C (negative controls) for 30 min. Cells 
were carefully washed and uptake of dextran was measured by flowcytometric analyses.
Real-Time Quantitative-PCR  (RQ-PCR)
Total RNA preparations sorted cell populations were performed using the RNeasy kit 
(Qiagen) and the integrity of RNA was checked before further use (Bioanalyzer, Agilent). 
mRNA expression of human eNOS and two murine normalization genes (Actin and 
GAPDH) were analyzed using quantitative RT-PCR.  cDNA was synthesized from total 
RNA samples using standard cDNA synthesis reagents and a 1:1 mixture of oligo dT(12-18) 
primers and random hexamer primers (Invitrogen). Quantitative analyses of the synthesized 
cDNA were performed with use of SYBR green I (Molecular Probes) in real-time PCR 
(Amplitaq Gold,Applied Biosystems), using an iCycler Thermal cycler (Biorad). Gene 
specific primer combinations were generated with Oligo Explorer (Gene link) and 
synthesized (Isogen). eNOS forward primer: GGCTCTCACCTTCTTCCTG, reverse 
primer: ACCACTTCCACTCCTCGTAG. For normalization genes, primer sets GAPDH 
forward: ACTCCCACTCTTCCACCTTC reverse: CACCACCCTGTTGCTGTAG and also 
actin forward:GACTTCGAGCAGGAGATG reverse:GGTACCACCAGACAGCAC were 
used. 
Samples were analyzed in triplicate and threshold cycle numbers and their SD were 
calculated using icycler v3.0a analysis software (Biorad) and further used to calculate 
expression ratio’s of the different samples in relation to both normalization genes.
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EPC colony formation (CFU-EC)
To assess the property of EPC to differentiate to EC and to proliferate we have used an 
established CFU-EC assay (Endocult,  StemCell Technologies). After 48 hours,  non-
adherent cells were collected and replated in fibronectin-coated 24-wells plates. After 3 
days, GFP+ colonies were detected using fluorescence microscopy.
 
Statistical analysis.
Results are expressed as mean ± SD. Probability values of P < 0.05 were considered 
statistically significant (Student t-test).
Results
Morphologic and Phenotypic comparison of EPC, DC and Mph derived from bone 
marrow.
Due to the high phenotypic overlap of EPC with other cells of the myeloid lineage it is 
important to define the criteria that characterize EPC in more detail. To that end, we first 
investigated morphological and functional differences between EPC, DC and Mph cultures 
obtained from mouse BM. In figure 1A (upper panel) the distinct morphology of the 
different cells at day 7 is shown. EPC showed typical spindle-shaped morphology, DC 
displayed long extended dendrites or veils and Mph were more rounded-up and attaching. 
EPC were capable of binding Ulex and taking up acLDL to the same extent as Mph. DC 
stained for Ulex but hardly took up acLDL particles. Therefore, Ulex staining combined 
with the uptake of acLDL are not appropriate markers restricted to EPC. 
Next we determined the expression of surface markers to further characterize EPC (CD31, 
MECA-20, MECA-32, BS-1 lectin, Flt-1, c-kit, Sca-1, KDR, VE-Cadherin and CD14), DC 
(CD11c and MHCII) and Mph (F4/80, CD11b) (Fig 1B, Fig I). EPC displayed a higher 
expression of MECA-20, CD14 and CD31, in comparison to Mph and DC (Fig 1B).   EPC 
and Mph showed a lower expression level of CD11c and MHCII when compared to DC. 
The Flt-1 receptor is highly up regulated in total population of the EPC but also on a small 
population of DC (Fig I). MECA-32 antibody showed expression on a very small subset of 
the EPC and no expression on Mph and DC, while MECA-20 (also reported as EC 
specific30,31) does show a higher expression on the EPC fraction when compared to DC an 
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Mph. Thus, a unique marker specifically defining EPC was lacking. At best, EPC could be 
characterized and distinguished from DC and Mph as spindle-shaped cells that were 
CD31hi, MECA-20hi, Flt hi and F4/80lo.  
Functional comparison of EPC, DC and Mph derived from bone marrow.
Conditioned medium (CM) of EPC, Mph and DC was tested for supporting formation of 
tube-like structures in an in-vitro angiogenesis assay.  While conditioned medium of DC and 
Mph hardly showed any induction of tube-like structures, EPC CM significantly augmented 
the formation of tube-like structures (Fig IIA). Secondly, using confocal microscopy, we 
compared the three different cell types for their ability to incorporate into and/or to 
 
Fig 1. Morphologic and phenotypic characterization of murine EPC compared to DC 
and Mph. 
(a) phase contrast microscopic morphological appearance (upper panel) and flow cytometric analyses 
of the ability of the different cells to bind the lectin Ulex and to take up DiI-labeled acLDL particles 
(lower panel). The analyses were plotted and non-stained cells served as negative controls (see 
quadrilles) (b) representative flow cytometric analyses of different lineage specific antigens. The thick 
green lines represent the DC, the thin dark line the EPC and the pink-dashed line the Mph. Cells were 
cultured for 7 days starting with total BM under optimized culture conditions as described in Methods.
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participate in the formation of tube-like structures.  While DC, Mph and EPC all attached to 
the protrusions of the EC, only EPC were able to specifically adhere to, and line up in tube-
like structures (Fig IIB, arrows). Thus, only EPC and not DC or Mph display genuine pro-
angiogenic properties by both factor production and participation in tube formation. 
Next, we addressed functional properties specific for Mph and DC. Macrophages 
endocytose to clear the body of pathogens, while DC mainly use their endocytic properties 
to present antigens to T  lymphocytes. Mph displayed a high endocytic capacity (fig IIC), 
 
Fig I. Additional phenotypical characterization of EPC, Mph and DC cultured for 7 days.
C57BL/6J BM was cultured under the appropriate conditions for all three cell types. Cells were harvested 
and stained for flow cytometric analysis with various antibodies. All antibody stainings (filled lines) were 
corrected with isotype controls (dotted line) and representative histograms are shown (5 experiments 
performed). Percentage of positive cells was calculated and staining of isotype controls were subtracted. No 
distinctive marker for EPC could be identified using these antibodies. Figure 1B, shows extra histograms for 
BS-1 lectin binding and for a myeloid marker CD11b.  
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 Fig II. Functional characterization of murine EPC compared to DC and Mph. 
(a) In vitro angiogenesis assay. Representative pictures of calcein-labeled tubular structures formed by HUVEC 
under conditioned media produced by EPC, DC or Mph. Quantitative analyses of the angiogenic capacity of the 
conditioned media were performed. Data are shown relative to non-conditioned media as control (-sup), which 
was set at 1.0. Only EPC were able to significantly (* P < 0.05) stimulate angiogenesis. (b) Incorporation into 
vessel like structures in vitro. The ability of EPC, DC and Mph to incorporate and/or participate in in vitro 
formed vessel structures was measured by using an in vitro angiogenesis setting. Thereby HUVEC were stained 
with PKH (red) and EPC, Mph and DC cultured for 7 days were stained with Calcein-AM (green). Cells were 
visualized by confocal microscopy and representative pictures show tubular EPC (arrowheads) while the 
morphology of DC and Mph did not change. (c) Endocytosis assay. The capacity of EPC, DC and Mph to take 
up large dextran-FITC molecules was examined on ice (filled blue plot; control) and at 37°C (green line). EPC   
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but EPC also showed an almost similar capacity to take up the dextran molecules. DC 
barely showed endocytic capabilities above control values. A typical feature of DC is 
antigen presentation to, and cytokine activation of, naïve T lymphocytes for instance in a 
mixed lymphocyte reaction (MLR). As expected, mature/activated DC were able to trigger 
T cell proliferation. EPC activated by LPS could do this as well, but to a lesser extent (Fig 
IID). Unstimulated EPC hardly induced T cell proliferation (data not shown). 
To evaluate the cytokine profile of EPC compared to that of DC and Mph we measured 
IL-6, IL-10, IL-12p70, IL-12p40 in CM of non-stimulated and LPS-stimulated cells. 
Although DC and Mph were capable of producing all four cytokines, EPC secreted 
detectable levels of IL-12p70 and IL-12p40 only. IL-12p70 was produced by the EPC to a 
similar level as Mph and DC and LPS stimulation of the EPC strongly enhanced this 
IL-12p70 production (Fig IIE). IL-12p40 was produced by EPC, although to a lower extent 
than by DC and LPS stimulated Mph. IL-12p70 has been shown to be an active subunit of 
IL-12, which can regulate T cell-mediated immune responses by promoting Th1 
development. It is striking that IL-12p70 is the predominant IL-12 subtype produced by 
EPC. Concluding, only EPC have the capacity to induce in vitro angiogenesis, yet they 
share with DC and Mph the capability to endocytose and are also able to act,  to some 
extend, as APC with IL-12 producing capacity. 
Tracking EPC differentiation by using the endothelial specific marker eNOS coupled to 
GFP.
Since there was a considerable phenotypic and also some functional overlap between the 
EPC, DC and Mph, we aimed to specifically track BM derived cells differentiating towards 
the endothelial lineage (EPC). Therefore a transgenic mouse model was used in which the 
mice show an endothelium-specific GFP expression pattern27. When BM of eNOS-GFP 
transgenic C57Bl/6J mice was harvested  (day 0) a small population of cells (about 0.05% 
 
and Mph efficiently phagocytozed dextran, whereas DC showed less capacity above control levels (ice). (d) 
Mixed lymphocyte reaction. The proliferation of T-lymphocytes was measured by incorporation of 3H-
thymidine at day 4 after initial contact with LPS-stimulated EPC, DC or Mph. The 3H-thymidine incorporation 
was counted and plotted in cpm. LPS stimulated EPC induced T cell proliferation to ~20% of the levels found 
by adding equal cell numbers of DC, but clearly showed stimulatory capacity in MLR compared to EPC only or 
T cell only. Values represent the means of triplicate measurements ± SD. This stimulatory capacity was slightly 
lower than the levels of LPS stimulated Mph. (e) ELISA’s were performed for IL6, IL10, IL12p70 and IL12p40 
with conditioned media of non-stimulated (light bars) as well as LPS-stimulated (dark bars) EPC, DC or Mph. 
Values represent the means of triplicate measurements ± SD. The only detectable cytokines produced by EPC 
were IL12p70 and IL12p40. LPS stimulation increased IL12p70 production, but not IL12p40 production.  
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of total cells) expressed GFP in the transgenic mice (tg) which is not present in control BM 
isolates (day 0) of wild type mice (wt) (fig.2A). At day 7 of culture under EPC culture 
conditions, about 15% (n=6, representative experiment shown) of the attached cells were 
GFP+ in the tg EPC. There is a high autofluorescent background of cells in the EPC cultures 
at day 7 in both FL1 and FL2 channels, which is seen in transgenic BM cultures as well as 
wildtype BM cultures.
When EPC cultures were flow-sorted at day 7 and the GFP- and GFP+ populations were 
replated separately at the same concentrations, only the GFP+ fraction (by definition 
expressing eNOS, fig IV) cells displayed the typical EPC morphology of spindle-shaped 
 
Fig 2. EPC from eNOS-GFP transgenic mice show a specific expression of GFP. 
(a) Expression of eNOS was measured in total BM of eNOS-GFP C57Bl/6J transgenic (tg) mice and 
compared with wildtype (wt) controls at day 0 and in day 7 EPC cultures using flow cytometry and GFP as a 
fluorescent marker. The FL2 channel shows autofluorescent staining. GFP+ and GFP– cells from day 7 EPC 
cultures were then sorted. Clear spindle shaped morphology typical for EPC was observed in the GFP+ 
fraction by phase-contrast microscopy. (b) DC and Mph were cultured for 7 days under their specific growth 
conditions and measured for eNOS-GFP expression. DC and Mph were stained with antibodies against typical 
mouse DC (CD11c) and Mph (F4/80) antigens. Only BM cells differentiated under EPC conditions showed a 
high eNOS-GFP expression, whereas Mph and DC cultures displayed no or hardly any GFP expression in 
combination with lineage specific antigens. (c) BM cells cultured in an CFU-EC assay, give rise to GFP+ 
colonies after 3 days of culturing, demonstrating the specificity of the eNOS marker for the EC lineage.  
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cells. The GFP- population hardly re-attached, indicating that these did not represent EPC. 
To ensure that the GFP reporter specifically tracks EC and EPC, BM cells of the transgenic 
mice were cultured with either GM-CSF to differentiate them to DC or with M-CSF for 
Mph- (fig 2B).  In the Mph culture no GFP+ cells were present and over 90% of the culture 
was F4/80hi. In the DC culture only a very small percentage (3%) of cells was found to 
express GFP at a low level. However these GFP+ cells did not express CD11c suggesting 
that these few GFP+ cells were not DC. 
To assess the property of BM-derived EPC to differentiate and proliferate in an in vitro 
colony assay and to exclude the possibility of a minute fraction of mature EC growing out 
in our cultures, we performed an established CFU-EC assay. BM of transgenic mice was 
plated on fibronectin-coated dishes for 48 hours and non-attaching cells were then replated 
and assessed for colony outgrowth (GFP+ colonies). There were hardly any cells attached to 
the plates after two days and these few cells did not survive and/or proliferate in the next 3 
days (data not shown). The non-attached fraction however did form GFP+ colonies as 
shown in figure 2C. This observation was extended when we sorted out the very small 
GFP+ population, presumably corresponding to a minute fraction of mature EC in BM. 
When cultured under EPC culture conditions, the GFP+ population did not survive and did 
 
Fig IV. Expression of eNOS mRNA in sorted cell populations. 
EPC were cultured for 7 days and GFP+ fraction was separated from the negative cells as 
shown in upper panel. Total RNA was extracted from the purified populations and eNOS 
mRNA expression was measured in both fractions relative to normalization genes GAPDH 
and Actin(not shown) using real time PCR techniques. Relative expression of eNOS 
normalized to GAPDH was calculated and is shown in lower left panel. 
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not expand (data not shown), while the GFP- population proliferated significantly and 
differentiated into eNOS+ GFP+ cells. 
We conclude that using this mouse model EPC differentiation can be tracked allowing 
identification and separation of true EPC from cells not committed to the endothelial 
lineage.  
 
Fig 3. Kinetics of EPC differentiation varies between different mouse strains. 
(a) BM of FVB- (FVB tg) and C57BL/6J-transgenic mice (BL6 tg) was cultured to generate EPC and 
the expression of eNOS-GFP was measured in time by flow cytometry for 7 days. The FL2 channel 
shows autofluorescence. (b) The percentage of GFP+ cells of the attached cells in culture was measured 
by flow cytometry and plotted (n=6, for both groups FVB tg and BL6 tg). At day 7, BM from BL6 tg 
mice showed fewer eNOS-positive EPC than BM from FVB tg, * P< 0.01, BL6 tg versus FVB tg.
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EPC differentiation varies between different mouse strains.
To further explore commitment of BM-derived cells towards the endothelial lineage, GFP 
expression was followed in time up to 7 days.  Because there could be differences between 
mouse strains we studied the kinetics of EPC differentiation in two different genetic 
backgrounds, C57BL/6J - and FVB eNOS-GFP transgenic mice.  At day 0,  there was no 
significant difference in the already very low number of GFP+. At day 1 the attached cells 
were GFP- (Fig.3A),  however, at day 4 eNOS-GFP+ cells appeared in both strains that 
expanded further in time. At day 4, a trend of higher numbers of GFP+ cells was observed 
in the FVB background mice, but this was not statistically significant. At day 7, over four 
fold more GFP+ cells were observed for FVB over the C57BL/6J strain (FVB mice 65 ± 
11% GFP+ cells (n=6) vs. C57BL/6J 15 ± 7.5% (n=6), *P<0.01) (Fig.3B). These data 
indicate that eNOS expressing EPC can be derived from BM of both strains tested, but 
more readily from FVB mice. 
Ex vivo expanded EPC from BM are mainly derived from a specific myeloid precursor 
fraction. 
Next we investigated which sub-fraction of the BM contains progenitors for EPC. Based on 
a two color flow cytometry analysis with ER-MP12 (anti-CD31) and ER-MP20 (anti-
Ly-6C), total BM cells can be separated in six phenotypically and functionally distinct 
subsets29.  We previously showed that three of these subsets contain myeloid progenitor 
cells28,32,33 that can give rise to macrophages and dendritic cells. Here, based on CD31/
Ly-6C profiles, all six subsets were flow-sorted from total BM of both eNOS-GFP 
transgenic mice and cultured under EPC conditions (Fig 4). 
In 4 out of 4 sort experiments GFP+ EPC appeared in the cultures derived from the CD31+/
Ly-6C+ (P4) subset. As expected, significantly fewer GFP+ cells appeared in the culture of 
the eNOS-GFP C57BL/6J background compared to the eNOS-GFP FVB. We previously 
demonstrated that almost 80% of this CD31+/Ly-6C+ (P4) cell fraction are myeloid 
progenitor cells indicating that the majority of EPC are derived from these cells. In 2 out of 
4 experiments we observed a few GFP+ cells in the CD31lo/Ly-6Chi (P6) subset but only in 
the FVB background. In 1 out of 4 sorting experiments a very small fraction of GFP+ cells 
was also seen in the CD31dim/hi/Ly-6Clo (P1/2) sub-fraction. As this fraction contains 
lymphoid progenitor cells and hematopoietic stem cells it could be that it takes longer to 
induce EPC differentiation from this fraction, or that the necessary factors are missing in 
the in vitro culture system used here.  In conclusion, the main source of EPC from BM is 
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the CD31+/Ly-6C+ (P4) subset, whereas DC and Mph can also be differentiated from the 
P1/2 and P6 fraction.   
Additional phenotyping of the CD31+/Ly-6C+ (P4) subpopulation in comparison to cultured 
EPC and mature EC (mEC, bEnd3 cells) showed that c-kit was markedly present in the BM 
 
Fig 4. EPC are mainly derived from a specific myeloid CD31+ /Ly-6C+ precursor fraction 
of the BM. 
(a) Fresh BM (day 0) of C57BL/6J (BL6 tg)- and FVB transgenic mice (FVB tg) was stained with CD31 
and Ly-6C antibodies revealing different myeloid fractions of the BM. (b) Several fractions P1/2  (P1 
and P2 together), P4 and P6 were sorted by flow cytometry and the fractions were cultured separately. 
After 7 days the cells were isolated and measured for eNOS-GFP expression by flow cytometry. Cells 
sorted from the P4 (CD31+/Ly-6C+) subpopulation differentiated most efficiently into EPC. FVB tg mice 
revealed higher numbers and more efficient EPC differentiation when compared to BL6 tg mice. 
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 Fig III: Phenotypical 
characterization of EC 
differentiation. 
A panel of stem cell markers and EC 
markers was used to characterize three 
different populations of cells in EC 
differentiation. These gated cell 
populations were CD31high/Ly6Chigh 
cells in freshly isolated BM, GFP+ cells 
derived from a 7 day EPC culture of 
eNOS-GFP transgenic FVB mice and as 
positive EC control we used a murine 
brain endothelial cell line also known as 
bEnd3 cells (A). 
Harvested cells were stained with a 
panel of antibodies and representative 
histograms out of 3 experiments 
performed are shown (filled line). 
Isotype controls were used (dotted line) 
and the percentages of positive cells 
above this background were calculated 
(figure 2B). 
Panel C shows extra characterization of 
the GFP+ EPC cells compare to mature 
EC. CD31 expression as well as CD11b 
expression was analyzed. As expected, 
an up regulation of CD31 was observed 
and on the contrary a diminished 
expression of CD11b, a myeloid marker 
could be seen. BS-lectin showed strong 
binding on both cell types and this 
binding was confirmed with 
immunohistochemistry, showing a 
distinct pattern of lectin binding. 
Similar results were obtained with 
cultured lung mEC cells derived from 
lung tissue of eNOS-GFP tg mice, when 
gated on the eNOS (GFP+) fraction 
(data not shown). The expression of 
GFP, reflecting eNOS expression was 
about 2.5 times higher on mEC 
compared to EPC. We also observed a 
marked difference in the side scatter of 
mEC and EPC (300 vs. 500 
respectively, data not shown)  
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P4 fraction, however very minor in the EPC cultures and absent in the mature EC cultures 
(Fig III B). A subpopulation of 11% of this P4 fraction showed Sca-1 expression, whereas 
Sca-1 expression seemed to be highly present on EPC as well as mature EC. The 
observation that Sca-1 is expressed on EC and even a possible function of expression of 
Sca-1 on EC has been proposed previously by Luna et al.34. VEGF-1 (flt-1) is highly 
expressed on eNOS+ cells, while KDR is not yet detectable. VE-cadherin is positive on a 
small subset of cells and has been confirmed by immunohistong (data not shown). CD31 is 
upregulated in EPC fraction and showed an even higher expression on mature EC (Fig 
IIIC). Myeloid markers such as CD11b were downregulated on GFP+ EPC and even further 
on mature EC, especially when compared to Mph and DC. BS-1 lectin staining of the total 
population of both EPC and mEC was confirmed by flowcytometric as well as 
immunohistochemical analyses. We conclude that, with the notable exception of Sca-1, 
EPC express higher levels of progenitor/stem cell markers than mature EC and begin to 
express EC-specific markers while downregulating classical myeloid markers, consistent 
with a further narrowing of differentiation potential towards the EC lineage.
 
Fig 5. Addition of specific growth factors to EPC cultures has different effects depending on 
the source of the EPC. 
EPC were cultured using either BM (a) or spleen-MNC (b). The cells were cultured under standard optimized 
EPC conditions (MH-) or with addition of M-CSF (10 ng/ml), GM-CSF (20 ng/ml) or a combination of both. 
These cytokines were either refreshed every 2 days (black bars) or they were only added once at day 0 (grey- 
bars). After 7 days cells in culture were counted and the total number of GFP+ cells per well was determined 
by FACS. A 2-3-fold increase in the number of GFP+ EPC was observed by addition of growth factors in 
cultures from spleen-derived cells, but not with BM cells. Refreshing the growth factors every two days or 
addition only once at day 0 showed a similar proliferation/differentiation pattern. A representative experiment 
is shown.
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Spleen derived EPC can be expanded using myeloid specific growth factors
The therapeutic potential of EPC has elicited a number of studies that demonstrated that 
myeloid growth factors can stimulate recruitment, differentiation or outgrowth of EPC and 
may have favorable effects on their function35-37.  Therefore, the effects of GM-CSF and M-
CSF on EPC differentiation from BM were determined. Addition of these myeloid growth 
factors to the cultures lowered the numbers of EPC (GFP+ cells) derived from the BM 
precursors (Fig 5A).   Other sources than BM have been used to derive human EPC and 
murine EPC. Human EPC can be cultured from CD14+ mononuclear cell fractions isolated 
from peripheral blood mononuclear cells (PB-MNC)10,11 or from CD34+ progenitor cells 
isolated from G-CSF-mobilized peripheral blood (PB) stem cells37 umbilical cord blood13 
or BM38.  Murine EPC have been cultured from BM and spleen. The mononuclear cell 
fraction of the spleen is often used as a homologue of PB-MNC from mice as it is described 
as a reservoir of peripheral blood stem/progenitor cells39. Spleen-derived murine EPC have 
similar functional (angiogenic) and phenotypic characteristics as BM-derived EPC (data not 
shown), but they show a lower proliferation capacity. Using the same culture conditions as 
described above for the generation of BM-derived EPC, spleen-derived cultures yielded 
10-50 fold lower numbers of GFP+ EPC (Fig 5B).  Addition of myeloid growth factors to 
spleen-derived cultures showed an increase in the number of EPC. Thus addition of 
myeloid growth factors as GM-CSF and M-CSF could be useful for expanding PB-or 
spleen derived EPC ex vivo, but not for BM derived EPC.
Discussion
 
In this study we characterized the ex vivo commitment of BM-precursors towards 
endothelial cells in terms of phenotype, lineage potential,  differentiation from BM 
precursors and angiogenic properties. In order to address these issues in detail and to have 
an endothelium specific marker we made use of eNOS-GFP transgenic mice. This well 
characterized system27 allows a careful appreciation of the relationship between myeloid 
and endothelial lineages. Our report emphasizes the high phenotypic overlap and close 
relationship of EPC, DC and Mph. Consequently, frequently used markers for EPC, such as 
the uptake of acLDL and binding of Ulex, are relatively unspecific as these are also markers 
for Mph. Despite this high phenotypic overlap of EPC, DC and Mph, the capacity of EPC 
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to support angiogenesis is a unique feature of EPC when compared to DC and Mph. While 
we could demonstrate a potent angiogenic capacity in the CM of EPC, we observed that 
only a small fraction of the EPC did incorporate (as do mature EC) in tubes. The majority 
of the EPC appears to function as pericytes and localize around the tubes and under the 
junctions, but do not form an integral part of it. Other investigators also found that 
attaching cells derived from BM or PBMC under culture conditions with VEGF did not 
differentiate into EC, but stimulated angiogenesis in other ways11,40.  Therefore, the term 
endothelial progenitor cells might not be an adequate definition of the total cell culture,  as 
not all cells might become true endothelial cells under the conditions used. Although we 
generally refer to these attaching cells with angiogenic capacity as EPC, following the 
consensus in the field, the term angiogenic myeloid cells may be more appropriate. 
Nevertheless, the cells referred to as EPC are different from mature EC, as demonstrated in 
the CFU-EC assays and by phenotypic analysis.  EPC also express higher levels of stem 
cell markers, but lower levels of eNOS, although they are clearly positive for this marker.
We showed that there is a strain difference between FVB and C57Bl/6J mice in their 
capacity to generate EPC from BM precursors. FVB mice are less susceptible for 
atherosclerosis41 and this might possibly indicate a role for the plasticity of bone-marrow 
precursors to differentiate towards EC. As a corollary, we conclude that C57Bl/6J mice 
might not be the best strain to choose for studying short-term cultured murine EPC.  
A number of studies indicated that myeloid growth factors like GM-CSF can be used to 
augment neovascularization in animal models and in patients42.  In this study, only for 
spleen-derived EPC the number of eNOS-GFP+ EPC increased. In BM, addition of M-CSF 
and GM-CSF to the culture resulted in a decreased number of EPC, probably due to 
extensive expansion of myeloid progenitors that are driven into another differentiation 
lineage than EC, such as DC and Mph.
It is becoming increasingly apparent that cells of the myeloid lineage display a high 
plasticity and that some of these seemingly “lineage-committed” myeloid cells can, under 
specific growth conditions, differentiate into cells of another lineage with distinct 
functional properties20,25,43. For instance, in the presence of inflammatory cytokines,  the 
normal differentiation of monocytes into macrophages can be skewed to yield dendritic 
cells26. Another example is the differentiation of myeloid cells into cells of the 
mesenchymal lineages44. Likewise, several reports have described the myeloid character of 
endothelial cells12,20,45.  Cultures of adhered mononuclear cells12 or dendritic cells46,47 grown 
under stringent angiogenic differentiation conditions have been shown to differentiate into 
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endothelial like cells.   We argue that this large degree of plasticity among cells of the 
myeloid lineage and the close phenotypic overlap between many of these different myeloid 
lineages (including cells that stimulate angiogenesis) cautions the use of these cells in 
clinical cell transplantation protocols aimed to augment neovascularization in peripheral or 
cardiac ischemia. In particular when early outgrowth EPC are derived from patients that are 
subject to chronic systemic inflammation, transplanted cells might have sub-optimal 
angiogenic properties or even induce an unwanted immunological response.
In the present study, we observed that LPS-stimulated EPC cultures have the capacity, 
although to a low extent, to induce T-cell proliferation in an MLR. 
Using short cultured cell sorting experiments, we here show that the best and almost 
exclusive source for murine EPC are the myeloid progenitors in the BM. This myeloid 
character of EPC is in line with a recent study from Dimmeler and co-workers showing that 
CD34lowCD14+ cells in peripheral blood are a major source of EPC10. Translating our 
results to the human situation suggest that further purification of human CD34+ cells to 
include only CD33+ (immature myeloid marker) /CD34+ myeloid progenitors,  but exclude 
contaminating cells that may yield unwanted side-effects, could be of clinical relevance. 
Further experiments have to determine whether human myeloid progenitor cells from BM 
or cord blood provide a superior source of EPC.
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Abstract
Bone marrow (BM)-derived endothelial progenitor cells (EPC) contribute to endothelial 
maintenance and repair. Risk factors for ischemic vascular disease such as diabetes mellitus 
not only affect the mature endothelium, but also lead to EPC dysfunction. To explore the 
impact of hyperglycemia on the differentiation of EPC from bone marrow progenitor cells, 
mice were maintained hyperglycemic for 6 weeks. Cultures generating EPC, macrophages 
(Mph) or dendritic cells (DC) from hyperglycemic BM yielded 40% fewer EPC and 50% 
more Mph compared to control bone marrow. These changes were directly related to the 
HbA1C levels of the donor mice. In contrast, BM-derived DC numbers were not affected 
by hyperglycemia. The composition of the BM was not altered; in particular the numbers of 
CD31+/Ly6C+ cells,  which serve as common progenitors for EPC, Mph and DC were 
unaffected. In addition to their lower quantity, BM-derived EPC from hyperglycemic mice 
were less angiogenic and more pro-inflammatory in terms of endocytosis,  T-cell activation 
and IL-12 production. HMGCoA reductase inhibition by statin supplementation of the 
culture medium counteracted these hyperglycemia-induced changes. Our data indicate that 
EPC dysfunction in diabetes is BM-derived,  due to hyperglycemia-induced alteration of 
myeloid progenitor cell differentiation. 
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Introduction
Loss of endothelial integrity and an impaired capacity for ischemia-induced 
neovascularization leads to ischemic vascular disease in diabetes1-3.  A recently identified 
risk factor for these vascular complications is dysfunction of bone marrow (BM)-derived 
endothelial progenitor cells (EPC).  Under normal circumstances, EPC contribute to 
vascular homeostasis by replacing apoptotic or lost endothelial cells4,5. In addition, EPC 
can home to sites of denudation6, ischemia or elevated shear stress to stimulate 
neovascularisation or arteriogenesis7,8. In patients with type 19 and 2 diabetes10 and in 
diabetic animals11-13,  the number of circulating EPC  is decreased and functional parameters 
such as adhesion, migration and the paracrine secretion of proangiogenic factors are 
impaired,  likely as a consequence of hyperglycemia. Moreover, a recent study showed that 
the number of circulating EPC inversely correlates with the severity of peripheral vascular 
complications of patients with type 2 diabetes further supporting a role for EPC dysfunction 
in the pathogenesis of ischemic vascular disease14. Following these notions, EPC are 
increasingly recognized as a potential therapeutic target for the prevention of ischemic 
vascular disease. However, the molecular mechanisms underlying EPC dysfunction in 
diabetes are complex and may include reduced cell survival11,15 due to an increased 
sensitivity to oxidative stress16 or activation of a p53-dependent pathway that leads to 
cellular senescence16,17. 
Human EPC can be derived from either CD34+, CD34- or CD34low cells and can be cultured 
from BM aspirates and peripheral blood CD14+ mononuclear cell fractions18-21. This 
heterogeneity in precursor cells likely reflects the different stages of EPC as they mature 
from the early bone marrow-derived stem cells towards mature vascular endothelial cells. 
Many studies have shown that cells of the myeloid lineage display high plasticity and that 
seemingly “lineage-committed” myeloid cells,  given the appropriate conditions, can 
differentiate into cells of another lineage with different functional properties22. For 
example, in the presence of inflammatory cytokines, the normal differentiation of 
monocytes into macrophages (Mph) can be skewed to yield dendritic cells (DC)23.  We 
recently demonstrated that angiogenic EPC develop from an immature, CD31+/Ly-6C+ 
myeloid progenitor fraction in mouse BM24. Upon stimulation by the proper differentiation 
factors, Mph and DC are also derived from this fraction25,26, suggesting a common myeloid 
progenitor pool for EPC, Mph, granulocytes, monocytes and DC. 
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As diabetes is increasingly appreciated as a systemic pro-inflammatory state27,28 that might 
affect cell-fate specification or developmental decisions, we here investigated the 
differentiation of EPC, Mph and DC from BM-derived myeloid progenitor cells of 
hyperglycemic and normoglycemic mice. Our results support the hypothesis that EPC 
dysfunction in diabetes is bone marrow-derived due to hyperglycemia-induced alterations 
in differentiation of myeloid progenitor cells.
Materials and methods
Animals
Moderate to severe hyperglycemia was induced in 6 week old C57BL/6J and FVB/N mice 
(Harlan,  Horst, The Netherlands) by intraperitoneal (IP) injections of streptozotocin (STZ, 
80 mg/kg body weight; Sigma-Aldrich) in 0.05 mol/l Na-Citrate buffer pH 4.5,  on two 
consecutive days. Blood glucose levels were examined by glucose-oxidase technique 
(OneTouch Ultra system, Lifescan) 1 week after STZ injection and mice with blood glucose 
levels below 20 mmol/l mice received two additional injections on two consecutive days. 
When necessary this procedure was repeated a third time. STZ treatment was stopped when 
blood glucose levels above 20 mmol/l were reached and glucose levels and total body 
weight were monitored weekly for a period of 6 weeks. Control mice were injected with 
buffer only at the onset of the experiments. Mice from the STZ treatment groups that 
showed no elevated blood glucose levels (below 15 mmol/l) were excluded from the study. 
All procedures involving animal handling were in accordance to national and institutional 
guidelines of the Erasmus MC, Rotterdam, The Netherlands.
Glycosylated hemoglobin
Glycosylated hemoglobin (HbA1C) levels were measured by High Performance Liquid 
Chromatography (HPLC) using a reverse-phase cation exchange column and detected by a 
dual wavelength colorimetric (415 and 500 nm) analyzer (ADAMS A1c HA8160; Arkray). 
Isolation and differentiation of murine EPC, DC and Mph 
BM-cell suspensions were prepared by flushing femora and tibiae with RPMI medium 
(Gibco) supplemented with 10% FCS (Gibco) and antibiotics (penicillin/streptomycin, 
Gibco). To culture EPC, total BM cell suspensions were plated at a density of 1.25 x 106 
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cells per cm2 in 24-well plates (Nunc) coated with fibronectin (10 µg/ml, Sigma). Cells 
were cultured for 7 days in M199 medium supplemented with 20% FBS (Invitrogen), 0.05 
mg/ml Bovine Pituitary Extract (Invitrogen), antibiotics, and 10 units/ml heparin (Leo 
Pharma BV). 
For Mph and DC, 2 x106 BM cells were cultured in complete RPMI medium described 
above and plated on 10 cm Petri dishes (BD Biosciences). Medium was replaced every two 
days. For DC and Mph cultures, the medium was supplemented with 20 ng/ml recombinant 
murine GM-CSF (Biosource) and 10 ng/ml recombinant murine M-CSF (Peprotech), 
respectively. Atorvastatin (Pfizer) was dissolved in ethanol and,  in indicated experiments, 
added to the medium to a final concentration of 0.1 µmol/l.  Medium used in the control 
experiments contained ethanol at a similar final concentration (5x10-5 %) as present in the 
cultures treated with atorvastatin.  
Monoclonal antibodies, conjugates and flow-cytrometric analysis
Undiluted culture supernatant of the hybridoma F4/80 was directly used for staining. ER-
MP12/CD31 was purified and biotinylated and ER-MP20/Ly-6C was conjugated to 
FITC25,29.  Phycoerythrin-(PE-) labeled CD11c and biotinylated anti-MHC class II 
antibodies were purchased from BD Biosciences.  Secondary FITC- or R-PE-labeled goat 
anti-rat IgG antibodies (mouse-absorbed; GαR-FITC or GαR-PE) were purchased from 
Caltag Laboratories. Biotinylated antibodies were detected with allophycocyanin-
conjugated streptavidin (BD Biosciences). For EPC characterization, cells were stained 
with rhodamine-labeled Bandeiraea simplicifolia lectin (10µg/ml,  BSL-1, Vector Labs) for 
1 h.  To measure the uptake of Dil-labeled acetylated LDL (acLDL, Molecular Probes), cells 
were incubated with acLDL (2.4 µg/ml) at 37°C for 2h. Flowcytometric analyses were done 
on a Calibur flowcytometer (BD Biosciences) using CellQuest software (BD Biosciences). 
Cytokine detection
For cytokine measurements EPC were incubated with 50 ng/ml lipopolysaccharide (LPS, 
Sigma) overnight at 37°C. Culture supernatants were collected and cells were counted for 
normalization.  IL-12p40 and IL-12p70 ELISA kits (R&D) were used according to the 
manufacturer’s protocol. 
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MLR assay 
Mixed leukocyte reactions (MLR) were done with allogeneic T cells from C57BL/6J or 
FVB/N splenocytes. Cells were incubated with antibodies recognizing CD11b, CD45 and 
MHCII and anti-rat IgG microbeads. Naive T  cells were obtained by negative selection 
using a magnetic cell sorter. DC, Mph and EPC were irradiated sub-lethally.  T cells (1.5 x 
105 cells/well) were added to varying concentrations of stimulator cells depending on the 
desired stimulator-responder cell ratio. Proliferation of T cells was measured after 4 days by 
uptake of ³H-thymidine (1 µCi/well, DuPont-NEN) and measured as counts per minute 
(cpm).
In vitro angiogenesis assay. 
Conditioned media were obtained by replacing the medium of 6-day EPC cultures with 
serum-free EC basal medium-2 (Clonetics) supplemented with EGM-2 single aliquots 
(without vascular endothelial growth factor and basic fibroblast growth factor) and 
culturing the cells for an additional 20 h. EPC were counted and conditioned media were 
diluted to correct for cell numbers. After 14 h, tube formation by HUVECs was measured 
by staining the viable cells with Calcein-AM (5 µg/ml, Molecular Probes). HUVEC 
cultures were isolated as described30 and used at passage 3 or less. For quantification, total 
tube area was determined using images obtained with an inverted fluorescence microscope 
and Scion Imaging software (Scion Corporation) and expressed in arbitrary units of tube 
length.
Endocytosis assay
Uptake of dextran-FITC was determined for 30 min,  both at 4°C and 37°C. Subsequently, 
the cells were washed three times with PBS/BSA1% and total uptake of FITC label was 
measured by FACS analyses and expressed by the difference in geometric mean that 
resulted from subtracting the values obtained at 4°C from the values obtained at 37°C.
Statistical analysis
Differences between treatment groups were analyzed Student’s t test. Results are expressed 
as mean ± SD. Linear regression analyses and Pearson correlation were used for 
comparison of the number of EPC/Mph and HbA1c. Probability values of P < 0.05 were 
considered statistically significant.
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Results
Hyperglycemia induction in mice 
In both mouse strains used (C57BL/6J and FVB/N), STZ treatment increased blood glucose 
levels up to 3.5 fold,  associated with increased HbA1C levels (Table 1).  Body weight was 
25-30% reduced in hyperglycemic mice of both strains when compared to normoglycemic 
control animals. Total BM cell isolations from tibiae and femora yielded an equal number 
of cells in hyperglycemic and control C57BL/6J mice whereas in FVB/N mice the 
hyperglycemic state was associated with a minor 1.3 fold increase in the number of BM-
derived cells. 
Hyperglycemia differentially alters the potential of BM cells to yield EPC, Mph and DC
To determine the effects of hyperglycemia on the potential of BM progenitors to generate 
EPC, total BM cells were harvested from hyperglycemic and control mice and equal 
numbers of cells were cultured for 7 days to differentiate into EPC. We previously provided 
evidence that EPC, Mph and DC may share a common myeloid progenitor pool in the 
BM24. Therefore, the potential of the BM cells to differentiate into F480+ Mph and CD11c+ 
DC, in M-CSF- and GM-CSF-stimulated cultures, respectively, was assessed in parallel to 
the EPC cultures. In EPC cultures from BM of hyperglycemic mice from both strains we 
observed on average a 40% reduction in the number of EPC, identified as cells positive for 
 
C57BL/6J
Control
C57BL/6J
STZ
FVB/N
Control
FVB/N
STZ
n 18 26 17 23
Blood glucose (mmol/l) 6.7 ± 2.0 24.1 ± 5.5 * 9.1 ± 1.8 27.8 ± 4.5 *
HbA1c % 3.9 ± 0.2 7.6 ± 0.7 * 4.1 ± 0.5 5.9 ± 0.5 *
Weight (gram) 28.5 ± 2.2 20.0 ± 1.2 * 30.5 ± 2.3 22.5 ± 2.9 *
Bone marrow cells x108 0.8 ± 0.3 0.8 ± 0.2 0.7 ± 0.2 0.9 ± 0.3 
Table 1. Mouse characteristics. 
Parameters were measured after 6 weeks of STZ-induced hyperglycemia or in littermate control mice 
matched for age and gender that were injected with buffer. Values represent mean ± SD, *: P < 0.05 
v.s. buffer. 
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CD31 and acLDL (Fig. 1A). In contrast,  the number of Mph was approximately 50% 
increased. No differences were observed in the yield of DC in cultures from both strains of 
mice. Figure 1B shows that the number of EPC obtained inversely correlated with 
peripheral blood HbA1c levels of individual mice, indicating that the observed decrease in 
EPC numbers directly relates to the degree of hyperglycemia. In contrast,  the number of 
Mph showed a positive correlation with the degree of hyperglycemia whereas the varying 
numbers of DC derived from the cultures showed no relationship with HbA1c levels. Taken 
 
Figure 1. Hyperglycemia alters the differentiation potential of myeloid progenitors in BM. 
(A) Relative change in the number of bone marrow-derived EPC, Mph and DC from STZ-treated mice 
(black bars) compared to control mice (white bars). Values for EPC, Mph and DC derived from BM from 
mice treated with buffer are set to 100%. Top panel: number of CD31high /Dil-acLDL-positive, attaching 
cells in EPC cultures (C57BL/6J; 4 experiments, nbuffer = 18 and nSTZ = 26 and FVB/N; 5 experiments, 
nbuffer= 17 and nSTZ = 23). Middle panel: the number of F4/80 positive cells in M-CSF-stimulated Mph 
cultures (C57BL/6J; 3 experiments, nbuffer = 13 and nSTZ = 18 and FVB/N; 3 experiments, nbuffer = 13 and 
nSTZ = 16). Bottom panel: number of CD11c positive cells in GM-CSF-stimulated dendritic cell cultures 
(C57BL/6J; 3 experiments, nbuffer = 13 and nSTZ = 18 and FVB/N; 3 experiments, nbuffer = 13 and nSTZ = 
16). (B) Correlations between the number of cultured EPC (top panel), Mph (middle panel) and DC 
(bottom panel) and hyperglycemia as assessed by HbA1c. Representative experiment using BM from 
hyperglycemic C57BL/6J mice (n = 9).
Chapter 6
134
together, hyperglycemia affects myeloid progenitor cells in BM and alters their potential to 
differentiate into different myeloid lineages.  
Hyperglycemia has no major quantitative impact on the subpopulation composition of 
myeloid progenitors of the BM
To evaluate if the observed altered number of bone marrow-derived EPC and Mph from
 hyperglycemic mice was due to quantitative shifts in myeloid progenitor fractions of the 
BM, total BM was immunostained using ER-MP12 (anti-mouse CD31) and ER-MP20 
(anti-mouse Ly-6C) and analyzed by flowcytometry. Using this combination of markers25, 6 
distinct subpopulations of BM cells can be identified, each with varying degrees of lineage 
commitment and progenitor potential (Figure 2). The populations consist of: (P1) 70% blast 
 
Figure 2. Hyperglycemia has no major quantitative impact on the myeloid progenitor 
fractions of the BM. 
BM of the control and hyperglycemic mice was harvested and immediately stained with anti-CD31 
and anti-Ly-6C. Using this combination of markers, 6 distinct populations can be identified (P1-
P6). For each subpopulation, the average increase or decrease in BM cell fractions from 
hyperglycemic mice is depicted as the percentage change relative to nondiabetic mice. In the top 
panel representative scatter plots from hyperglycemic BM are shown for each strain. For both 
strains the average percentage and standard deviations were calculated from 3 experiments 
(C57BL/6J: nbuffer = 15 and nSTZ = 18 and FVB/N; nbuffer = 13 and nSTZ = 14, *P < 0.001) 
C57BL/6J
Change % 
FVB/N
Change %
CD31high/Ly6Clow   (P1) 112 ±  34 104 ± 62
CD31med/Ly6Clow    (P2) 58 ± 10* 57 ± 30*
CD31low/Ly6Clow     (P3) 108 ± 18 104 ± 16
CD31high/Ly6Chigh  (P4) 128 ± 54 121 ± 56
CD31low/Ly6Cmed    (P5) 148 ± 63 104 ± 35
CD31low/Ly6Chigh    (P6) 112 ± 95 129 ± 98
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cells and 25% lymphoid cells; (P2) lymphoid cells; (P3) erythroid cells; (P4) myeloid 
progenitors and plasmacytoid cells; (P5) granulocytes; (P6) 75% monocytes and 20% 
monocyte progenitors25.  As previously shown, Mph and DC can originate from CD31high/
Ly6Clow(P1), CD31high/Ly6Chigh(P4) and CD31low/Ly6Chigh(P6) fractions25,26.  However, 
short term cultured EPC are mainly derived from the CD31high/Ly6Chigh fraction24.  When 
comparing the BM myeloid cell subpopulations from hyperglycemic and control mice, we 
found no significant quantitative differences in the three fractions from which EPC, Mph 
and DC can be derived in short term cultures (Figure 2). The only subpopulation that was 
altered was the CD31med/Ly6Clow lymphoid and HSC fraction (P2) that was 40% decreased 
in the BM of hyperglycemic mice of both strains. In line with the observation that the total 
cell number that can be harvested from the BM of these mice is not, or only marginally 
changed (Table 1),  we conclude that hyperglycemia does not affect the quantitative 
composition of the myeloid progenitor subpopulations in the BM, but rather alters their 
differentiation potential. 
BM-derived EPC from hyperglycemic mice display a pro-inflammatory phenotype
To investigate whether functional properties of EPC cultured from hyperglycemic BM are 
altered in comparison to those from control BM, we compared their angiogenic and pro-
inflammatory potentials (Table 2).  We first determined the angiogenic properties of EPC-
conditioned medium in an in vitro angiogenesis model. When HUVEC were seeded on 
matrigel and maintained for 14 h in conditioned medium of EPC derived from control 
C57BL/6J and FVB/N mice, tube formation was markedly stimulated when compared to 
non-conditioned medium (non-conditioned media 0.37 ± 0.13 A.U. of tube formation (n = 
3) P = 0.04 and P < 0.001 respectively). Conditioned media of EPC from FVB/N mice 
induced more capillary formation than EPC-conditioned media of C57BL/6J mice (P = 
0.01). In contrast, conditioned media of EPC from hyperglycemic mice supported tube 
formation by only 43% (C57BL/6J, P = 0.03) and 35 % (FVB/N,  P = 0.02) compared to the 
control values (Table 2).  Next we examined to what extent the different EPC display pro-
inflammatory properties that are typical for myeloid antigen-presenting cells like the ability 
to endocytose, the capacity to activate T cell proliferation and the expression of pro-
inflammatory cytokines. Table 2 shows that EPC from hyperglycemic mice displayed a 
trend towards a higher capacity to endocytose large dextran molecules,  when compared to 
EPC from normoglycemic mice. C57BL/6J EPC show a higher capacity to endocytose 
when compared to FVB/N mice (P < 0.001). To assess whether the capacity of Mph derived 
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from hyperglycemic mice to endocytose was altered, Mph were cultured from 
hyperglycemic and control mice. Mph derived from hyperglycemic BM from C57BL6/J 
mice showed a trend towards a higher capacity to take up large dextran molecules, while 
FVB/N-derived Mph showed a small but not significant decrease when derived from 
hyperglycemic BM. 
When the EPC fractions were tested for their capacity to stimulate T-cell proliferation in 
mixed lymphocyte reaction assays (MLR),  again for both strains we observed a trend 
towards a higher inflammatory capacity of the EPC from hyperglycemic BM. This was 
supported by our findings on the ability of the cells to produce IL-12 upon LPS stimulation 
IL-12p70, the active form of the pro-inflammatory IL-12, can regulate T  cell-mediated 
immune responses by promoting Th1 development and we have previously shown that it is 
the predominant IL-12 subtype produced by EPC24. As shown in table 2, IL-12p70 levels 
were elevated in the conditioned medium of EPC from hyperglycemic mice,  ranging from 
2.3 fold for C57BL/6J mice (P = 0.006) up to 4 fold for FVB/N mice (P < 0.001). The 
IL-12p40 subunit was also about 2 fold higher in supernatants from EPC derived from 
hyperglycemic mice as compared to the supernatants of control EPC (C57BL/6J mice (P = 
0.001), FVB/N mice (P = 0.02).  Because elevated inflammatory properties were observed 
under hyperglycemic conditions, BM-derived EPC were further phenotypically 
 
C57BL/6J
Control (n)
C57BL/6J
STZ (n)
P value FVB/N
Control (n)
FVB/N
STZ (n)
P value
Angiogenesis length tubes (A.U.) 0.47 ± 0.17 (8) 0.27 ± 0.12 (8) 0.03 * 0.77 ± 0.19 (12) 0.50 ± 0.20 (12) 0.02*
Endocytosis EPC Δ geo mean 63.6 ± 18.0 (9) 78.8 ± 21.2 (15) 0.12 20.7± 17.9 (8) 42.3 ± 15.2 (8) 0.09
Endocytosis Mph Δ geo mean 47.0 ± 8.6 (3) 62.7 ± 8.0 (3) 0.13 78.3 ± 7.6 (3) 68.8 ± 11.4 (3) 0.28
MLR  3H-thymidine incorporation (%) 100 (9) 176 ± 71 (15) 0.15 100 (6) 139 ± 27 (8) 0.08
IL-12p40 concentration (pg/ml) 26.9 ± 13.2 (8) 64.4 ± 19.3 (8) 0.001* 29.3 ± 13.5 (8) 56.6 ± 24.3 (8) 0.02*
IL-12p70 concentration (pg/ml) 78.4 ± 28.1 (8) 155 ± 52.5 (8) 0.006* 62.7 ± 44.3 (8) 262 ± 63.1 (8) < 0.001*
Table 2. Angiogenic and pro-inflammatory properties. 
Functional analyses of EPC and Mph cultured for 7 days from control and hyperglycemic BM. Listed are the 
capacity of EPC-conditioned media to stimulate in vitro formation of tubular structures by HUVEC (n = 8, each 
group), the capacity of EPC and Mph to endocytose large dextran molecules labeled with FITC as measured by 
FACS analyses and expressed as the delta geo mean (Δ), the capacity of EPC to stimulate T cell proliferation as 
assessed by allogeneic MLR (determined by measuring 3H-thymidine incorporation and expressed in percentage 
compared to EPC from controls), and the expression of the pro-inflammatory cytokine  IL-12p40 and IL-12 p70 
production by EPC after LPS stimulation (n = 8 per group). 
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characterized by flow cytometry analyses. However, when EPC from hyperglycemic and 
control mice were stained with either anti-F480 or anti-CD11c antibodies, to reveal a more 
Mph- or DC-like phenotype, no significant differences could be observed (data not shown). 
Taken together, EPC derived from hyperglycemic mice have a reduced angiogenic capacity 
but are more pro-inflammatory as they secrete more IL-12 and they show a trend for an 
elevated capability to endocytose exogenous material and to stimulate naïve T cells. 
 
Figure 3. Atorvastatin reverses hyperglycemia-induced changes in progenitor 
commitment and EPC function. 
Number of EPC (A) and Mph (B) cultured from BM of control and hyperglycemic mice (n = 6 
per group). (C) Tube formation in arbitrary units (AU) in response to medium conditioned by 
EPC from control and hyperglycemic mice (n = 6 per group) cultured in the absence (white bars) 
or presence of atorvastatine (black bars). 
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Statin treatment in vitro restores affected progenitor commitment and EPC function of 
hyperglycemic mice
HMG-CoA reductase inhibitors have been shown to be potent anti-inflammatory agents31. 
Moreover, they elevate EPC numbers in vitro32 and in vivo33 and interfere with the 
differentiation of monocytes towards Mph34,35. Therefore, in separate experiments, we 
explored the effect of atorvastatin on the hyperglycemia-induced effects on BM-derived 
EPC and Mph. BM cells of hyper- and normoglycemic C57BL/6J mice were cultured for 7 
days to obtain EPC and Mph. As expected, lower numbers of EPC were derived from BM 
of hyperglycemic mice (P = 0.04). When atorvastatin (0.1 µmol/l) was present in EPC 
cultures from hyperglycemic mouse BM, the number of EPC was normalized to levels 
obtained from control mice (Figure 3A). Conversely, the number of Mph generated in M-
CSF stimulated cultures of both hyperglycemic and control BM was markedly reduced in 
the presence of atorvastatin (P < 0.001; Figure 3B). 
To evaluate the effect of atorvastatin on EPC function,  an in vitro angiogenesis assay was 
performed with conditioned medium of EPC cultured in the presence of atorvastatin.  As 
shown in figure 3C, we again observed significant reduction in tube formation when 
HUVEC were subjected to conditioned media of EPC derived from hyperglycemic mice (P 
= 0.05). This loss in paracrine angiogenic capacity was attenuated when the EPC from 
hyperglycemic mice were cultured in the presence of atorvastatin. 
Discussion
Diabetes can be envisioned as a disease characterized by a chronic systemic inflammatory 
state disturbing the function of multiple vital body systems,  in particular the 
vasculature27,28.  We hypothesized that hampered differentiation of EPC from myeloid 
progenitor cells in the BM might contribute significantly to the suboptimal endothelial 
repair under hyperglycemic conditions. Indeed, we observed a marked 40% reduction in the 
number of EPC that could be cultured from BM of mice that were made hyperglycemic by 
streptozotocin treatment. Similar to what we previously observed for the number of EPC 
that could be cultured from PB-MNC from patients with type 1 diabetes9, the observed 
reduction was inversely correlated with HbA1C levels suggesting a causal role for 
hyperglycemia. In addition, EPC from hyperglycemic murine BM displayed impaired 
angiogenic activity. Again, EPC from patients with type 1 diabetes are likewise impaired in 
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angiogenicity9. Our findings confirm that EPC-mediated neovascularization may be 
impaired in diabetes due to a reduction in number and angiogenic capacity of the 
circulating EPC, caused by their defective development from myeloid BM progenitors. 
Indeed, others have shown that when progenitor cells derived from a hyperglycemic 
background are transplanted into mice they fail to augment ischemia-induced 
neovascularization12,13 and have decreased capacity for re-endothelialization following 
arterial injury36. However, our results also demonstrate that EPC derived from 
hyperglycemic BM display a pro-inflammatory phenotype as their capacities to endocytose, 
to activate T-cells and to produce IL-12 are increased. By mRNA expression profiling we 
recently demonstrated that human EPC from patients with type 1 diabetes over express 
numerous pro-inflammatory genes known to be associated with hyperglycemia and 
oxidative stress, including osteopontin, plasminogen activator type 1,  lectin-like oxidized 
LDL receptor,  thrombomodulin and type IV collagen37. Together these data suggest that 
when EPC from a diabetic background home to sites of ischemia or vascular injury, the pro-
inflammatory nature of these cells may contribute to an adverse (immune) response that 
may be pro-atherogenic or contribute to the formation of neointima. EPC dysfunction was 
previously proposed to explain the pro-atherogenic nature of transplanted BM-MNC from 
apolipoprotein E-knockout mice38 and may limit the direct use of autologous progenitor cell 
transplantation for therapeutic angiogenesis in patients with ischemic vascular disease39,40. 
Surprisingly, the reduction in the number of EPC obtained from hyperglycemic BM was 
associated with a concomitant increase in the ability of these BM cells to generate Mph 
while the number of DC that could be obtained upon appropriate stimulation was not 
changed. We have previously shown that Mph and DC can be derived from common 
myeloid progenitor cell subsets in murine BM25,26, and recent findings by Fogg et al. 
confirm this notion as they indicate that Mph and DC share a common BM progenitor41. 
Here, we observed that the frequency of the different myeloid progenitor subsets in BM 
was not changed by hyperglycemia. Therefore, we propose that myeloid lineage 
differentiation potential of the BM progenitors was skewed as a consequence of the 
hyperglycemic state. Our observations suggest that inflammatory cytokines or elevated 
redox signaling may directly regulate the differentiation of various myeloid lineages from 
progenitor cells.   NF-κB is a major transcription factor responsive to cytokines and reactive 
oxidant species.  Indeed, recent studies indicate that NF- κB, acting via IRF4, directly 
influences DC vs. macrophage differentiation42.
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Recently we demonstrated that EPC, Mph and DC show a  significant phenotypic overlap 
and that a major source of EPC from the BM is the CD31high/Ly6Chigh fraction that 
predominantly contains myeloid progenitor cells that can also generate Mph and DC24. This 
myeloid origin of EPC is consistent with the observation that CD34lowCD14+ cells in 
peripheral blood are a major source of human EPC21.  Assuming that the EPC, the Mph and 
the DC all originate from a common myeloid progenitor, we speculate that the pro-
inflammatory milieu in diabetes not only skews the differentiation of the myeloid 
progenitor cell towards the Mph but that it does so at the cost of the generation of EPC. 
Several recent studies support this concept of heterogeneity of myeloid cells in response to 
environmental stimuli. In mice, diet-induced obesity was shown to induce a phenotypic 
switch of the adipose tissue macrophages from an anti-inflammatory towards a pro-
inflammatory state43.  Another study showed that a subfraction of circulating Ly6Chigh 
monocytes was selectively and progressively expanded under hypercholesterolemic 
conditions. This subfraction,  compared to Ly6Clow monocytes, displayed a highly pro-
inflammatory and atherogenic phenotype44. As pointed out before, short-term cultured BM-
derived EPC are mainly derived from a myeloid cell fraction with high levels of Ly6C. As 
EPC display a higher pro-inflammatory phenotype under hyperglycemic conditions, their 
possible role in progression of atherogenesis in this metabolically altered environment 
needs to be further explored. Our data imply that hyperglycemia-dependent alterations on 
cell-fate specification are not restricted to embryonic development45 but may also affect the 
differentiation of adult progenitor cells. The ultimate proof of this concept may involve the 
use of techniques that monitor clonal expansion of the myeloid progenitor cells and HSC-
like cells and are the subject of current investigations.
HMG-CoA reductase inhibitors, statins, have been shown to increase the number of 
circulating EPC both in animal models32,33 as well as in patients with stable coronary artery 
disease46.  Also,  statins generate potent anti-inflammatory actions31 and can improve 
properties of dysfunctional EPC populations in vitro4,33,46. In addition, statins  appear to 
modulate the in vitro differentiation of monocytes to Mph35. Therefore, we assessed 
whether the addition of atorvastatin,  in vitro, could reverse diabetes-associated changes in 
the EPC and Mph cultures. Indeed, we observed that atorvastatin restored EPC 
differentiation to control levels, and also strongly decreased the elevated number of Mph 
generated in the BM cultures from hyperglycemic mice. Also the angiogenic capacity of the 
EPC derived from hyperglycemic BM was partially recovered when cells were cultured in 
the presence of atorvastatin. 
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In conclusion, our study shows that EPC dysfunction in diabetes stems from the BM due to 
hyperglycemia-induced alteration in differentiation of myeloid progenitor cells. The 
inflammatory nature of EPC in hyperglycemia may not only impair EPC function but 
potentially also contributes to premature atherosclerosis when these cells incorporate into 
the vessel walls. Our observation that statins can, at least in part, counteract these effects 
may not only provide a helpful tool to elucidate the molecular mechanism underlying EPC 
dysfunction but may also contribute to the beneficial effect of statin therapy on the 
circulating levels of EPC in patients.
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Abstract.
Myeloid cells have been identified as key players in the development of atherosclerosis and 
organ damage. While cells from myeloid origin have the potential to repair the vessel wall 
by differentiation into endothelial cells and by stimulating angiogenesis and arteriogenesis, 
they may also cause injury when differentiation into inflammatory phenotypes such as 
macrophages or dendritic cells occurs.  It appears that inflammatory and metabolic stimuli 
determine the fate of myeloid cells. As PPAR agonists have been shown to have potent anti-
inflammatory effects,  we investigated whether short-term treatment with the PPARγ  agonist 
pioglitazone modulates the inflammatory signature of circulating myeloid cells as well as 
the capacity to differentiate into an endothelial phenotype (EPC) in patients with type-2 
diabetes. Transcriptional profiles of myeloid cells, committed to the monocytic lineage, as 
well as EPC were analyzed from patients treated for four weeks with pioglitazone and 
compared with patients who received placebo. A marked overall transcriptional repression 
was observed in differentially expressed genes of both monocytes (83.3%) and EPC 
(91.9%). Validation experiments with real-time PCR could further demonstrate that EPC’s, 
in comparison to monocytes,  show characteristics of immature immune cells with high C1q 
expression and low expression of the complement propagation factor properdin. 
Pioglitazone treatment shifted this profile in monocytes towards that of immature immune 
cells. Despite the transrepression, no difference in the ability of myeloid progenitor cells to 
differentiate towards endothelial cells was observed. This study provides the first in vivo 
evidence of transcriptional transrepression in myeloid cells in diabetes and points to a new 
therapeutic mode of action of thiazolidinediones. 
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Introduction
Over the last years myeloid cells have been identified as key players in the pathobiology of 
atherosclerosis and target organ damage. Circulating myeloid cells may differentiate into 
monocytes that subsequently can develop into foam cells when recruited into the vessel 
wall. Moreover myeloid cells also are a source of dendritic cells in the vessel wall1. This 
results in antigen presentation and local adaptive immune responses. Apart from these pro-
inflammatory effects of myeloid cells, we and others recently found that myeloid 
progenitors may also differentiate into an endothelial phenotype and restore endothelial 
integrity2,3. Moreover, myeloid cells have been involved in lymphangionesis and clearance 
of inflamed tissue4. Inflammatory stimuli and cytokines seem to influence the fate and 
plasticity of such myeloid cells5. For example,  in the presence of cytokines such as GM-
CSF and interleukin-4 the formation of dendritic will be promoted6.  The presence of VEGF 
and shear stress may facilitate endothelial differentiation7,8 while VEGF-C and its receptor 
VEGF-3 have been shown to be a stimuli for formation of new lymph endothelium from 
these cells4. We previously demonstrated that diabetes is associated with a reduced capacity 
to form endothelial progenitor cells (EPC) from peripheral-blood mononuclear cells (PB-
MNC) while function of these EPC was hampered as well9. In a recent study,  we 
demonstrated that in mice hyperglycemia affects myeloid differentiation in the bone 
marrow resulting in a reduced differentiation of myeloid progenitor cells into EPC and a 
concomitant increase in the differentiation of myeloid progenitor progenitor cells into 
macrophages (in submission). Prevention of cellular cytokine responses and the 
transcription of inflammatory genes may therefore be a target to modulate the balance of 
myeloid cells towards repair and less to inflammatory phenotypes.
In the setting of diabetes, the synthetic PPARγ agonists are of particular interest in this 
respect. These drugs were designed and developed to induce PPARγ-dependent 
transcription in adipocytes, thus influencing differentiation and metabolic function of 
adipocytes10. This results in improved free fatty acid metabolism and enhanced glucose 
sensitivity11.  However,  more recently PPARγ  agonists have also been shown to negatively 
regulate inflammatory gene expression12-14. The PPAR ligands exert these anti-
inflammatory effects by inhibiting various transcription factors including NFκB15. 
In the current study we assessed whether the PPARγ agonist pioglitazone modulates 
transcriptional activation of myeloid cells as well as the capacity to differentiate into 
endothelial phenotype. For this purpose mononuclear cells that were committed to the 
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monocytic lineage and to the endothelial lineage, as well as late outgrowth endothelial 
progenitor derived cells, were characterized for their transcriptional signature. 
Subsequently, the transcriptomes of these cells were investigated in patients with type II 
diabetes, comparing pioglitazone treatment to placebo.
Subjects and methods
Patient characteristics.
Ten male, non-smoking patients with type 2 diabetes were recruited into this study. All 
patients were treated with oral antihyperglycemic agents that were continued during the 
study. Subjects with poor glycemic control (HbA1c > 9%) were excluded. Other relevant 
exclusion criteria were presence of macro- or microvascular disease and use of vasoactive 
medication (eg, [beta]-blockers, calcium entry blockers, ACE inhibitors, angiotensin type-1 
receptor blockers,  statins, aspirin, or non-steroidal inflammatory drugs). The ethical review 
board of the University Medical Center Utrecht (UMCU) approved the protocol. All 
subjects gave written informed consent. Measurements were carried out in accordance with 
local institutional guidelines in a Good Clinical Practice-certified unit16.
Study design
The study was designed as a prospective, randomized, crossover, placebo-controlled, 
double blind trial. Patients eligible to take part in the study were randomized to receive 
pioglitazone 30 mg once daily (Eli Lilly) or placebo for 4 weeks in addition to their oral 
antihyperglycemic agents. These 4 weeks were followed by a washout period of 6 weeks. 
Peripheral blood was drawn at the end of each 4-week treatment period (placebo and 
pioglitazone). Patients were instructed to fast for at least 10 hours before the tests. No study 
medication or other medication was used on the morning of the study days.
 
Laboratory assessment
Fasting peripheral blood was drawn, and plasma was frozen at -20°C until further analysis. 
Glucose, creatinine,  total cholesterol, triglycerides,  and high-density lipoprotein cholesterol 
(HDL-C) were measured by standard enzymatic laboratory methods (Vitros 250; Johnson & 
Johnson). Low-density lipoprotein cholesterol (LDL-C) was calculated with the Friedewald 
formula. HbA1c and free fatty acids (FFA) were photometrically performed (Hitachi 911; 
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Roche). Insulin levels were determined with an immunologic method (Immulite 2000; 
Diagnostic Products Corp). Measurements of plasma adiponectin, interleukin-6 (IL-6),  and 
high-sensitivity C-reactive protein (hs-CRP) were performed with a commercially available 
kit (ELISA; R&D Systems Inc).
EPC isolation and characterization
Peripheral blood was obtained in blood collection tubes containing EDTA (Venoject).  EPC 
were cultured as described9. Briefly, PB-MNC were isolated from 100 ml whole blood by 
density gradient centrifugation (Histopaque 1077). 50x106 PB-MNC were plated at a 
density of 1 X 106 cells per cm2 on 6-well culture plates coated with 2% gelatin (Sigma) in 
M199 medium supplemented with 20% FBS (Invitrogen), 0.05 mg/ml Bovine Pituitary 
Extract (Invitrogen), antibiotics and 10 U/ml heparin (Leo Pharma BV). After four days of 
culture, EPC characteristics were confirmed on the basis of morphology and by fluorescent 
confocal immunohistochemistry using Ulex europaeus agglutinin (UEA-1: Vector), a CD31 
antibody (DAKO Diagnostics) and DiI-labeled acetylated LDL (Molecular Probes). EPC 
were isolated, counted and stored at –80°C as cell pellets until use. 
To culture late-outgrowth endothelial cells with a cobblestone like morphology (CLC), 
MNC fractions of cord blood were isolated and cultured as short-term EPC (see above). 
After 7 days medium was replaced with EBM endothelial cell medium supplemented with 
bulletkits (Cambrex). Cells were cultured for over 4 weeks,  until colonies with cobblestone 
morphology appeared. When they reached confluence, the cells were passaged for maximal 
4 times in gelatin coated culture flasks. Before use, the CLC were analyzed by 
immunofluorecence techniques staining for mature EC characteristics with vWF 
(DakoCytomation),  Endoglin (BD, transduction Laboratories) and eNOS (Pharmingen) 
antibodies. 
Human Umbilical cord Vein Endothelial Cells (HUVEC) were also cultured in EGM 
medium on gelatin-coated culture flasks up to four passages. Total RNA was isolated using 
an RNeasy kit (Qiagen) and the integrity of RNA preparations was validated before use.
Monocyte (CD14+) isolation by magnetic cell sorting 
CD14+ cells were purified from PB-MNC (see above) by positive selection with magnetic 
beads conjugated to anti-CD14 antibodies (Miltenyi) using an autoMACS system and 
according to the manufacturers protocol. CD14+ monocyte fractions were reproducibly over 
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95% pure as determined by flowcytometric analyses (FACScan) and were stored at -80°C 
for protein (whole cell lysate) and/or total RNA isolations (Rneasy kit, Qiagen). 
In vitro angiogenesis assay.
To evaluate CLC cells for their capacity to form tube-like structures, 0.7*105 cells/cm2 
passage 4 CLC were seeded on human fibrin matrices and cultured in M199 medium 
supplemented with 10% human serum, 10% newborn calf serum, penicillin/streptomycin, 
basic fibroblast growth factor (bFGF) and tumor necrosis factor- (TNF-)17. Fresh medium 
was added every second day and the appearance of invading cells and tubular structures 
was evaluated by phase-contrast microscopy 7 days after seeding. 
Microarray analyses
For gene expression profiling of CD14+ cells, EPC cultured for 4 days, late-outgrowth EC 
(CLC) and HUVEC, total RNA preparations were obtained and analyzed using Affymetrix 
high-density HG-U95Av2 oligonucleotide microarrays interrogating 12.600 transcripts, 
according to the manufactures protocol.  To reduce individual-specific variation in gene 
expression, CD14+ and EPC RNA samples were derived from a pool of equal amounts of 
total RNA from 5 (healthy) volunteers. Also CLC and HUVEC RNA was derived from 5 
donors and pooled. 
For gene expression profiling of CD14+ and four-day EPC cultures obtained from patients 
with type-2 diabetes, messenger RNA profiles were analyzed using Affymetrix high-density 
HG-U133A oligonucleotide microarrays interrogating 18.400 transcripts. Equal amounts of 
total RNA from 5 patients with either placebo or pioglitazone treatment were pooled. 
All the scanned images were analyzed using Affymetrix Microarray Software (MAS) and 
significant differentially expressed genes (placebo as background signal) were further 
analyzed.  Scaling factor, background, noise and 3’/5’ GAPDH ratios (always less than 1.2) 
were such that valid comparisons between similar arrays could be made. For further 
analyses commercially available programs Matlab and Spotfire were used.
Quantitative rt-PCR 
For validation of the microarray analyses, mRNA expression levels of C1q, Factor P, 
CDKN1A and S100A9 and two normalization genes (Actin and GAPDH) were measured 
using quantitative RT-PCR.  cDNA was synthesized from total RNA samples (same as used 
for profiling) using standard cDNA synthesis reagents and a 1:1 mixture of oligo dT(12-18) 
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primers and random hexamer primers (Invitrogen).  Quantitative analyses of the 
synthesized cDNA were performed with use of SYBR green I (Molecular Probes) in 
optimised real-time PCR (Amplitaq Gold,  Applied Biosystems), using a iCycler Thermal 
cycler (Biorad). Gene specific primer combinations were assembled with Oligo Explorer 
(Gene link). Primer sets of the various genes used were from 5’ to 3’: C1q forward: 
tcaccaaccaggaagaaccg, reverse: atgggaagatgaggaagccg. Factor P (Properdin) forward: 
cctaatcctacccgtgcc, reverse: cttctcgccctgaccttc.  Cyclin-dependent kinase inhibitor-1A 
(CDKN1A) forward: gattagcagcggaacaagg, reverse: caacgttagtgccaggaaag. S100A9 
forward: gctggaacgcaacatagag, reverse:ggtcctccatgatgtgttc. For normalization, GAPDH 
forward: ttccaggagcgagatccct, reverse: cacccatgacgaacatggg and actin forward: 
tgcgtgacattaaggagaag and reverse:tgaaggtagtttcgtggatg.  Samples were analyzed in triplicate 
and threshold cycle numbers and their SD were calculated using iCycler v3.0a analysis 
software (Biorad) and further used to calculate expression ratio’s of the different samples in 
relation to both normalization genes. 
Results
Patient characteristics
Ten subjects were included in this study. No carryover effects between the 2 treatment 
periods were observed for any parameter16.  When treatments of either placebo or 
pioglitazone were compared (table 1) a significant reduction in FFA was observed (640±38 
versus 504±34 µmol/L, P=0.04; respectively. A significant increase in adiponectin plasma 
levels was obtained during pioglitazone treatment compared with placebo after only 4 
weeks (7421± 147 versus 4264±856 ng/mL, P=0.005 respectively). No further significant 
differences were seen in the measured values.
CD14+ monocyte isolation and EPC characterization 
To assess the myeloid properties and the purity of the sorted CD14+ cells the cells were 
stained with an anti-CD14 FITC-labeled antibody and analyzed by flowcytometric analysis. 
Figure 1A shows a representative dot plot of the sorted  CD14+ fraction that was 
reproducibly over 95% pure (96.5% ± 2.4%, n=10). After 4 days of cultivation under EC 
differentiation conditions, attached cells were analyzed for EC characteristics. EPC 
appeared with a typical spindle-shaped morphology (figure 1B, upper right) and over 90% 
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of the attaching cells showed uptake of DiI-labeled acLDL (red) and could bind an EC 
specific lectin UEA-1 (figure 1B, upper left). Further characterizations show that EPC 
comprise more EC properties as they have a high CD31 surface expression and they 
express low levels of eNOS. Von Willebrand factor was also detected at low levels in the 
EPC although no Weibel Pallade body-like structures could be observed (data not shown). 
Typical clonal cell expansion is seen in the late-outgrowth cultures (CLC) after 4 weeks of 
culture (figure 1B, middle left). These colonies were further cultured until they formed a 
monolayer of cells with cobblestone morphology. Endothelial characteristics of these cells 
were analysed and confirmed using immunofluorescent staining of vWF (in Weibel Palade 
bodies, figure 1B, middle right), CD31 (figure 1B, lower right), eNOS (mostly perinuclear 
staining) and Endoglin (data not shown). To assess whether the CLC also display functional 
 
Placebo 
(n=10)
Pioglitazone  
(n=10)
P-value
Weight (kg) 99.3 ± 3.0 98.6 ± 3.9 0.71
SBP (mm Hg) 137 ± 7.0 130 ± 3.0 0.44
DBP (mm Hg) 73 ± 2.0 74 ± 3.0 0.90
Fasting glucose (mmol/L) 7.2 ± 0.5 6.6 ± 0.6 0.25
Insulin (mU/L) 21.0 ± 4.2 17.1 ± 3.3 0.33
HbA1C % 6.7 ± 0.2 6.4 ± 0.2 0.08
Total cholesterol (mmol/L) 4.8 ± 0.2 4.9 ± 0.3 0.34
HDL cholesterol (mmol/L) 0.9 ± 0.05 0.9 ± 0.1 0.92
LDL cholesterol (mmol/L) 3.0 ± 0.2 3.1 ± 0.3 0.57
Triglycerides (mmol/L) 1.8 ± 0.2 1.8 ± 0.2 0.72
Free fatty acids (µmol/L) 640 ± 38 504 ± 34.0 0.04 *
Adiponectin (ng/ml) 4264 ± 856 7421 ± 1147 0.005 *
Creatine (µmol/L) 71 ± 3.0 69 ± 2.0 0.11
CRP (mg/L) 3.9 ± 0.8 2.7 ± 0.6 0.11
Interleukine-6 (pg/ml) 2.0 ± 0.3 1.7 ± 0.2 0.17
Values are mean ± SEM.
P-values calculated Placebo vs. Pioglitazone.
*P<0.05
Table 1  
Clinical characteristics of the patients after treatment
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EC characteristics, the ability of these cells to form vessel like structures in an in vitro 
angiogenesis assay was examined. Indeed, CLC readily formed capillary-like structures to 
the same extend as mature EC upon stimulation with angiogenic factors like bFGF (figure 
1B, lower right). 
To demonstrate the myeloid lineage properties of the isolated CD14+ cells and the myeloid / 
EC character of the cultured EPC, mRNA profiles were analyzed for monocyte and 
endothelial cell specific gene expression (table 2). Genes that are associated with 
monocytes are shown at the top of the table, while genes known to be EC specific are 
depicted at the bottom. The middle represents a transition phase, as monocytes and EC are 
known to share some antigens.  The table validates the myeloid character the sorted CD14+ 
cells reveals that EPC share many genes with these myeloid CD14+ cells and have only 
upregulated some EC specific genes (e.g. endoglin) at a low level. These data further 
support the concept that short term cultured EPC are derived from the myeloid lineage. 
Consistent with the phenotypic and functional analyses of the CLC, profiles of the late-
outgrowth EPC (CLC) show a high similarity in gene expression with mature EC 
(HUVEC). 
 
Figure 1: Morphological, phenotypical and 
functional analyses of the different cell 
populations. 
(A) Flowcytometric analyses of the purity of CD14+ 
cells in the positive cell fraction after magnetic cell 
sorting. 
(B) Morphology of cell clusters of EPC appearing 
after 4 days (upper left).  Upper right shows uptake of 
Di-labeled acLDL(in red)  by EPC cultured for 4 days 
as well as binding of lectin UEA-1 (in green). Almost 
all cultured cells are double positive for both EC 
markers. When EPC are cultured further as CLC they 
start out as colonies with cobble-stone appearance 
(middle left panel). CLC grown as monolayer all show 
vWF staining in Weibel pallade bodies (middle right 
panel) and CD31 membrane staining (lower right) 
similar to mature EC. Furthermore, CLC are able to 
form 3-D vessel structures in in vitro angiogenesis 
assays (lower right panel).
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Pioglitazone treatment does not induce differences in the number of monocytes or EPC
To investigate whether pioglitazone treatment did affect the number of circulating CD14+ 
cells, the purified CD14+ fractions derived from equal amounts of MNC fractions were 
quantified.   As shown in figure 2A, no significant difference in CD14+ cells numbers were 
observed. Pioglitazone treatment did also not have an effect on the differentiation of 
myeloid cells into the EC lineage, as the number of attaching EPC cells (4 day cultures) 
derived from 50x106 MNC was similar compared to the cultures from placebo treated 
patients (figure 2B). 
 
Table 2
Myeloid/Endothelial characteristics of CD14+ cells, EPC, and CLC. Micro array analyses were 
screened for monocytic and endothelial genes and expression (laser signals) of these genes are 
depicted as high (dark green), intermediate (light green) and low or below detection (orange). 
Figure 2: Effect of pioglitazone treatment on number of cells.
The treatment of the patients with pioglitazone (Pio) had no significant effects on the total number of isolated 
CD14+ cells (A) and the total number of cultured EPC at day 4 (B) when compared to placebo treatments.
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Transrepression of differentially expressed genes by pioglitazone treatment. 
As the overall average expression of the raw data signals of all microarrays were 
comparable (data not shown), the effects of different treatments on the two different cell 
types could be compared using MAS microarray analyses. Significantly differentially 
expressed genes (1.5x cut-off value) in CD14+ cells and in EPC were extracted from the 
panel and their Signal Log Ratio’s were plotted (figure 3). There were more significant 
differentially expressed genes in the EPC panel when compared to the CD14+ cell panel 
(1178 genes vs. 514 respectively). Strikingly, almost all differentially expressed genes were 
down regulated in both CD14+ cells and EPC (83.3% and 91.9% respectively),  suggesting a 
highly dominant transrepressive effect of pioglitazone treatment in subsets of myeloid cells 
derived from diabetes patients.
Signature of inflammatory responsive genes by pioglitazone treatment. 
In order to evaluate the effect of pioglitozone treatment on inflammatory responsive genes 
in both cell types we looked for the genes present on the HG-U133A that represent the gene 
ontology class “Immune response” (GO:00069). We extracted about 50 different probe sets 
from this GO-class and we calculated the ratios of the probe signals (placebo= 
background).  By plotting these ratios, the fingerprint of this specific GO-class of genes 
became visible (figure 4). 
 
Figure 3: Transrepression of differentially expressed genes occurred in both CD14+ 
cells and EPC in patients treated with Pioglitazone. 
Genetic profiles of both pioglitazone and placebo treatments (background values) are compared of 
CD14+ cells and EPC and only the differentially expressed genes are depicted.  
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Validation of microarrays by quantitative real time PCR analyses
To validate if the gene arrays were representing the mRNA levels in the different cells,  four 
genes of interest were analyzed by quantitative rt-PCR. Expression ratio’s of the different 
genes were normalized to two different normalization genes (GAPDH/Actin) and results 
are shown in figure 5A.  Raw data signals from the various genes (figure 5B) were 
assembled from the array analysis and compared to the expression data derived from the 
 
Figure 4: The effect of pioglitazone treatment on inflammatory responsive genes in CD14+ cells 
and EPC. 
Some of the genes are represented several times in the figure but different probe sets were analysed for these.
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quantitative rt-PCR. Complement factor C1q was analyzed in the patient samples (figure 
5A) as well as in the various differentiation stages of endothelial cells (figure 5C). C1q, a 
major component of the classical complement pathway, was not significantly differentially 
regulated by treatment of pioglitazone in both cell types (figure 5A); however it showed a 
marked upregulation in the EPC differentiation stage when compared to monocytes or 
mature EC (figure 5C). Quantitative analyses of factor P mRNA levels, also known as 
Properdin, a positive regulator of complement activation showed marked higher levels in 
CD14+ cells when compared to EPC. No significant differential expression after 
pioglitazone treatment was observed in EPC, however in CD14+ cells we found a marked 
reduction in Factor P (P = 0.05). P21 mRNA levels showed the same pattern as mRNA 
levels of C1q in the patient samples, revealing no significant differential expression in both 
 
Figure 5: Validation of microarrays by quantitative real time PCR analyses. 
Gene expression profiles of CD14 cells and EPC derived from patients with (Pio) or without (placebo) 
pioglitazone treatment were validated. Normalized relative expression ratio’s of mRNA levels of C1q, 
Factor P, P21 and S100A9 were analyzed using quantitative real time PCR techniques (A). Raw data 
signals of the microarrays were plotted to be able to compare these expression levels with the expression 
ratio’s generated by quantitative PCR (B). In addition to the patient samples C1q profiles of various 
differentiation stages of endothelial cells were further explored using quantitative PCR. Table 2 shows the 
raw data signals of the microarray experiments and here these data are verified (C). 
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cell types when patients were treated with pioglitazone but a marked increased expression 
in EPC when compared to CD14 cells. When we quantified S100A9, a Ca2+-binding protein 
known to be involved in inflammatory responses of monocytes and macrophages18, we 
noticed that CD14+ cells had a higher expression of the protein when compared to EPC but 
EPC showed a significant reduction in the level of S100A9 after pioglitazone treatment (P 
= 0.05).
In summary, for all genes tested, observations obtained by quantitative rt-PCR were in line 
with the microarray analyses, showing that the gene expression levels from the microarray 
analyses did represent mRNA levels in the cell isolations.
Discussion 
Recently attention has been drawn to the anti-inflammatory and anti-atherosclerotic effects 
of synthetic PPAR-y ligands. The current study provides a rationale for these effects by 
demonstrating generalised trans-repression in myeloid cells that are involved in 
inflammation and repair processes in patients with type II diabetes by the PPAR-y agonist 
pioglitazone. 
The classical paradigm is that thiazolidinediones, synthetic ligands for PPARγ, act through 
transcriptional activation in adipocytes resulting in improved free fatty acids metabolism 
and glucose handling10,11. However, in recent years data have emerged that also show direct 
vascular effects of these drugs. For example inhibition of atherosclerosis progression was 
observed in non-diabetic patients19. It was suggested that this effect was independent of 
changes in metabolism and could possibly be attributed to anti-inflammatory effects. 
Indeed, thiazolidinediones have been shown to reduce tissue inflammation in conditions 
such as psoriasis and kidney disease20. The exact nature of these effects is not exactly 
known yet. 
The current study shows that patients with type 2 diabetes that have been treated with 
pioglitazone have a generalised transcriptional repression in circulating monocytes (figure 
3). This trans-repression includes important genes involved in cell activation such as cell 
surface receptor linked mechanisms, the cytokine and chemokine production and genes 
involved in control of transcription (figure 4).  It has been proposed that such trans-
repression may be secondary to a physical interaction between PPAR-γ and the co-repressor 
complexes that keep inflammatory transcription suppressed15. Binding of PPAR-γ to this 
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repressive complex prevents recruitment of the ubiquitination machinery normally required 
to clear the co-repressor complex from the activation site.  The current study extrapolates 
these in vitro concepts to the in vivo situation in patients with type 2 diabetes.  As monocyte 
activation and transformation into foam cells is fundamental to atherogenesis and plaque 
disruption,  one may postulate that these molecular effects of thiazolidinediones contribute 
to the beneficial effects on atherosclerotic disease of these drugs. Indeed, reduced 
progression of intima media thickness, as an intermediate marker of atherosclerosis, has 
been observed both in diabetic patients21 as well as in non-diabetic patients19. Moreover in 
a recent large endpoint driven study, the PRO-active study, it was shown that pioglitazone 
could produce cardiovascular events and associated mortality22.
The present short-term study only shows very limited effects on metabolic indices. Only 
small changes in free fatty acid fluxes could be observed, while glucose and lipid levels did 
not change significantly. For metabolic changes the treatment period could be too short as 
they are generally only seen from 8 weeks of treatment20. This makes a direct transrepressor 
effect by pioglitazone more likely than an indirect effect through improvement of insulin 
resistance.
We recently could demonstrate that myeloid cells may not only give rise to inflammatory 
cells but are also implicated in repair processes of the vessel wall. For example they have 
been shown to be able to reendothelialize2 and to enhance angiogenesis23,24 and 
lymphangiogenesis4,25. The current study shows that despite the generalized trans-
repressive effects of pioglitazone, differentiation into an endothelial cell phenotype is still 
possible. The number of endothelial like cells (general referred to as endothelial progenitor 
cells, EPC) that can be cultured from the mononuclear cells is the same whether the patients 
are treated with placebo or with pioglitazone (figure 2B). Nevertheless when these cells are 
in the process of transdifferentiation towards an endothelial phenotype they show a similar 
profound reduction in expression of genes that are involved in cell activation. Previously, 
using a mice model it was observed that thiazolidinediones might even increase the 
capacity to form endothelial cells from bone marrow. It should, however, be noticed that 
these were healthy mice that did not have diabetes-associated recruitment ad differentiation 
defects26.
We also characterised the expression profiles of myeloid cells while they are in transition of 
myeloid to endothelial cells. When cells are cultured for 4 days under conditions that 
promote the formation of endothelial cells, expression of endothelial specific genes such as 
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endoglin, VEGF-B become upregulated (table 2). However these cells still bear more 
characteristics of myeloid cells. For example they express HLA-DR and CD14. Only after 
prolonged culture a full endothelial phenotype (CLC) with a similar expression signature to 
that of e.g.  HUVEC appears. This would imply that the early re-endothelializing cells still 
could be considered as cells that are part of the innate immune system. In this respect they 
demonstrated some interesting features that do distinguish them from monocytes. For 
example the complement factor C1q is strongly upregulated. (figure 5C, table 2).  Recent 
data from our laboratory have shown that C1q produced by myeloid cells acts as an 
immune-modulatory factor that allows for phagocytosis and clearance of apoptotic cells but 
blocks T-cell activation27,28. This suggests that these EPC also participate in immune 
surveillance. It is of interest to notice that treatment with pioglitazone upregulates C1q in 
the monocytes while the monocyte complement propagation factor porperdine, which 
allows for full complement activation, is downregulated. In this respect pioglitazone 
treatment shifts the expression in monocytes of diabetes patients towards that of immature 
immune cells. 
In sum, our study provides first in vivo evidence of a novel mode of action of 
thiazolidinediones that may contribute to organ protection in diabetes.
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8.1 Conclusions, general discussion
As described in chapter 1, EPC are bone-marrow derived cells that participate in postnatal 
neovascularization. Once they are mobilized into the periphery they home towards injured 
or hypoxic areas to facilitate angiogenesis and vasculogenesis.  Postnatally, EPC are needed 
to maintain the integrity of the endothelium (reendothelialization) and to augment wound 
healing or to vascularize hypoxic areas (neovascularization). In patients with classical risk 
factors for ischemic vascular disease, EPC numbers have been shown to be reduced and 
their function has been shown to be impaired. The work presented in this thesis explored 
EPC in healthy subjects and focused on their altered properties under hyperglycemic 
conditions using cells from patients with diabetes mellitus and cells of STZ-induced 
diabetes in mice. 
The nature of EPC
Although various EPC containing cell preparations have already been explored for 
therapeutic application, to date, EPC are poorly characterized and the nature of the optimal 
cells for therapy is unknown. As many groups use different methods and surface markers to 
isolate these cells the studies are hard to compare. Especially for short-term cultured EPC 
the different protocols use different growth factors and adhesive surfaces. To my opinion, to 
date there are no distinct markers to identify true EPC, that rule out mature EC and or other 
myeloid lineage cells like DC and Mph in both human or wild-type mouse.  This makes it 
hard to distinguish and study endothelial progenitors and their sources.  For that reason, the 
data described in chapter 5 are important as a they introduce a transgenic mouse model, in 
which GFP is placed before an EC-specific human eNOS promoter1. Although, some 
groups have described eNOS protein in alveolar lung-derived Mph2,3, we could not show 
any eNOS expression in mature monocytes, Mph or DC derived from bone marrow cells 
cultured under various conditions. Therefore, this transgenic mouse model gives us and 
other researchers a valuable tool to further explore origin and function of BM-derived EPC 
cultures under different experimental conditions.  In chapter 5,  mostly BM-derived EPC 
cultures were studied but when we used the spleen as another source of EPC, we saw that 
progenitor cells from the different origins reacted different to various growth stimuli 
suggesting a “different” nature of the EPC-like progenitors in the periphery when compared 
to those cultured from the progenitors in the BM. This intriguing finding is important and 
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needs to be taken in consideration when determining which progenitor fraction is best to 
use for cell therapies.
Another aspect of EPC that has not been described and understood yet is the differentiation 
lineage of EPC.  The study in chapter 5 shows us that short-term cultured EPC are mainly 
derived from a specific myeloid precursor fraction of the BM, with an abundant expression 
of both CD31 and Ly6C on their surface. This is in line with several studies that show 
monocytic features on the progenitors of EPC4-7.  Taken together our data for short-term 
mouse bone marrow derived EPC, supports a myeloid transition phase in the differentiation 
of EPC toward the mature endothelial cell. However, if EPC also can differentiate from 
“full” monocytes is not known. In chapter 5 we describe that we failed to culture EPC from 
a more mature monocyte population (Ly6C+, CD31-) of murine BM suggesting that there is 
a less mature myeloid progenitor cell that still has the potential to develop into the EC- 
lineage. This is somehow unexpected as other groups have shown that circulating human 
EPC can be derived from “mature” circulating CD14+ monocytes. 
It has to be taken into consideration that Mph and DC can be cultured from the same 
myeloid progenitor fraction and similar to EPC, osteoclasts can be solely cultured from this 
same fraction (data Leenen et al, not published). It is not completely sure if all these 
myeloid derived cells are truly derived from the same fraction or if the CD31+/Ly6C+ 
fraction contains different subfractions of progenitors. Mph and DC likely do have the same 
progenitor as switching different growth factors in vitro can completely shift the fate of the 
total population to the desired population of cells8. Recently, other studies described a 
common progenitor for adipocytes and endothelial cells9, showing an even wider diversity 
and plasticity of the differentiation lineage of EPC. These data indicate a tight regulation of 
the differentiation of myeloid progenitor cells, a topic that needs to be further explored.  In 
particular, the use of clonal assays may give answers to the relation of these the myeloid 
lineage derived phenotypes. 
Using the eNOS-GFP transgenic mouse model, we were able to look at the heterogeneity 
between different mouse strains and a marked difference was observed in the capacity of 
BM-progenitors from C57BL/6J and FVB mice to differentiate into EPC. In particular in 
FVB mice a 40% increase in the total number of EPC derived after 7 days culture was 
shown. Given the fact that FVB mice are much less susceptible for atherosclerosis 
compared to C57BL/6J mice, one could speculate about the importance of the capacity to 
form EPC in a relative short time. This heterogeneity may also be observed in humans, 
however because of a lack of good distinct EPC markers it is hard to reveal this difference. 
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Function of EPC 
EPC have been shown to enhance neovascularization in many preclinical and in vitro 
studies10-12.  In this thesis,  a couple of additional insights in the function of EPC are 
presented. Chapter 2 describes a model that can dissect different mechanisms involved in 
neovascularization like migration,  proliferation, differentiation, stimulation of, and 
integration in capillary-like structures. With an in vitro, 3-dimensional angiogenesis model 
we were able to study the effect of different subsets of EPC on neovasculogenesis. Early 
HSC CD34+ cells were used and compared to cultured EPC, previously shown to be mainly 
derived from myeloid CD34- fractions7.  CD34+ cells were shown to home to sites of 
neovasculogenesis and proliferate at site. Furthermore, a small part of the CD34+ cells did 
differentiate and incorporate in the mature EC monolayer and these cells were shown to 
enhance neovasculogenesis. However, CD34- cells could enhance this neovasculogenesis 
even further and to a similar extend as cultured EPC indicating that interactions between 
CD34+ cells and CD34- cells can contribute to stimulation of capillary growth. Many 
studies have suggested an angiogenic paracrine effect of CD34- cells5,6. 
Another study describes that incorporation of CD34-CD14+ cells in to capillary-like 
structures requires co-injection with CD34+ cells, indicating that direct leukocyte-leukocyte 
interactions may play a critical role in in vivo neovascularization4. Studies and models as 
presented in chapter 2 can give more insight in cell-cell interactions, diverse mechanisms of 
neovasculogenesis and different functions and capacities of the various subsets of EPC in 
future experiments.  
Data presented in chapter 7 suggest that EPC may also function as cells involved in 
immune surveillance as gene expression data reveal that early cultured EPC (that express 
many myeloid cells markers) highly express immunoregulatory genes like C1q when 
compared to monocytes or mature EC. C1q is a component of the complement system 
which is designed to allow rapid and efficient activation and clearance of either foreign 
targets or  altered/apoptotic/necrotic cells13. Furthermore, C1q has been implicated in 
preventing autoimmunity and maintaining tolerance by modulating professional phagocytes 
by for instance regulating IL-12p40 production and reducing NFκB activity14. The latter has 
been studied in immature dendritic cells derived from BM. If the same mechanisms play a 
part in BM-derived EPC still needs to be further explored. The finding that EPC do produce 
IL-12p40 (chapter 5) further supports the idea that these cells could regulate immune 
responses. These responses could imply another important role for EPC in process like 
wound healing. 
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EPC in hyperglycemia 
At the onset of the studies described in this thesis no such thing as EPC dysfunction had 
been reported. Our hypothesis that EPC might be dysfunctional under hyperglycemic 
conditions arose from the finding that diabetic conditions could severely impair endothelial 
function and induce ischemic vascular events15.  If EPC are really so important in vascular 
maintenance and repair there could be either less or dysfunctional EPC in Diabetes 
Mellitus, contributing to the pathogenesis of vascular disease in these patients.
Effect of hyperglycemia on the number of EPC 
In chapter 3 it is described that we indeed observed a 40% reduction in the circulating 
number of short-term cultured EPC in patients with type 1 diabetes. This finding was 
directly related to the severity of the disease as we demonstrated a significant inverse 
correlation between the number of EPC and glycemic control (HbA1C).  Similar results 
were also found in a hyperglycemic mouse model (chapter 6), further supporting the 
hypothesis that indeed hyperglycemia could affect EPC numbers. Likewise, Tepper et al 
found a reduced number of EPC in type 2 DM patients, however these patients, next to 
hyperglycemia, could also have other prevalent risk factors for EPC dysfunction16. Many 
pathophysiological mechanisms could account for this reduction in the number of EPC 
including impaired mobilization, impaired differentiation, increased apoptosis or cell 
senescence, reduced adherence capacities or exhausted pools of progenitor cells.  Impaired 
mobilization due to a lack of eNOS has for instance been described17. Although, no 
reduction in the total number of circulating CD34+ cells in diabetes patients was 
observed18,19, a closer look at the distribution of different subsets of CD34+ cells (KDR+) 
might provide more insight in this matter.  Altered differentiation could well be a 
mechanism involved in lower numbers of EPC as chapter 6 describes a possible skew of 
BM myeloid progenitors towards the macrophage lineage. Next to the reduced number of 
EPC, we observed an increased number of Mph that also related to the glycemic control of 
the mice.  We speculate that the altered milieu in diabetes not only directs differentiation of 
progenitor cells towards Mph but that it does so at the cost of the generation of EPC.
Effect of hyperglycemia on the function of EPC 
Chapter 3 not only describes a reduced number of EPC in type-1 DM patients but also that 
EPC isolated from the diabetes patients have an impaired angiogenic capacity compared to 
healthy control subjects. A similar observation in STZ-induced diabetic mice is described in 
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chapter 6 also revealing an impaired paracrine angiogenic function of hyperglycemic EPC. 
In addition, these dysfunctional EPC also display higher pro-inflammatory capacities 
(chapter 6). By using gene expression profiles (chapter 4), we show that human EPC from 
type 1 DM patients upregulate numerous pro-inflammatory genes known to be associated 
with hyperglycemia and oxidative stress.  The pro-inflammatory nature of EPC in type 1 
DM patients is a concern as they may contribute to an adverse (immune) response that may 
be pro-atherogenic and contribute to progressive ischemic vascular disease. This may be 
particularly relevant when using autologous EPC for therapeutic purposes. EPC are thought 
to function in sites of ischemia or reperfused tissue, which can be characterized as an 
inflammatory site. Inflammatory sites are known to be a high oxidative stress environment, 
which could be another mechanism for EPC dysfunction as described in chapter 420. Given 
the central role of oxidative stress in type 1 diabetes, oxidative stress or altered redox 
signaling may also directly affect the survival,  differentiation and function of EPC. As 
described in chapter 4, another potential mechanism for altered EPC function is the 
hyperglycemia associated formation of intra- and extra-cellular advanced glycation 
endproducts (AGE). Differential gene expression profiles support these hypotheses as we 
observed a striking number of genes upregulated in the EPC from type 1 DM patients that 
have been have been reported to be associated with diabetes mellitus in general,  with 
hyperglycemia, oxidative stress or AGE formation. It is somehow remarkable that these 
different gene profiles, and consequently altered functional behavior, of EPC derived from 
either diabetic patients or hyperglycemic mice are found as these EPC are cultured for 
either 4 (chapter 3, 4 and 7) or 7 days (chapter 6) under normoglycemic conditions. So 
somehow EPC are “biosensors” that translate metabolic cues into altered gene expression 
partially imprinted for at least a week.
EPC in therapeutic applications.
Since the discovery of EPC, the cells have been of great interest as therapeutic entities. As 
mobilization of progenitor cells after injury, an important natural response to vascular 
injuries21-23,  did correlate with the long term outcome of cardiovascular disease24 
autologous cell transplantations became relevant. Over the last years, many promising 
preclinical studies have shown evidence that transplantation of different angiogenic cell 
populations did indeed contribute to repair of vascular injuries25,26. A series of clinical pilot 
studies, using cell transplantation in vascular diseases yield promising data27-29,  however 
some larger trails and longer follow-up studies did not reveal any benefits30 or some very 
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minor benefits as discussed in chapter 1.  It needs to be pointed out that treatments of 
myocardial infarction were less promising than treatments of in critical ischemia of 
extremities28,31. So far, most studies have mainly focused on unselected mononuclear cell 
fractions of bone marrow or peripheral blood. A recent clinical study showed that 
intracoronary administration of early hematopoietic CD133+ BM derived cells in patients 
with recent myocardial infarction was associated with increased incidence of coronary 
events32. So although cell transplantation was associated with improved heart function there 
were unexpected side effects when using these early progenitor cells.  
These and other discouraging outcomes sharpen the field of progenitor cell use for vascular 
therapy a bit and make researchers think about major questions like: what subset of cells 
should we transplant, an early progenitor or a further differentiated and maybe more 
dedicated cell?  And what are the exact mechanisms these cells work by? To my opinion 
these questions have to be addressed first before further clinical trails can be initiated. 
The work presented in this thesis gives insight into some of these questions. Chapter 5 
shows a BM specific fraction (CD31+/Ly6C+) from which EPC could be derived but it also 
reveals a very high plasticity in this precursor fraction. This high plasticity of early 
progenitor cells could be a problem in cell transplantation therapies in general as precursors 
could differentiate to unwanted phenotypes depending on local differentiation/growth 
factors and inflict unwanted side-effects. 
Chapters 3 and 6 show EPC dysfunction in type 1 diabetes patients and in hyperglycemic 
mice respectively. These EPC dispose dysfunctional properties in their angiogenic 
capacities (chapter 3 and 6) but they also reveal a higher inflammatory phenotype (chapter 
6). Furthermore, our data implicate a possible skew of myeloid progenitors towards 
macrophage-like phenotypes. It can not be excluded that transplantation of these autologous 
myeloid progenitor cells would inflict adverse side effects. Chapter 6 and 7 suggest 
possible mechanisms to (partially) overcome these effects with statin interventions (Chaper 
6, in vitro) or with PPARγ  agonist interventions (chapter 7, in vivo). HMG-CoA reductase 
inhibitors have been shown to increase the number of circulating EPC19,33,34 and they have 
been shown to generate potent anti-inflammatory actions35 and can improve properties of 
dysfunctional EPC populations in vitro19,34,36. In addition, statins were shown to reduce the 
in vitro differentiation of monocytes to Mph37. Indeed we find that in vitro addition of 
atorvastatin (chapter 6) increases the number of EPC and conversely decreases the number 
of macrophages (in vitro).  Statins could also recover the altered angiogenic properties of the 
EPC cell population derived from hyperglycemic mice. 
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Short treatment of diabetic patients with PPARγ  agonists do show transrepression of many 
genes involved in inflammation, which might be another option to decrease the 
inflammatory phenotype of EPC. 
Optimal treatment of diabetic patients to overcome EPC dysfunction and its side effects 
would still first be controlling the HbA1C levels of the patients and secondly find 
adjunctive therapy like statin/PPARγ agonist interventions to improve EPC functions. 
Recently an interesting paper appeared discussing the potential to augment experimentally-
induced ischemia of peripheral CD34+ - and monocytic-like CD14+ endothelial cell 
progenitors in diabetes38. The same group had found before that CD34+ cells were 
dysfunctional in diabetic conditions18 and they claim in that CD14+ cells are less affected 
by diabetes when compared to more primitive CD34+ cells39. The group suggests that 
CD14+ cells could provide a therapeutic option for people with diabetes, as these cells 
improve wound healing and vascular growth. This thesis shows that CD14+ cells are 
definitely affected in patients with diabetes and that autologous cells could only be used for 
transplantation if these progenitors could somehow be converted from pro-inflammatory 
phenotype to a pro-angiogenic phenotype. 
8.2 Future directions
A couple of suggestions for future directions have already been made including better 
characterization of true EPC and their progenitors. Clonal assays will be needed to answer 
questions about precursor subsets. The proposed mouse model (chapter 5) could help 
exploring these fields. Another interesting concept is skew of progenitor cells under adverse 
metabolic conditions. It would be very interesting to see if this observation can be 
confirmed in patients? 
Recently microRNAs have been implicated in the regulation of hematopoietic lineage 
development40. MicroRNAs might be candidates to direct EPC and macrophage 
differentiation. It would be very interesting to elucidate whether microRNAs are indeed 
involved in these processes and to see if these microRNAs are altered under hyperglycemic 
conditions. If so, microRNA profiling of circulating progenitor populations could provide a 
potent means to monitor the susceptibility of patients to hemodynamic and metabolic risk 
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factors. Finally, future research on the reversal of EPC dysfunction needs to be directed 
towards interventions that convert pro-inflammatory phenotypes towards pro-angiogenic 
phenotypes.
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English Summary
Endothelial Progenitor Cells (EPC) are bone-marrow derived cells that play important roles 
in several vascular processes.  Progenitor cells in the bone marrow can be triggered to 
expand and to mobilize into the periphery through a cascade of stimulatory signals released 
by damaged or ischemic tissue. Homing of these progenitor cells towards injured or 
hypoxic areas can facilitate necessary processes like angiogenesis and vasculogenesis at the 
site. 
Postnatally, EPC are needed to maintain the integrity of the endothelium (re-
endothelialization) and to augment wound healing or to vascularize hypoxic areas 
(neovascularization).  Complex networks of different signals and regulators have been 
identified to be involved in these processes, but the exact mechanisms are not completely 
understood. Unraveling these complex systems, however, could be very beneficial for the 
treatment of vascular diseases. 
In this thesis,  we focus on different aspects of EPC biology. We look at the nature of these 
progenitor cells in a normal environment, but we also look at the possible role of EPC in 
the pathogenesis of vascular disease in patients with diabetes mellitus. 
In chapter 5, a transgenic mouse model expressing a green fluorescent protein under the 
control of an endothelial specific promoter is introduced, in which the origin and function 
of BM-derived EPC could be further explored. Using this transgenic mouse model, cells 
with endothelial-lineage commitment could be distinguished from other closely related 
myeloid cells like Macrophages (Mph) and Dendritic cells (DC). We show that short-term 
cultured EPC are mainly derived from a specific myeloid precursor fraction in the BM, with 
an abundant expression of both CD31 and Ly6C proteins. In chapter 2 we look at more 
basic functional properties of different subsets of EPC and we found that in an in vitro 
angiogenesis model, EPC did home in to sites of neovasculogenesis and also proliferate at 
these sites. Furthermore, part of these EC progenitors did differentiate into Endothelial 
Cells and they were capable of incorporating into the newly formed vessel structures. 
Moreover, EPC were able to enhance neovasculogenesis. 
Data presented in chapter 5 and 7 suggest a new role for EPC as they may also function as 
cells involved in immune surveillance. Endothelial function can be severely impaired and 
ischemic vascular events induced in the diabetic state.  Therefore, we investigated if EPC 
could somehow play a role in the pathophysiology of vascular disease in patients with 
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diabetes. In Chapter 3, we indeed observed a 40% reduction in the circulating number of 
short-term cultured EPC in patients with type 1 Diabetes. This finding was directly related 
to the severity of the disease as we demonstrated a significant inverse correlation between 
the number of circulating EPC and glycemic control (HbA1C %). Similar results were also 
found in a hyperglycemic mouse model (chapter 6), further supporting the hypothesis that 
hyperglycemia indeed does affect EPC numbers.
Chapter 6 describes a mechanism possibly involved in this lower number of EPC found in 
hyperglycemic conditions,  namely altered differentiation of myeloid precursor cells. Data 
show that differentiation of myeloid progenitors from BM derived from hyperglycemic 
mice is more directed towards Mph and that this happens at the cost of the generation of 
EPC. In addition to a reduced number of EPC due to hyperglycemia, chapter 3 and 6 also 
describe an impaired angiogenic capacity of the EPC derived from hyperglycemic subjects. 
Chapter 3 describes how processes like oxidative stress, known to be induced by high 
glucose levels in EC, could be involved in this so-called EPC dysfunction. Data from 
chapter 6 show that the dysfunctional EPC also display higher proinflammatory capacities, 
which is a concern as they may contribute to an adverse (immune) response that may be 
pro-atherogenic, contributing to progressive ischemic vascular disease.
Chapter 6 and 7 suggest possible mechanisms and drug treatments to (partially) overcome 
the effects of hyperglycemia on EPC by intervention with either a statin (Chapter 6, in 
vitro) or with a PPARγ agonist (chapter 7, in vivo). 
Adding atorvastatin in vitro to BM differentiation cultures increases the number of EPC and 
conversely decreases the number of macrophages. In addition, the altered angiogenic 
properties of the EPC derived from the hyperglycemic animals could be recovered with 
atorvastatin use. Our observation that statins can counteract these unfavorable effects, may 
not only provide a helpful tool to elucidate the molecular mechanism underlying EPC 
dysfunction but may also contribute to new treatment strategies or even prevention 
strategies for vascular disease in patients with diabetes. In Chapter 7, transcriptional 
profiles of myeloid cells, committed to the monocytic lineage, as well as EPC were 
analyzed from type 2 diabetes patients treated for four weeks with the PPARγ  agonist 
pioglitazone and compared with patients who received placebo. A marked overall 
transcriptional repression was observed in differentially expressed genes of both monocytes 
(83.3%) and EPC (91.9%). This study provides in vivo evidence of transcriptional 
transrepression and the potent anti-inflammatory properties of pioglitazone in myeloid cells 
in diabetes and might point to a new therapeutic mode of action of thiazolidinediones.
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Nederlandstalige Samenvatting
Endotheel Progenitor Cellen (EPC) zijn in het bloed circulerende cellen die uit het 
beenmerg afkomstig zijn. Zij kunnen niet alleen een belangrijke bijdrage leveren aan het 
onderhoud van het endotheel maar ze kunnen ook bijdragen aan de vorming van nieuwe 
bloedvaten. Onder invloed van verschillende prikkels kunnen de voorlopercellen,  of 
stamcellen, aangezet worden tot celdeling en kunnen deze vanuit het beenmerg mobiliseren 
naar het perifeer bloed.  In de bloedbaan kunnen de EPC gerekruteerd worden naar de 
beschadigde vaatwand of naar de plaats waar nieuwe vaatjes gevormd moeten worden, vaak 
ischemisch weefsel. Daar kunnen de EPC zelf tot endotheel cel differentiëren of angiogene 
processen aansturen om nieuwe vaatjes te vormen of ze kunnen beschadigd endotheel 
vervangen door nieuw endotheel. Bij bovengenoemde processen zijn vele factoren 
betrokken en het is niet bekend hoe EPC precies werken. Het ontrafelen van deze processen 
kan een doorbraak betekenen op het gebied van hart- en vaatziekten, waarbij het endotheel 
van de patiënten voortdurend onder hoge druk staat door metabole veranderingen en deze 
EPC dus van groot belang zouden kunnen zijn.
In dit proefschrift beschrijven we verschillende aspecten van de EPC biologie. Enerzijds 
kijken we naar het gedrag van EPC in een normale omgeving, maar we gaan ook uitgebreid 
in op een mogelijke rol voor EPC in het vaatlijden van diabetes patiënten. In hoofdstuk 5 
introduceren we een transgeen muizen model waarin de muizen een groen fluorescerend 
eiwit produceren onder de controle van een endotheel specifieke promotor. In dit transgeen 
muizen model kunnen we de oorsprong van de EPC en de functie van de EPC bekijken en 
kunnen we de EPC gemakkelijk onderscheiden van gerelateerde andere myeloide cellen als 
macrofagen en dendritische cellen. We laten zien dat EPC afkomstig uit het beenmerg voor 
een groot gedeelte ontstaan uit een specifieke myeloide voorloper fractie van het beenmerg 
met een hoge expressie van zowel CD31 als Ly6C eiwitten. Meer functionele 
eigenschappen van EPC worden besproken in hoofdstuk 2, waar zowel homing van EPC als 
de proliferatie op plaatsten waar vaat-nieuwvorming plaatsvindt worden beschreven in een 
in vitro angiogenese model. Ook wordt beschreven dat een gedeelte van de EPC kan 
differentiëren tot EC,  dat deze kunnen incorporeren in een monolaag van volwassen 
endotheel cellen en dat ze mate van vaatvorming kunnen stimuleren. Een potentiële nieuwe 
rol voor EPC in het immuunsysteem wordt beschreven in hoofdstukken 5 en 7. Diabetische 
condities, waaronder hoge bloedsuikers, kunnen endotheel disfunctie veroorzaken en 
diabetes mellitus is geassocieerd met verhoogde kans op hart- en vaatziekten. Daarom 
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hebben wij onderzocht of EPC een rol spelen in de ontwikkeling van vaatlijden in deze 
patiënten. Hoofdstuk 3 laat zien dat type 1 diabetes patiënten een sterk verminderd (40%) 
aantal circulerende EPC hebben. De reductie in het aantal cellen was negatief gerelateerd 
aan de mate van bloedglucose instelling van de patiënten. Het concept dat verhoogde 
glucose bloedspiegels het aantal EPC kan beïnvloeden wordt verder gesteund door 
observaties in hoofdstuk 6, waar in een hyperglycemisch muizen model ook een 
verminderd aantal EPC wordt gevonden eveneens negatief gerelateerd is aan de HbA1c 
percentages van de muizen. Een mechanisme mogelijk verantwoordelijk voor het 
verminderde aantal EPC is een veranderde differentiatie van myeloide precursors onder 
hyperglycemische condities (hoofdstuk 6). We laten zien dat er een verschuiving is in de 
differentiatie van myeloide precursors naar macrofagen ten koste van de EPC. Naast een 
verminderd aantal EPC vinden we ook een verstoorde angiogene capaciteit van de EPC van 
zowel type 1 diabetes mellitus patiënten (hoofdstuk 2) als die van hyperglycemische 
muizen (hoofdstuk 6). Daarnaast beschrijft hoofdstuk 6 ook dat deze disfunctionele EPC 
hogere pro-inflammatoire eigenschappen hebben. Dit zou in vivo een ongunstige 
ontstekingsreactie kunnen opleveren op de plaats van een endotheel beschadiging, 
bijdragend aan de progressie van atherogene processen in de vaatwand.
Hoofdstuk 3 beschrijft een mogelijk ander mechanisme achter EPC disfunctie, namelijk 
oxidatieve stress. Hoge glucose kan zorgen voor oxidatieve stress in endotheel cellen en 
mRNA profielen laten zien dat deze mechanismen stress en disfunctie zouden kunnen 
veroorzaken in EPC.
Nu dat we weten dat EPC disfunctie mogelijk een rol zou kunnen spelen in de 
pathofysiologie van vaatlijden in diabetes patiënten is het de vraag of we deze disfunctie 
kunnen overwinnen met behulp van bestaande therapeutische middelen. Hoofdstuk 6 laat 
zien dat in vitro toevoeging van de HMG-CoA reductase remmer atorvastatine, het aantal 
EPC verhoogd en tegelijkertijd het aantal macrofagen kan verminderen. Daarnaast heeft 
atorvastatine ook een positieve invloed op de angiogene capaciteiten van EPC. Deze 
observaties, dat statines een positieve invloed hebben op het aantal EPC en tevens ook op 
de  functie,  zorgt voor meer inzicht in de pathofysiologie achter EPC disfunctie en kan 
(mits het dezelfde effecten laat zien in vivo) invloed hebben op betere 
behandelingsstrategieën voor diabetes patiënten met vascularaire complicaties of zelfs voor 
preventie van hun vaatlijden.
In hoofdstuk 7 worden effecten van een andere therapeutisch middel pioglitazone 
besproken. Pioglitazone is een PPARγ agonist en wordt gebruikt voor verbetering van 
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insulinegevoeligheid van type 2 diabetes mellitus patiënten. In een gerandomiseerde, 
crossover, placebo-gecontroleerde, dubbel blinde studie van type 2 diabetes mellitus 
patiënten die voor korte tijd behandeld werden met pioglitazone, zijn transcriptionele 
mRNA profielen geanalyseerd van zowel monocyten als EPC. Een duidelijke algemene 
transcriptionele onderdrukking werd waargenomen in de differentieel gereguleerde genen 
van zowel monocyten (83,3%) als EPC (91,9%). Naast de algemene transcriptionele 
transrepressie zagen we een down-regulatie van pro-inflammatoire genen in zowel 
monocyten als EPC door pioglitazone behandeling, wat therapeutisch een nieuwe weg zou 
kunnen inleiden om progressie van atherogene complicaties in diabetes patiënten tegen te 
gaan.
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List of abbreviations:  
ACE  Angiotensin I-Converting Enzyme
acLDL  acetylated Low-Density Lipoproteins
AGE  Advanced Glycation Endproducts
Ang  Angiotensin
AU  Arbitrary Units
bFGF  basic Fibroblast Growth Factor
BMI   Body Mass Index
BM-MNC  Bone marrow Mononuclear Cells
BP  Blood Pressure
BS-1  Bandeiraea Simplicifolia -1
CAC  Circulating Angiogenic Cells
CAD  Coronary Artery Disease
CB  Cord Blood 
CDKN1A  Cyclin-Dependent Kinase Inhibitor 1A
CEP  Circulating Endothelial Progenitor Cells
CFU-EC  Colony Forming Unit –Endothelial Cells
CLC  Cobble Stone-Like Cells
CM   Conditioned Media
cpm  counts per minute
CVD   Cardiovascular disease
DC  Dendritic Cells
DM  Diabetes Mellitus
DNA  Deoxyribonucleic Acid
EC   Endothelial Cells
ECGF  Endothelial Cell Growth Factor
ECM  Extracelllular Matrix
EGM  Endothelial Cell Growth Medium
eNOS  Endothelial Nitric Oxide Synthase
EPC   Endothelial Progenitor Cells
EPO  Erythropoietin
FACS  Fluorescence-activated cell sorting 
FFA  Free Fatty Acids
FITC  Fluorescein Isothiocyanate
Flt-1  FMS-related Tyrosine kinase 1
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase
G-CSF  Granulocyte Colony Stimulating Factor
GFP  Green Fluorescence Protein
GM-CSF  Granulocyte-Macrophage Colony Stimulating Factor
GTPase  Guanosine TriPhosphatase 
H2O2  Hydroperoxide
HbA1c  Glycosylated Hemaglobin
hCB-MNC Human Cord Blood Mononuclear Cells
HIF  Hypoxia Inducible Factor
HLA  Human Leucocyte Antigen
HMG-CoA 3-hydroxy-3-methyl-glutaryl-CoA reductase
HSC  Hematopoietic Stem Cell
HUVEC  Human Umbilical Vein Endothelial Cells
ICAM  Intra Cellular Adhesion Molecule
IL  Interleukin
IP  Intraperitoneal
IRF4  Interferon Regulatory Factor 4
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KDR  Kinase insert Domain Receptor
LNGFR  Low-Affinity Nerve Growth Factor Receptor
LPS  Lipopolysaccharide
Ly6c  Lymphocyte antigen 6c 
MACS  Magnetic Affinity Cell Sorting
MCP-1  Monocytes Chemo attractant Protein-1
M-CSF  Macrophage Colony Stimulating Factor
MECA  Mouse Endothelial Cell Antigen
MH  Murohara Endothelial Cell Growth Medium
MHC  major histocompatibility complex 
MLR  Mixed Lymphocyte Reaction
MMP  Matrix Metalloproteinase
MNC  Mononuclear cells
MnSOD  Magnesium Superoxide dismutase
Mph   Macrophages
MVEC  Microvascular Endothelial Cells
NADPH  reduced form of Nicotinamide Adenine Dinucleotide Phosphate
NFκB  Nuclear factor κ
NO  Nitric oxide
PB-MNC  Peripheral Blood Mononuclear Cells
PDGF  Platelet-derived Growth Factor
PE  Phycoerythrin
PI3  Proteinase Inhibitor 3
Pio  Pioglitazone
PKB/Akt  Protein Kinase B
PKC  Protein Kinase C
PPAR  Peroxisome Proliferator-Activated Receptors
RAAS  Renin-Angiotensin A
RAGE  Receptor for Advanced Glycation Endproducts
RNA  Ribonucleic Acid
ROS  Reactive Oxygen Species
SCA-1  Stem Cell Antigen 1
SD  Standard Deviation
SDF  Stromal cell-Derived Factor
SEM  Standard Error of Mean
SMC  Smooth Muscle Cell
SP  Side Population
STZ   Streptozotocin
tg  transgenic
Th1  T helper cell 1
TNFα  Tumor Necrosis Factor Alpha
UEA  Ulex europaeus agglutinin
VCAM  Vascular Cell Adhesion Molecule
VE   Vascular Endothelial
VEGF  Vascular Endothelial Growth Factor
VEGFR  Vascular Endothelial Growth Factor Receptor
vWF  von Willebrand factor
wt   wildtype
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